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ABSTRACT 
Zinc Supported by Nitrogen-Rich Ligands: Applications Towards Catalytic 
Hydrosilylation And Modeling Zinc Enzymes 
Serge Ruccolo 
 
In chapter 1, I discuss how ligand architecture in tripodal nitrogen-rich ligands can 
drastically affect the structure of zinc complexes featuring these ligands. The synthesis 
and characterization of zinc tris(1-methylimidazol-2-ylthio)methyl ([TitmMe]) and tris(1-
Pribenzimidazol-2-ylthio)methyl ([TitmiPr,benzo]) complexes is presented. The ligand in 
[TitmMe]Zn complexes binds the metal to form carbatrane structures that exhibit 
unusually long and flexible Zn–C bonds. The bonding between the zinc and the carbon 
in these complexes can therefore be more accurately described as a zwitterionic 
interaction between a carbanion and a zinc cation. Density functional theory 
calculations demonstrate that the energy profile for the Zn–C bond is shallow, such that 
large variations of the Zn–C distance result in very little change in the energy of the 
complex. The benzannulated ligand [TitmiPr,benzo] allows access to a rare monomeric zinc 
hydride species [κ3-TitmiPr,benzo]ZnH that can react with either CO2 to produce a zinc 
formate, or B(C6F5)3 to form the ion pair [κ4-TitmiPr,benzo]ZnHB(C6F5)3. The coordination 
chemistry of the [TitmiPr,benzo] ligand also extends to the other metals of group 12. 
 
In chapter 2, I report the use of the [TitmMe] and [TitmiPr,benzo] zinc complexes presented in 
chapter 1 as biomimetic models for zinc enzymes. First, [TitmMe] zinc complexes present 
structural similarities with the active site of carbonic anhydrase, and can be used to 
study the binding of carbonic anhydrase inhibitors to the enzyme active site. Then, [κ4-
TitmiPr,benzo]ZnX (X = MeB(C6F5)3, BPh4) complexes and their interactions with ligands of 
relevance towards antibiotic resistance is reported. The non coordinating nature of the 
anions in [κ4-TitmiPr,benzo]ZnX (X = MeB(C6F5)3, BPh4) lead to the formation of a Lewis acidic 
zinc cationic center, which can be coordinated by an additional ligand of biological 
interest. The binding of simple β-lactams to the [κ4-TitmiPr,benzo]ZnX complexes can be 
probed using X-ray diffraction and Nuclear Magnetic Resonance (NMR) spectroscopy, 
thereby providing a way to model the binding of antibiotics to the active site of the 
metallo-β-lactamases enzymes responsible for broad antibiotic resistance. The binding 
of β-lactams can be compared to larger ring size lactams and linear amides. [κ4-
TitmiPr,benzo]ZnX (X = MeB(C6F5)3, BPh4) also allows for the study of the binding of potential 
metallo-β-lactamases inhibitors, such as, for example, glycinamide, picolinamide, and 
piperazine-2,3-dione. Binding studies between [κ4-TitmiPr,benzo]ZnX and substrates bearing 
structural similarities to antibiotics reveal secondary interactions involving peripheral 
functional groups the cationic zinc center in [κ4-TitmiPr,benzo]ZnX. These studies provide 
guidelines to modify existing antibiotics, in order to decrease their sensitivity to 
metallo-β-lactamases. 
 
In chapter 3, I explore the reactivity of previously characterized tris(2-
pyridylthio)methyl [Tptm] zinc complexes. First, an improved synthesis of [κ4-
Tptm]ZnF using Me3SnF as the fluorinating agent is reported. The fluorine atom in [κ4-
Tptm]ZnF acts as a Lewis base, as illustrated by its reaction with B(C6F5)3 to form [κ4-
Tptm]ZnFB(C6F5)3, in which the fluorine is transferred to the borane group. The fluoride 
ligand in [κ4-Tptm]ZnF also acts as a hydrogen bond and halogen bond acceptor and is 
capable of forming adducts with H2O, indole, and iodopentafluorobenzene. [κ4-
Tptm]ZnF undergoes metathesis with Ph3CCl to form Ph3CF, thereby providing a rare 
example of C–F bond formation promoted by a zinc complex. Then, [κ3-Tptm]ZnH is 
used as a catalyst for the hydrosilylation of aldehydes and ketones using phenylsilane 
to produce tris alkoxysilane products. The catalyst is very active with aldehydes, and 
shows slower reactivity towards dialkyl ketones. The reaction proceeds via insertion of 
the carbonyl group in the Zn–H bond to form a zinc alkoxide, which then undergoes 
metathesis with the silane to generate the desired product and regenerate the zinc 
hydride species. The complicated NMR spectroscopic features of the products resulting 
from the hydrosilylation of prochiral ketones are explained by the presence of different 
diastereomers. Finally, we report that [κ3-Tptm]ZnH is a catalyst for the hydrosilylation 
of silylformates to methoxy silanes with (EtO)3SiH, (MeO)3SiH and κ4-
N(CH2CH2O)3SiOMe. We show that CO2 can be reduced to methoxy silane species in a 
one pot reaction using (MeO)3SiH and catalytic amounts of [κ3-Tptm]ZnH. 
 
In chapter 4, I report the synthesis and characterization of a silicon based analogue of 
[TitmiPr,benzo], namely the tris(1-Pribenzimidazol-2-yldimethylsilyl)methyl [TismiPr,benzo] ligand. 
The ligand possesses unique structural features, due to the proximity between the 
dimethylsilyl groups and the methyl carbanion. The formation of [κ4-TismiPr,benzo]Li 
proceeds via the doubly base stabilized silene intermediate [κ3-C(SiMe2benzimidiPr)2]SiMe2. 
[κ4-TismiPr,benzo]Li can be used as a precursor for copper and nickel [TismiPr,benzo] and [C3-
TismiPr,benzo] complexes, where [C3-TismiPr,benzo] represents the isomerized tris carbene version 
of [TismiPr,benzo]. [κ3-C(SiMe2benzimidiPr)2]SiMe2 reacts with ZnMe2 to produce [κ3-
C(SiMe3)(SiMe2benzimidiPr)2]ZnMe, which can be transformed to the phenoxide 
compound. This compound acts as a catalyst for the hydrosilylation of CO2 to silyl 
formates and methoxy silanes. [κ3-C(SiMe2benzimidiPr)2]SiMe2 itself reacts with CO2 to 
produce an unusual β-lactone. 
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Multidentate ligands are ubiquitous in coordination chemistry. Their high binding 
affinity towards metals through chelating effects, and the variety of coordination 
environments that can be accessed via the combination of different binding groups have 
led to a voluminous amount of complexes with a wide range of applications from 
catalysis to biomimetic models.1 The architecture of the multidentate ligands is 
fundamentally important, as it determines the bonding between the metal and the 
coordinating groups, as well as the geometry around the metal center. In that regard, 
well-designed multidentate ligands have allowed to access unusual complexes with 
unprecedented structures, or enhanced reactivity.2 In this chapter, we discussed how 
subtle changes in the ligand architecture in zinc complexes featuring multidentate 
tripodal, nitrogen-rich ligands lead to profound changes in the structure of the 
corresponding complexes.  
 
1.1.1 Tripodal nitrogen-rich ligands 
Tripodal ligands featuring a nitrogen-rich coordination environment have emerged as a 
major ligand class in inorganic chemistry. One example, the tris(pyrazolyl)hydroborato 
ligand, [TpR,R], first synthesized by Trofimenko,3 was one of the first, and is still to date, 
one of the most widely used tripodal N3 ligands (Figure 1).4 [TpR,R] is classified as an L2X 
donor ligand and is often compared to the cyclopentadienyl fragment. Complexes of 
[TpR,R] have been reported for most elements in the periodic table,4 thus highlighting the 
versatility of the [TpR,R] ligand. The R groups on the pyrazoles can easily be modified to 
tune the steric and electronic properties around the metal center and the boron center, 













Figure 1: Structure of the [TpR,R] ligand 
Tripodal N3 ligands are not limited to the L2X [TpR,R] motif, and many other systems 
have been synthesized, such as, for example, tris(4,4-dimethyl-2-oxazolinyl)-
phenylborate,6 tris(pyrazolyl)methane,7 tris(pyrrolyl)ethane,8 and 
tris(imidazolyl)carbinol.9  
 
In contrast to tripodal N3 ligands, tetradentate tripodal ligands allow for an additional 
interaction between the metal and the bridgehead donor to form an atrane structure 
(Figure 2).10 This change in the architecture of the ligand is not only significant because 
of the different geometry around the metal center, but also because atrane structures 
tend to be more flexible than the [TpR,R] systems. Indeed, the distance between the 
bridgehead donor and the metal in atranes can vary quite significantly depending on 
the geometry around the metal center and the ligand trans to the bridgehead donor.11 
Interestingly, the majority of ligands that form atrane structures contain a neutral L-
type nitrogen atom donor in the bridgehead position,12 such as, for example, the tris(2-












Figure 2: Atrane motif (left) and tris(2-pyridylmethyl)-amine complex (right) 
 
Similarly, the ligand tris(2-benzimidazolylmethyl)amine [Tbma] can be used to access 
atrane structures (Figure 3). The interesting features of the [Tbma] ligand are the large 
variations observed in the bonding between the metal and the bridgehead nitrogen as a 
function of the ligand trans to this particular nitrogen. For example, the Zn-N bond 
length ranges from 2.27 Å to 2.58 Å13,14,15 in [κ4-Tbma]Zn complexes. However, such 
flexibility in the bond length is not surprising for dative bonds, as they tend to be 












Figure 3: Molecular structure of [κ4-Tbma]ZnNCS. 
 
1.1.2 Metallacarbatranes 
Atranes containing a carbon atom at the bridgehead position are much more scarce than 
their nitrogen counterparts, mainly because they require the formation of a reactive 
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carbanion to form the atrane motif. However, the replacement of the bridgehead 
nitrogen with a carbon in the ligand architecture has a significant influence on the 
reactivity of the resulting complexes. The most prominent example of a ligand capable 
of forming metallacarbatranes is the tris(2-pyridylthio)methyl [Tptm] ligand. Although 
complexes have been reported for several first row metals,17 the chemistry of [Tptm] 
zinc complexes has been shown to be particularly rich. Indeed, the [Tptm] ligand 
allowed for the isolation of a monomeric alkyl zinc hydride compound [κ3-Tptm]ZnH,18 
which is an effective catalyst for transformations such as hydrosilylation of aldehydes, 
ketones and carbon dioxide.19,20 In addition, [κ4-Tptm]ZnOC(O)OH has provided a rare 
example of a terminal zinc bicarbonate compound, which is relevant to the mechanism 
of action of carbonic anhydrase (Figure 4).21 An interesting feature of the [Tptm] ligand 
is the ability to vary coordination modes depending on the apical ligand present on the 
zinc. The ligand can bind either in a hypodentate22 κ3 manner, such as in [κ3-
Tptm]ZnMe, [κ3-Tptm]ZnN(SiMe3)2, and [κ3-Tptm]ZnH, or in a κ4 manner, such as in 




















Figure 4: Molecular structure of [κ3-Tptm]ZnH (left) and [κ4-Tptm]ZnOC(O)OH (right) 
 
In contrast to the [Tptm] ligand, there are few reports on the use of the closely related 
imidazole derivative tris(1-methylimidazol-2-ylthio)methyl [TitmMe] ligand. The 
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precursor [TitmMe]H has been reported,24 but apart from one structurally characterized 
silver complex [[TitmMe]HAg](BF4), there has been no report of its use as a ligand 















Figure 5: Molecular structures of [TitmMe]H (left) and [[TitmMe]HAg](BF4) (right) 
 
In view of the interesting reactivity of the various [Tptm] zinc complexes developed in 
the Parkin group, we decided to pursue the synthesis of zinc complexes of the related 
[TitmMe] ligand, in order to determine if the switch from the 6-membered ring pyridine 
group in [Tptm] to the 5-membered ring imidazole group in [TitmMe] would lead to a 
difference in the structure and the reactivity in the corresponding zinc complexes. One 
would not expect major differences between the binding of the two ligands, however, 
we observed that this small change in the ligand architecture has a profound effect on 
the structure of the resulting complexes. 
 
1.2  [TitmMe]Zn complexes 
In this chapter, we report the synthesis and characterization of a variety of zinc 
complexes containing the [TitmMe] ligand. Unlike [Tptm] zinc complexes, [TitmMe] zinc 
complexes exhibit unusually long Zn–C interactions, such that the bonding in these 
complexes is better described as zwitterionic. Density functional theory (DFT) 
calculations established a very shallow energetic profile for the Zn–C bond, such that 
little modification in the energy of the complexes lead to large changes in the Zn–C 
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bond length. The [TitmMe] ligand was also modified to produce a bulkier system 
[TitmPri,benzo], which allows for the isolation of a terminal zinc hydride capable of 
inserting CO2 to produce a formate derivative. Finally, we report that both the [TitmMe] 
and [TitmPri,benzo] can bind a variety of different metals.  
 
1.2.1 Synthesis of [TitmMe]ZnX complexes 
The synthesis of [TitmMe] zinc complexes can be achieved via two synthetic strategies. 
First, the metallation of [TitmMe]H can be achieved by deprotonation of the methine CH 
using a base and a metal precursor. Traditional bases such as n-BuLi readily reacts with 
[TitmMe]H to form [TitmMe]Li, which can be reacted with a zinc salt such as ZnCl2 to 
produce [κ4-TitmMe]ZnCl. However, this strategy is limited by the low solubility of both 
zinc salts and [TitmMe]Li in the solvents of interest that are benzene, Et2O and THF. 
Moreover, the high sensitivity of [TitmMe]Li towards acidic reagents requires strictly 
anhydrous zinc salts, which are often tedious to obtain. Finally, [κ4-TitmMe]ZnCl shows 
very little solubility and reactivity, such that it is not suitable for further 
functionalization through ligand exchange with the chloride. 
 
Alternatively, it is possible to simplify the metallation and reduce the number of steps 
by using reactive zinc complexes. For example, the methyl group of ZnMe2 is 
sufficiently basic to deprotonate the central CH group of [TitmMe]H to form [κ3-
TitmMe]ZnMe in one step. Similar reactivity is observed with Zn[N(SiMe3)2]2, where the 
amide group acts as the base to deprotonate [TitmMe]H and form [κ3-
TitmMe]ZnN(SiMe3)2 and HN(SiMe3)2 (Scheme 1). The volatility of the side product 
generated by these two reactions makes purification of these compounds easier, as it 
























[κ3-TitmMe]ZnMe and [κ3-TitmMe]ZnN(SiMe3)2 are convenient precursors to many 
[TitmMe]ZnX complexes. Indeed, [κ3-TitmMe]ZnMe readily reacts with the acidic proton 
of H–X (X = Br, OSiMe3, OAr, SPh, SePh, OC(O)Ph) to generate the respective 
[TitmMe]ZnX and methane (Scheme 2). Additionally, [κ4-TitmMe]ZnOSiMe3 can react 












































X = Br, OAr, SPh
SePh, OC(O)Ph
Me3SiX






Figure 6. Molecular structures of [κ3-TitmMe]ZnMe (left) and [κ4-TitmMe]ZnCl (right) 
 
1.2.2 Structural characterization of [TitmMe]ZnX complexes 
The molecular structures of most of the [TitmMe]ZnX compounds synthesized in the 
preceeding section have been determined by X-ray diffraction (Figure 6). Interestingly, 
[κ3-TitmMe]ZnMe exhibits a hypodentate κ3 coordination mode similar to that of [κ3-
Tptm]ZnMe and [κ3-Tptm]ZnN(SiMe3)2. 1H NMR spectroscopy studies show that the 
compounds that feature κ3 cordination are fluxional in solution. Specifically, two 
different imidazole signals appear at temperatures below -70°C in a 2:1 ratio for [κ3-
TitmMe]ZnMe, which then merge into one signal at room temperature (Figure 7). 
Interestingly, variable temperature 1H NMR spectroscopic studies indicate that the 
dynamic process is significantly more facile for [κ3-TitmMe]ZnMe than for [κ3-
Tptm]ZnMe. For example, the rate of exchange for [κ3-TitmMe]ZnMe is a factor of ca. 200 




Figure 7: Variable temperature 1H NMR spectroscopy of [κ3-TitmMe]ZnMe (only 
aromatic region shown for clarity). 
 
The other [TitmMe]ZnX compounds structurally characterized exhibit a κ4 coordination 
mode in an approximate trigonal bipyramid geometry. The structures resemble that of 
[κ4-Tptm]ZnX, with a metallacarbatrane motif. However, some major differences can be 
noted between the [TitmMe] and the [Tptm] ligand systems, especially in the distances 
between the zinc center and the bridgehead carbon. For example, the Zn–C bond length 
in [κ4-Tptm]ZnX compounds spans a narrow range of 2.11 to 2.22 Å, whereas the bond 
lengths in [κ4-TitmMe]ZnX are substantially longer and range from 2.44 to 2.68 Å. 
Notably, the Zn–C distances in [κ4-TitmMe]ZnX are 0.43 – 0.67 Å longer than the mean 
Zn–C bond length of 2.01 Å for compounds listed in the CSD. The extent of the 
elongation and the large range of Zn–C observed is especially surprising, since the 
standard deviation of Zn–C bond lengths listed in the CSD is only 0.07 Å. Although 
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variable bond distances between the bridgehead atoms in atrane compounds are not 
unusual, they tend to involve dative bonds rather than covalent bonds. Such a flexibility 
is, however, much more surprising for normal covalent bonds, which tend to be more 
rigid.26 















Br 2.580(2) 1.998 0.93 0.336 0.010 











OSiMe3 2.684(3) 2.012 0.92 0.410 0.009 
OPh 2.646(2) 2.009 0.88 0.367 0.007 
O-p-C6H4Br 2.607(4) 2.002 0.89 0.339 0.020 











O-p-C6H4OMe 2.599(2) 2.010 0.86 0.344 0.012 
O-p-C6H4Me•(HO-
p-C6H4Me) 
2.436(2) 2.027 0.76 0.269 0.012 
OC(O)Ph 2.513(4) 2.017 0.80 0.301 0.041 
SPh 2.564(2) 2.020 0.95 0.345 0.002 
SePh 2.555(3) 2.019 0.98 0.335 0.009 
Table 1. Comparison of Zn–C and Zn–N bond lengths for [TitmMe]ZnX. Δ(out of plane) 





Interestingly, the Zn–C bond length in [κ3-TitmMe]ZnMe [2.166(2) Å] is similar to the 
Zn–C distances observed in the [κ4-Tptm]ZnX complexes, but does not present the 
typical atrane motif. Another interesting illustration of the variability of the Zn–C bond 
distance in [κ4-TitmMe]ZnX is the extent to which the Zn–C bond elongates in [κ4-
TitmMe]ZnOAr (Ar = p-Tol) upon hydrogen bonding of an additional ArOH (Ar = p-Tol) 
molecule to the oxygen of the aryloxy ligand. Indeed, whereas the Zn–O bond 
lengthens only by 0.070 Å upon hydrogen bonding, the Zn–C bond contracts by 0.197 
Å.  
 
In comparison, the Zn–N bond lengths [1.998(2) Å – 2.027(2) Å] in [κ4-TitmMe]ZnX do 
not vary significantly and are similar to those of [κ4-Tptm]ZnX [2.04 – 2.16 Å]. This 
observation suggests that the Zn–N bonds take a greater part in determining the 
structure of [κ4-TitmMe]ZnX compounds than does the Zn–C bond. Indeed, the most 
stable geometry for the [TitmMe] ligand in [κ4-TitmMe]ZnX is a compromise between the 
optimal Zn–N and Zn–C overlap, but the architecture of the [TitmMe] ligand is such that 
optimization of the Zn–N bonds happens at the expense of the Zn–C bond. In 
particular, the geometrical characteristics of the 5-membered ring imidazole are such 
that the nitrogen lone pairs are directed away from the [N3] plane and the carbanion, in 
an ideal C3v geometry for [κ4-TitmMe]ZnX (Figure 8). In fact, in the [κ4-TitmMe]ZnX 
molecular structures, the zinc atoms of [κ4-TitmMe]ZnX are displaced by 0.27 Å to 0.41 Å 
from the respective [N3] plane. As a comparison, the zinc atoms are displaced from the 
[N3] plane by only 0.05 Å to 0.16 Å in [κ4-Tptm]ZnX structures, because the nitrogen 











[Tptm] [TitmMe]  
Figure 8. The different angles associated with the five- and six-membered rings results 
in the nitrogen lone pair orbital being more displaced from the [N3] plane for the 
[TitmMe] system, thereby favoring a longer M–C bond.  
 
The observation that the Zn–C bond is part of a 3-center-4-electrons ω interaction28 
rather than a conventional 2-center-2-electron bond explains the weakness of the Zn–C 
bond and its secondary role in the determination of the structure of [κ4-TitmMe]ZnX 
compounds. Indeed, such axial bonds are often longer than typical covalent bonds. 28,29 
Because of the unusually long and flexible Zn–C bonds observed in [κ4-TitmMe]ZnX, it is 
evident that the Zn–C interaction in [κ4-TitmMe]ZnX cannot be described as a normal 
covalent bond, but rather as a zwitterionic interaction between a formally anionic 
carbon and cationic zinc center (Figure 9).  
 
Zwitterionic compounds featuring a carbanionic center are relatively rare and are 
geometrically constrained to prevent the lone pair from interacting with the metal. For 
example, in the zwitterionic tris(3,5-dimethylpyrazolyl)methyl zinc compounds, 
[C(pzMe2)3]ZnX [X = Me, Cl, N(SiMe3)2],30 the geometry of ligand forces lone pairs on the 
carbon to point directly away from the metal center (Figure 9). In a sense, the carbanion 
and the cationic zinc center in [κ4-TitmMe]ZnX are in a situation that resembles 
Frustrated Lewis pair31 where two Lewis acidic and basic centers are prevented to 






















Figure 9. The two atom linker between carbon and zinc in [C(pzMe2)3]ZnX (left) directs 
the lone pair away from the metal atom, whereas the more flexible three atom linker in 
[TitmMe]ZnX allows the lone pair to point towards the metal atom. 
 
1.2.3 Energetic profile of the Zn–C interaction 
The proper description for the bonding is therefore better described by the two 
zwitterionic structures, [C– Zn+–Cl] and [C–Zn+ Cl–], with a dominant contribution from 
the structure with the negative charge on the carbon atom. Molecular orbital diagram 
calculations also support the zwitterionic description of the bonding in [κ4-TitmMe]ZnCl. 
The three orbitals involved in the 3-center-4-electron interaction are the Cl 3pz, the Zn 
4s, and the sp3 hybdrid on the carbon. The lowest filled orbital resulting from the 
interaction of these three orbitals is largely comprised of the chlorine orbital (Figure 
10c), while the highest occupied orbital is mainly located on the carbon, and contains 
very few percent of the other orbitals, such that it can mainly be described as a spn 
hybrid lone pair orbital (Figure 10a). In comparison, the highest occupied orbital in [κ4-
Tptm]ZnCl is mainly located on the carbon, but contains a greater proportion of the 






Figure 10. The occupied orbitals of the 3c–4e interactions of [TitmMe]ZnCl and 
[Tptm]ZnCl. a)The HOMO of [TitmMe]ZnCl is largely a carbon based spn hybrid lone 
pair orbital. b) The HOMO of [Tptm]ZnCl shows a greater contribution of the zinc. c) 
The Zn–Cl bonding orbital of [TitmMe]ZnCl shows no contribution of the carbon. d) the 
The Zn–Cl bonding orbital of [Tptm]ZnCl shows a greater contribution of the carbon. 
The molecular orbital diagrams were provided by Yi Rong. 
 
The origin of the flexibility of the Zn–C interaction is revealed through density 
functional theory (DFT) calculations. A series of DFT calculations on the [κ4-
TitmMe]ZnCl structure with different Zn–C bond lengths demonstrate that the energy 
surface of the Zn–C bond in [κ4-TitmMe]ZnCl is remarkably shallow, such that the 
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energy of [κ4-TitmMe]ZnCl varies only by small amounts when the Zn–C is stretched or 
contracted (Figure 11). Specifically, the energy of the optimized structure of [κ4-
TitmMe]ZnCl varies only by 0.38 kcal mol–1 when the Zn–C bond is lengthened by 0.2 Å, 
and by 0.41 kcal mol–1 when the Zn–C bond is shortened by 0.2 Å. 
 
Figure 11. Relative energies of [TitmMe]ZnCl, [Tptm]ZnCl and MeZnCl as a function of 
Zn–C distance.  
 
A similar series of DFT calculations has been performed on [κ4-Tptm]ZnCl, and 
revealed that changes in Zn–C bond lengths lead to much larger changes in energy for 
the optimized geometry of [κ4-Tptm]ZnCl. For example, the energy of the molecule 
increases by 1.51 kcal mol–1 upon lengthening of the Zn–C bond by 0.2 Å. In addition, 
the flexibility of the Zn–C bond in MeZnCl was probed using DFT calculations. 
Unsurprisingly, the energy of MeZnCl is much more affected by variations of the Zn–C 
bond in MeZnCl, such that an increase in 0.2 Å raises the energy of the molecule by 3.82 
kcal mol–1 (Figure 11). In that regard, the [TitmMe] ligand system is unique in the sense 
that it allows for very shallow energetic surfaces for the Zn–C bonds, which explains the 
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large differences observed in the Zn–C distances in the different [κ4-TitmMe]ZnX 
structures. 
 
1.3 Synthesis and applications of the bulky [TitmPri,benzo] ligand 
Despite the interesting structural features of the [κ4-TitmMe]ZnX complexes, the 
insolubility of most of the [TitmMe]ZnX compounds limits their use for further 
applications. We therefore decided to modify the [TitmMe] ligand to enable increased 
solubility. By replacing the 1-methylimidazolyl group with 1-i-propyl-1,3-dihydro-2H-
benzimidazole-2-thione, the tris(1-iPrbenzimidazol-2-ylthio)methyl [TitmPri,benzo] ligand 
was produced. In addition to higher solubility, the benzo groups on the 1-i-propyl-1,3-
dihydro-2H-benzimidazole-2-thione provide a protective pocket around the metal 
center.32,33 
 
The [TitmPri,benzo]H precursor synthesis was adapted from literature procedures for the 
synthesis of multidentate alkyl ligands,18,24 using NaH as the base to deprotonate 1-i-
propyl-1,3-dihydro-2H-benzimidazole-2-thione, and CHI3 as the central CH source 
(Scheme 3). Not only is the resulting [TitmPri,benzo]H compound more soluble in common 
organic solvents, it is also easier to purify and isolate than the [TitmMe]H precursor. The 
molecular structure of [TitmPri,benzo]H was determined by X-ray diffraction and is 




Figure 12: Molecular structure of [TitmPri,benzo]H  
 
Reaction of [TitmPri,benzo]H with ZnMe2 afforded the alkyl zinc methyl compound [κ3-
TitmPri,benzo]ZnMe (Scheme 3). X-ray diffraction studies show that the [TitmPri,benzo] ligand 
in [κ3-TitmPri,benzo]ZnMe coordinates in a hypodentate κ3 manner, but is fluxional in 
solution, as observed with [κ3-Tptm]ZnMe and [κ3-TitmMe]ZnMe (Figure 13). Although 
[κ3-TitmPri,benzo]ZnMe is generally less reactive than [κ3-TitmMe]ZnMe towards 
protonation, it reacts with HO-p-C6H4Br to form [κ4-TitmPri,benzo]ZnO-p-C6H4Br. 
Subsequent reaction of [κ4-TitmPri,benzo]ZnO-p-C6H4Br with PhSiH3 generates the zinc 
hydride [κ3-TitmPri,benzo]ZnH (Scheme 4). It is also possible to generate [κ3-
TitmPri,benzo]ZnH in a one pot reaction directly from [κ3-TitmPri,benzo]ZnMe, by treatment of 
one equivalent of HO-p-C6H4Br, followed by addition of PhSiH3 once the evolution of 

























Scheme 3  
 
Figure 13: Molecular structure of [κ3-TitmPri,benzo]ZnMe 
 
The molecular structures of [κ4-TitmPri,benzo]ZnO-p-C6H4Br and [κ3-TitmPri,benzo]ZnH were 
determined by X-ray diffraction, showing κ4 coordination for the aryloxy compound 
and κ3 coordination for the hydride compound (Figure 14 and Figure 16). The Zn–C 
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bond in the metallacarbatrane compound [κ4-TitmPri,benzo]ZnO-p-C6H4Br is longer 
[2.336(3) Å] than those observed in [κ4-Tptm]ZnX compounds. It is, however, 
significantly shorter than the non-benzannulated version [κ4-TitmMe]ZnO-p-C6H4Br 
[2.607(4) Å], which suggests that the benzannulation greatly affects the structure of 
[Titm]ZnX compounds. Analysis of the HOMO of [κ4-TitmPri,benzo]ZnO-p-C6H4Br shows 
that, while the orbital is still mainly a spn hybrid lone pair located on the carbon atom, 
although the percent of carbon in the lone pair (78%) is lower than that of the [TitmMe] 
counterpart (89%) (Figure 15). The shorter Zn–C bonds observed in the κ4 coordinated 
[TitmPri,benzo] compounds may be explained by the steric bulk brought by the benzo 
rings, which cause the [TitmPri,benzo] ligand to distort away from the C3v geometry of the 
[TitmMe] compounds. For example, while the three N-Zn-N angles between the different 
arms of the ligand are almost equal in [κ4-TitmMe]ZnO-p-C6H4Br [116.91°, 117.16°, 
117.49°], they are very different in [κ4-TitmPri,benzo]ZnO-p-C6H4Br [136.60°, 112.87°, 
105.58°]. This deformation of the [TitmPri,benzo] ligand results in a shortening of the 
distance between the zinc center and the plane formed by the nitrogen from 0.339 Å in 
[κ4-TitmMe]ZnO-p-C6H4Br to 0.259 Å in [κ4-TitmPri,benzo]ZnO-p-C6H4Br, and, consequently, 

























































Figure 14: Molecular structure of [κ4-TitmPri,benzo]ZnO-p-C6H4Br. 
 
Figure 15: HOMO in [κ4-TitmPri,benzo]ZnO-p-C6H4Br 
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The hypodentate binding in [κ3-TitmPri,benzo]ZnH is not surprising, as a similar binding 
motif is observed in [κ3-Tptm]ZnH. The Zn–C bond length in [κ3-TitmPri,benzo]ZnH 
[2.152(3) Å] is similar to the Zn–C distances observed in [κ3-TitmMe]ZnMe [2.166(2) Å] 
and in [Tptm]ZnX [2.11 – 2.22 Å]. The Zn–H moiety of [κ3-TitmPri,benzo]ZnH is 
characterized by a bond length of 1.71(3) Å and a chemical shift of δ 5.77, which is 
typical for zinc hydrides.34 [κ3-TitmPri,benzo]ZnH readily inserts CO2 to generate the 
formate compound [κ4-TitmPri,benzo]ZnOC(O)H, which was characterized by X-ray 
diffraction (Figure 17). The Zn–C bond of [κ4-TitmPri,benzo]ZnOC(O)H [2.264(5) Å] is 
shorter than that of [κ4-TitmMe]ZnO-p-C6H4Br, and approaches the values observed in 
[Tptm]ZnX [2.11 – 2.22 Å]. The formate moiety binds to the zinc center in a unidentate 
manner.35 Unlike [κ3-Tptm]ZnH,19 [κ3-TitmPri,benzo]ZnH is not a catalyst for 
hydrosilylation of CO2, as no reaction was observed even at elevated temperatures. It is 
possible that the steric hindrance of the bulky groups prevents the approach of the 




 Figure 16: Molecular structure of [κ3-TitmPri,benzo]ZnH.  
 
Figure 17: Molecular structure of [κ4-TitmPri,benzo]ZnOC(O)H. 
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The hydride reacts with the Lewis acid B(C6F5)3 to generate the ionic compound [κ4-
TitmPri,benzo]ZnHB(C6F5)3. The molecular structure of [κ4-TitmPri,benzo]ZnHB(C6F5)3 was 
determined by X-ray diffraction, and shows the formation of a metallacarbatrane motif 
with a quasi trigonal pyramidal geometry.36 The Zn–C bond length in [κ4-
TitmPri,benzo]ZnHB(C6F5)3 [2.106(3) Å] is closer to the values observed in [κ4-Tptm]ZnX 
[2.11 – 2.22 Å] than in [κ4-TitmPri,benzo]ZnO-p-C6H4Br [2.336(3) Å] and [κ4-TitmMe]ZnX 
[2.44 – 2.68 Å]. The Zn–C bonding interaction in the cation [κ4-TitmPri,benzo]ZnHB(C6F5)3 is 
therefore closer to a covalent Zn–C interaction, as opposed to a zwitterionic Zn–C 
interactions typically observed with the [TitmMe] ligand. The benzannulation of the 
imidazole arms is of primary importance in the formation of such cationic species, as it 
prevents the counterion from interacting with the zinc center by forming a protective 
pocket above the zinc center. Interestingly, the non-benzannulated compounds [κ4-




Figure 18: Molecular structure of [κ4-TitmPri,benzo]ZnHB(C6F5)3. 
 
[κ4-TitmPri,benzo]ZnHB(C6F5)3 has been investigated as a catalyst for the hydrosilylation of 
CO2 with a variety of silanes, unfortunately, no reaction was observed at room 
temperature, and high temperatures led to the decomposition of the cationic 
compounds. 
 
Variable temperature 1H NMR spectroscopic studies show that [κ3-TitmPri,benzo]ZnMe 
and [κ3-TitmPri,benzo]ZnH maintain κ3 coordination in solution, and are fluxional (Figure 
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19). Although such observations are not surprising since [κ3-Tptm]ZnMe, [κ3-Tptm]ZnH 
and [κ3-TitmMe]ZnMe exhibit similar behavior, it is interesting to notice that the rate of 
exchange in [κ3-TitmPri,benzo]ZnMe is the same magnitude as in the [Tptm] compounds, 
and about 200 times slower than the non benzannulated compound [κ3-TitmMe]ZnMe. 
Specifically, the rate of exchange for [κ3-TitmPri,benzo]ZnMe at 20°C is 750 x102 s-1, while 
that of [κ3-TitmMe]ZnMe is 1.5 x105 s-1. The increased size of the benzo arms is a possible 
reason for the slower exchange observed in [κ3-TitmPri,benzo]ZnMe and [κ3-
TitmPri,benzo]ZnH.  
 
Figure 19: Variable temperature 1H NMR spectroscopy of [κ3-TitmPri,benzo]ZnMe (only 
aromatic region shown for clarity). 
 
Surprisingly, NMR spectroscopy shows that [κ4-TitmPri,benzo]ZnOC(O)H is fluxional in 
solution, suggesting κ3 coordination of the [TitmPri,benzo] ligand in solution, despite the 
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fact that the solid state structure of the compound shows the [TitmPri,benzo] ligand binding 
in a κ4 tetradentate manner. In fact, the 1H NMR spectrum of [TitmPri,benzo]ZnOC(O)H at 
low temperature shows the clear presence of both the 2:1 pattern for the benzimidazole 
arms characteristic of κ3 coordination compounds, as well as signals characteristic of the 
κ4 coordination compound (Figure 20). The observation of both κ3 and κ4 coordination 
mode of the [TitmPri,benzo] ligand in the 1H NMR spectrum of [TitmPri,benzo]ZnOC(O)H at 
low temperatures is unprecedented, as variable temperature studies of the related [κ4-
Tptm]ZnOC(O)H show only κ4 coordination even at low temperatures.37 On the other 
hand, variable temperature studies of other fluxional [κ3-Tptm]ZnX (X = H, Me, 
N(SiMe3)2) and [κ3-TitmMe]ZnMe systems shows that the κ3 coordination mode is the 
major species at low temperatures. The coexistence of [κ3-TitmPri,benzo]ZnOC(O)H and [κ4-
TitmPri,benzo]ZnOC(O)H at low temperatures provides insights for the mechanism of 
exchange of the ligand arms in κ3 coordination. 
 
We propose that the general mechanism of exchange of the binding arms in κ3 
tetradentate ligands goes through a first associative step, in which the uncoordinated 
arm binds to the metal center to form the κ4 compound. The second step consists of 
dissociation of one of the arms to reform the κ3 compound (Figure 21). For systems in 
which the κ3 compound is the main species observed, the first coordination step is slow 
and the second decoordination step is fast, such that the κ4 compound does not appear 
in a significant amount in solution. In the case of [TitmPri,benzo]ZnOC(O)H, we propose 




Figure 20: Variable temperature 1H NMR spectroscopy of [TitmPri,benzo]ZnOC(O)H (only 
aromatic region shown for clarity). The minor product labeled corresponds the formate 
peak of the κ4 compound, whereas the major product labeled corresponds the formate 





























Figure 21: Mechanism of exchange between the arms in the κ3 coordination mode. The 
rate of the first step is k1 and the rate of the second step is k2. For systems in which the κ3 
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compound is the only species observed, k1 << k2. For [TitmPri,benzo]ZnOC(O)H, k1 ≈ k2, 
and both κ3 and κ4 compounds are observed in solution 
 
1.4 [Titm] and other group 12 metals 
The reactivity of the [Titm] ligand has also been expanded to the rest of the group 12 
elements. The reactivity of both [TitmMe] and [TitmPri,benzo] with cadmium has been 
investigated extensively by other colleagues in the Parkin group.39 Interestingly, the 
Cd–C bond lengths observed in [κ4-TitmMe]CdX [2.48 Å – 2.63 Å] falls in the same range 
as [κ4-TitmMe]ZnX compounds, suggesting that the bonding interactions between the 
cadmium and the carbon in [κ4-TitmMe]CdX are also best described as zwitterionic. In 
the case of the benzannulated ligand [TitmPri,benzo], Neena Chakrabarti has shown that 
the cadmium methyl compound [κ3-TitmPri,benzo]CdMe can isomerize to [κ4-S3-
TitmPri,benzo]CdMe upon heating at 60°C (Scheme 5). Interestingly, the isomerization of 
[TitmMe]H has been reported at high temperatures in the presence of Lewis acids,24 but in 
the case of [TitmMe]ZnX, the compounds tend to decompose at higher temperatures 






















Scheme 5  
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In the case of mercury, we found that [TitmPri,benzo]H and HgPh2 do not react at room 
temperature but, upon heating, the reaction proceeds smoothly to produce the 
isomerized compound [κ4-S3-TitmPri,benzo]HgPh (Scheme 6). The outcome of the reaction 
is not surprising as HgPh2 can act as the Lewis acid required for the isomerization of the 
[Titm] ligand at elevated temperatures.24 Moreover, it is well established that the 
binding of sulfur groups to alkylmercury compounds results in the activation of Hg–C 
bonds for protolytic cleavage.40 The molecular structure of [κ4-S3-TitmPri,benzo]HgPh was 
determined by X-ray diffraction, confirming the rearrangement of the 
thiobenzimidazole arms (Figure 22). The Hg exhibits a linear coordination environment 
typical for alkylmercury complexes.41 The Hg–CTitm distance in [κ4-S3-TitmPri,benzo]HgPh 
[2.241 Å] is longer than the average Hg–C bond reported in the CSD [2.09 Å], and the 
Hg–S (averaging 2.964 Å) are much longer than the average of 2.55 Å reported in the 
CSD. In that regard, it is more accurate to describe the Hg–S bonds as secondary 
interactions. Therefore, the Hg–C interaction in [κ4-S3-TitmPri,benzo]HgPh is more 
important in determining the structure of the compound than the Hg–S interactions, 
which is the opposite of what is observed in [κ4-TitmMe]ZnX (where the Zn–N 
interactions determine the structure at the expense of the Zn–C bond) and also 





















Figure 22: Molecular structure of [κ4-S3-TitmPri,benzo]HgPh 
 
The reactivity of [TitmMe] and [TitmPri,benzo] is not limited to group 12 elements, and 
reactions between [TitmPri,benzo]H and magnesium compounds are currently underway 




The synthesis and structural characterization of [κ4-TitmMe]ZnX compounds revealed 
unusual bonding features in these complexes. The long and flexible Zn–C bonds 
observed in [κ4-TitmMe]ZnX can be better described as zwitterionic interactions between 
a carbanion an a cationic zinc center. The clear difference in the structures of [κ4-
Tptm]ZnX and [κ4-TitmMe]ZnX originates from the geometrical differences induced by 
switching from a 6 to a 5-membered ring in the ligand binding groups. The energy 
surface of the Zn–C bond in [κ4-TitmMe]ZnCl is very shallow compared to Zn–C bonds 
in [κ4-Tptm]ZnCl and MeZnCl, which explains the flexibility of the Zn–C in [κ4-
TitmMe]ZnX compounds.  
 
The [TitmMe] ligand can be modified to produce the more soluble and bulkier 
[TitmPri,benzo] ligand. The switch to the benzannulated ligand allowed for the isolation of 
a rare monomeric zinc hydride [κ3-TitmPri,benzo]ZnH. The hydride readily inserts CO2 to 
generate a formate compound, and reacts with B(C6F5)3 to form the cationic compound 
[κ4-TitmPri,benzo]ZnHB(C6F5)3. The chemistry of [TitmMe] and [TitmPri,benzo] is not limited to 




1.6 Experimental section 
1.6.1 General Considerations 
All manipulations were performed using a combination of glovebox, high vacuum, and 
Schlenk techniques under a nitrogen or argon atmosphere,44 with the exception of the 
synthesis of [TitmMe]H. Solvents were purified and degassed by standard procedures. 
1H NMR spectra were measured on Bruker 300 DRX, Bruker 400 DRX, and Bruker 
Avance 500 DMX spectrometers. 1H NMR chemical shifts are reported in ppm relative 
to SiMe4 (δ = 0) and were referenced internally with respect to the protio solvent 
impurity (δ 7.16 for C6D5H).45 13C NMR spectra are reported in ppm relative to SiMe4 (δ 
= 0) and were referenced internally with respect to the solvent (δ 128.06 for C6D6). 
Coupling constants are given in hertz. Infrared spectra were recorded on Nicolet Avatar 
370 DTGS spectrometer and are reported in cm-1. Mass spectra were obtained on a 
Micromass Quadrupole-Time-of-Flight mass spectrometer using fast atom 
bombardment (FAB). All chemicals were obtained from Aldrich, with the exception of 
phenol (Acros), hydrobromic acid (Fischer) and dimethylzinc (Strem Chemicals). 
[TitmMe]H,24 and 1-isopropylbenzimidazole46 were synthesized according to literature 
methods.  
 
1.6.2 X-ray Structure Determinations 
X-ray diffraction data were collected on a Bruker Apex II diffractometer. Crystal data, 
data collection and refinement parameters are summarized in Table 2. The structures 
were solved using direct methods and standard difference map techniques, and were 
refined by full-matrix least-squares procedures on F2 with SHELXTL (Version 2014/7).47  
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1.6.3 Computational Details 
Calculations were carried out using DFT as implemented in the Jaguar 7.7 (release 107) 
suite of ab initio quantum chemistry programs.48 Geometry optimizations were 
performed with the B3LYP density functional49 using the 6-31G** (C, H, N, O, Si, S, F, 
Cl) and LAV3P (Br, I, Se and Zn) basis sets.50 The energies of the optimized structures 
were reevaluated by additional single point calculations on each optimized geometry 
using cc-pVTZ(-f)51 correlation consistent triple-ζ (C, H, N, O, Si, S, F, Cl) and LAV3P 
(Br, I, Se Zn) basis sets (Table 3). Molecular orbital analyses were performed with the 
aid of JIMP2,52 which employs Fenske-Hall calculations and visualization using 
MOPLOT.53 
 
1.6.4 Synthesis of [TitmMe]Li 
A suspension of [TitmMe]H (460 mg, 1.30 mmol) in toluene (ca. 5 mL) was cooled to -78° 
and treated dropwise with a solution of n-BuLi (2.5 M in hexanes, 0.55 mL, 1.38 mmol). 
The mixture was allowed to warm to room temperature and stirred for 12 hours. After 
this period, the mixture was filtered and the precipitate was dried in vacuo to give 
[TitmMeLi (450 mg, 96%) as an off white solid. ¹H NMR (C6D6): 6.94 [s, 3H, 
LiC(SC3H2N2Me)3], 6.07 [s, 3H, LiC(SC3H2N2Me)3], 2.54 [s, 9H, LiC(SC3H2N2Me)3]; M/z = 
359.0 [M+1]. 
 
1.6.5 Synthesis of [κ3-TitmMe]ZnMe 
A suspension of [TitmMe]H (800 mg, 2.27 mmol) in toluene (ca. 5 mL) was treated with 
Me2Zn (0.28 mL, 2.72 mmol). The mixture was stirred for 8 hours at room temperature, 
thereby resulting in the evolution of methane and precipitation of a white solid. The 
mixture was filtered and the precipitate was washed with pentane and dried in vacuo to 
give [κ3-TitmMe]ZnMe (770 mg, 79%). Crystals of [κ3-TitmMe]ZnMe suitable for X-ray 
 
 38 
diffraction were obtained by slow evaporation of a solution in benzene. 1H NMR (C6D6): 
7.05 [s, 3H, MeZnC(SC3H2N2Me)3], 5.99 [s, 3H, MeZnC(SC3H2N2Me)3], 2.40 [s, 9H, 
MeZnC(SC3H2N2Me)3], 0.32 [s, 3H, MeZnC(SC3H2N2Me)3]. 13C{1H} NMR (C6D6): 152.21 
[s, MeZnC(SC3H2N2Me)3], 126.70 [s, MeZnC(SC3H2N2Me)3], 122.02 [s, 
MeZnC(SC3H2N2Me)3], 32.00 [s, MeZnC(SC3H2N2Me)3], -15.68 [s, MeZnC(SC3H2N2Me)3], 
not observed [MeZnC(SC3H2N2Me)3]. Anal. calcd. for [TitmMe]ZnMe: C, 38.9%; H, 4.2%; 
N, 19.5%. Found: C, 39.4%; H, 3.9%; N, 18.7%. IR Data: 3126 (w), 3085 (w), 2935 (w), 
2830 (w), 1528 (w), 1472 (m), 1391 (m), 1280 (m), 1235 (w), 1150 (m), 1121 (w), 1084 (w), 
950 (m), 811 (w), 734 (s), 702 (w), 682 (s), 605 (m). Mass spectrum: m/z = 414.9 [M-CH3]. 
 
1.6.6 Synthesis of [κ4-TitmMe]ZnCl 
(a) A suspension of [TitmMe]Li (450 mg, 1.26 mmol) in THF (ca. 5 mL) was treated with 
ZnCl2 (170 mg, 1.25 mmol) and the mixture was stirred for 12 hours at room 
temperature. After this period, the mixture was filtered and the white solid was washed 
with Et2O (5 mL) and dried in vacuo to give [κ4-TitmMe]ZnCl (423 mg, 74%). Crystals of 
[κ4-TitmMe]ZnCl suitable for X-ray diffraction were obtained by slow evaporation of a 
solution in benzene. 1H NMR (C6D6): 8.03 [s, 3H, ClZnC(SC3H2N2Me)3], 5.81 [s, 3H, 
ClZnC(SC3H2N2Me)3], 2.28 [s, 9H, ClZnC(SC3H2N2Me)3], 13C{1H} NMR (C6D6): not 
observed [ClZnC(SC3H2N2Me)3], 122.06 [s, ClZnC(SC3H2N2Me)3], 31.36 [s, 
ClZnC(SC3H2N2Me)3], not observed [ClZnC(SC3H2N2Me)3]. IR Data (cm1) 3415 (w), 3116 
(w), 2868 (w), 1529 (m), 1476 (s), 1423 (m), 1389 (s), 1277 (s), 1151 (s), 1072 (m), 1028 (m), 
953 (s), 915 (w), 845 (w), 747 (s), 732 (s), 698 (s), 680 (vs), 518 (s), 463 (s). Mass spectrum: 
m/z = 452.9 [M+1]. 
(b) A solution of [κ4-TitmMe]ZnOSiMe3 (2.5 mg, 0.005 mmol) in C6D6 (ca. 0.5 mL) in an 
NMR tube equipped with a J. Young valve was treated with Me3SiCl (10 µL, 0.08 mmol). 
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The reaction was monitored by NMR spectroscopy, thereby demonstrating the 
conversion to [κ4-TitmMe]ZnCl over a period of 10 min at room temperature.  
 
1.6.7 Synthesis of [κ4-TitmMe]ZnBr 
(a) A suspension of [κ3-TitmMe]ZnMe (30 mg, 0.07 mmol) in benzene (ca. 2 mL) was 
treated with HBr(aq) (48% m/m, 0.04 mL, 0.07 mmol), thereby resulting in the evolution 
of methane over a period of 30 minutes. After this period, the volatiles were removed in 
vacuo to give [κ4-TitmMe]ZnBr (26 mg, 75%) as an off white solid. Crystals of [κ4-
TitmMe]ZnBr suitable for X-ray diffraction were obtained by slow evaporation from a 
solution in benzene. 1H NMR (C6D6): 8.16 [d, J = 1.6, 3H, BrZnC(SC3H2N2Me)3], 5.78 [d, J 
= 1.7, 3H, BrZnC(SC3H2N2Me)3], 2.25 [s, 9H, BrZnC(SC3H2N2Me)3]. 13C{1H} NMR (C6D6): 
not observed [BrZnC(SC3H2N2Me)3], 121.86 [s, BrZnC(SC3H2N2Me)3], 31.37 [s, 
BrZnC(SC3H2N2Me)3], not observed [BrZnC(SC3H2N2Me)3]. IR Data: 3120 (m), 2957 (w), 
1571 (s), 1484(m), 1367 (w), 1294 (w), 1256 (m), 1232 (w), 1101 (w), 1053 (m), 920 (w), 843 
(w), 810 (w), 755 (vs), 664 (vs), 619 (s). Mass spectrum: m/z = 496.8 [M+1]. 
(b) A suspension of [κ4-TitmMe]ZnOSiMe3 (2.5 mg, 0.005 mmol) in C6D6 (ca. 0.5 mL) in an 
NMR tube equipped with a J. Young valve was treated with Me3SiBr (10 µL, 0.08 
mmol). The reaction was monitored by NMR spectroscopy, thereby demonstrating the 
conversion to [κ4-TitmMe]ZnBr over a period of 10 min at room temperature.  
 
1.6.8 Synthesis of [κ4-TitmMe]ZnI 
A frozen suspension of [κ4-TitmMe]ZnOSiMe3 (10 mg, 0.02 mmol) in benzene (ca. 2 mL) 
was treated with an Me3SiI via vacuum transfer (ca. 20 µL, 0.14 mmol). The mixture was 
allowed to warm up to room temperature and the volatiles were removed in vacuo after 
ca. 15 minutes to give [κ4-TitmMe]ZnI (6 mg, 56%) as a light yellow solid. Crystals of [κ4-
TitmMe]ZnI suitable for X-ray diffraction were obtained by slow evaporation of a 
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solution in benzene. 1H NMR (C6D6): 8.31 [d, J = 1.6 Hz, 3H, IZnC(SC3H2N2Me)3], 5.79 [d, 
J = 1.6 Hz, 3H, IZnC(SC3H2N2Me)3], 2.23 [s, 9H, IZnC(SC3H2N2Me)3]. IR Data (cm-1): 3116 
(w), 2946(w), 1631 (w), 1572 (w) 1530 (w), 1468 (s), 1388 (m), 1278 (m), 1148 (s), 1049 (m), 
953 (m), 818 (m), 749 (vs), 729 (vs), 697 (s), 679 (vs). 
 
1.6.9 Synthesis of [κ4-TitmMe]ZnOSiMe3 
A suspension of [κ3-TitmMe]ZnMe (30 mg, 0.07 mmol) in benzene (ca. 2 mL) was treated 
with Me3SiOH (0.007 mL, 0.07 mmol), thereby resulting in evolution of methane. The 
mixture was shaken periodically until the evolution ceased (ca. 1 hour) and then 
filtered. The white solid was washed with benzene (3 × 1 mL) and dried in vacuo to 
afford [κ4-TitmMe]ZnOSiMe3 (23 mg, 65%). Crystals of [κ4-TitmMe]ZnOSiMe3 suitable for 
X-ray diffraction were obtained by slow evaporation of a solution in benzene. 1H NMR 
(C6D6): 7.72 [d, J = 1.6 Hz, 3H, Me3SiOZnC(SC3H2N2Me)3], 5.89 [d, J = 1.6 Hz, 3H, 
Me3SiOZnC(SC3H2N2Me)3], 2.33 [s, 9H, Me3SiOZnC(SC3H2N2Me)3], 0.81 [s, 9H, 
Me3SiOZnC(SC3H2N2Me)3]. 13C{1H} NMR (C6D6): 152.65 [s, Me3SiOZnC(SC3H2N2Me)3], 
126.99 [s, Me3SiOZnC(SC3H2N2Me)3], 121.81 [s, Me3SiOZnC(SC3H2N2Me)3], 31.40 [s, 
Me3SiOZnC(SC3H2N2Me)3], 5.76 [s, Me3SiOZnC(SC3H2N2Me)3], not observed 
[Me3SiOZnC(SC3H2N2Me)3]. Anal. calcd. for [TitmMe]ZnOTMS: C, 38.0%; H, 4.8%; N, 
16.6%. Found: C, 38.4%; H, 4.7%; N, 16.4%. IR Data (cm-1): 3123 (w), 2944 (m), 1529 (m), 
1476 (s), 1388 (s), 1277 (s), 1235 (s), 1148 (s), 1078 (m), 1053 (vs), 953 (s), 895 (s), 817 (vs), 
748 (vs), 729 (vs), 701 (vs), 679 (vs). 
 
1.6.10 Synthesis of [κ4-TitmMe]ZnOPh 
A stirred suspension of [κ3-TitmMe]ZnMe (150 mg, 0.35 mmol) in toluene (ca. 2 mL) was 
treated with PhOH (32.6 mg, 0.35 mmol), thereby resulting in the evolution of methane. 
Upon cessation of the evolution of methane (ca. 2 hours), the suspension was 
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lyophilized and the solid obtained was washed with pentane (2 mL) and dried in vacuo 
to give [κ4-TitmMe]ZnOPh (131 mg, 73%). Crystals of [κ4-TitmMe]ZnOPh suitable for X-
ray diffraction were obtained by slow evaporation of a solution in benzene. 1H NMR 
(C6D6): 7.59 [d, J = 1.5 Hz, 3H, PhOZnC(SC3H2N2Me)3], 7.56 [dd, J = 8.5, 7.0 Hz, 2H, 
PhOZnC(SC3H2N2Me)3], 7.45 [m, 2H, PhOZnC(SC3H2N2Me)3], 6.92 [tt, J = 7.1, 1.3 Hz, 1H, 
PhOZnC(SC3H2N2Me)3], 5.77 [d, J = 1.6 Hz, 3H, PhOZnC(SC3H2N2Me)3], 2.28 [s, 9H, 
PhOZnC(SC3H2N2Me)3]. 13C{1H} NMR (C6D6): 151.94 [s, PhOZnC(SC3H2N2Me)3], 129.98 
[s, PhOZnC(SC3H2N2Me)3], 122.25 [s, PhOZnC(SC3H2N2Me)3], 120.53 [s, 
PhOZnC(SC3H2N2Me)3], 113.08 [s, PhOZnC(SC3H2N2Me)3], 31.32 [s, 
PhOZnC(SC3H2N2Me)3], not observed [PhOZnC(SC3H2N2Me)3]. IR Data (cm-1): 3124 (w), 
2942 (w), 1589 (s), 1481 (s), 1392 (s), 1310 (m), 1279 (s), 1151 (s), 1070 (w), 993 (w), 954 
(m), 826 (m), 759 (s), 736 (m), 693 (s). 
 
1.6.11 Synthesis of [κ4-TitmMe]ZnOC6H4-p-Me 
A suspension of [κ3-TitmMe]ZnMe (20 mg, 0.046 mmol) in benzene (ca. 2 mL) was treated 
with p-cresol (0.005 mL, 0.048 mmol), thereby resulting in evolution of methane. The 
mixture was filtered upon cessation of the evolution (ca. 30 minutes), and the precipitate 
was washed with benzene (1 mL) and dried in vacuo to give [κ4-TitmMe]ZnOC6H4-p-Me 
as a white solid (18 mg, 74%). Crystals of [κ4-TitmMe]ZnOC6H4-p-Me suitable for X-ray 
diffraction were obtained by slow evaporation from a solution in benzene. 1H NMR 
(C6D6): 7.62 [d, J = 1.6 Hz, 3H, p-MeC6H4OZnC(SC3H2N2Me)3], 7.34 [m , 4H, p-
MeC6H4OZnC(SC3H2N2Me)3], 5.78 [d, J = 1.6 Hz, 3H, p-MeC6H4OZnC(SC3H2N2Me)3], 
2.46 [s, 3H, p-MeC6H4OZnC(SC3H2N2Me)3], 2.28 [s, 9H, p-MeC6H4OZnC(SC3H2N2Me)3]. 
13C{1H} NMR (C6D6): 168.42 [s, p-MeC6H4OZnC(SC3H2N2Me)3], 151.98 [s, p-
MeC6H4OZnC(SC3H2N2Me)3], 130.50 [s, p-MeC6H4OZnC(SC3H2N2Me)3], 122.22 [s, p-
MeC6H4OZnC(SC3H2N2Me)3], 120.15 [s, p-MeC6H4OZnC(SC3H2N2Me)3], 31.33 [s, p-
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MeC6H4OZnC(SC3H2N2Me)3], 21.08 [s, p-MeC6H4OZnC(SC3H2N2Me)3], not observed [p-
MeC6H4OZnC(SC3H2N2Me)3]. IR data (cm-1): 3117 (w), 2924 (w), 1602 (m), 1502 (s), 1477 
(s), 1391 (m), 1302 (s), 1278 (s), 1150 (s), 1086 (w) 955 (m), 753 (s), 730 (s), 700 (s), 681 (s) 
 
1.6.12 Synthesis of [κ4-TitmMe]ZnOC6H4-p-Me•HOC6H4-p-Me 
A suspension of [κ3-TitmMe]ZnMe (30 mg, 0.07 mmol) in benzene (ca. 2 mL) was treated 
with p-cresol (15 mg, 0.14 mmol), thereby resulting in evolution of methane. Upon 
cessation of the evolution after 1h, the mixture lyophilized to give [κ4-TitmMe]ZnOC6H4-
p-Me•HOC6H4-p-Me as a white solid (28 mg, 64%). Crystals of [κ4-TitmMe]ZnOC6H4-p-
Me•HOC6H4-p-Me suitable for X-ray diffraction were obtained by slow evaporation 
from a solution in benzene. 1H NMR (C6D6): 11.65 [bs, 1H, (p-MeC6H4OH)p-
MeC6H4OZnC(SC3H2N2Me)3], 7.60 [d, J = 1.6 Hz, 3H, (p-MeC6H4OH)p-
MeC6H4OZnC(SC3H2N2Me)3], 7.36 [bm , 8H, (p-MeC6H4OH)p-
MeC6H4OZnC(SC3H2N2Me)3], 5.80 [d, J = 1.6 Hz, 3H, (p-MeC6H4OH)p-
MeC6H4OZnC(SC3H2N2Me)3], 2.36 [bs, 6H, (p-MeC6H4OH)p-
MeC6H4OZnC(SC3H2N2Me)3], 2.29 [s, 9H, (p-MeC6H4OH)p-MeC6H4OZnC(SC3H2N2Me)3]. 
13C{1H} NMR (C6D6): 151.81 [s, (p-MeC6H4OH)p-MeC6H4OZnC(SC3H2N2Me)3], 130.43 [s, 
(p-MeC6H4OH)p-MeC6H4OZnC(SC3H2N2Me)3], 122.34 [s, (p-MeC6H4OH)p-
MeC6H4OZnC(SC3H2N2Me)3], 31.34 [s, (p-MeC6H4OH)p-MeC6H4OZnC(SC3H2N2Me)3], 
not observed [(HOC6H4-p-Me)p-Me-C6H4OZnC(SC3H2N2Me)3]. 
 
1.6.13 Synthesis of [κ4-TitmMe]ZnOC6H4-p-Br 
A suspension of [κ3-TitmMe]ZnMe (20 mg, 0.046 mmol) in benzene (ca. 2 mL) was treated 
with para-bromophenol (8 mg, 0.046 mmol), thereby resulting in evolution of methane. 
The mixture was filtered upon cessation of the evolution (ca. 30 minutes) and the 
precipiate was washed with benzene (1 mL) and dried in vacuo to give [κ4-
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TitmMe]ZnOC6H4-p-Br as a white solid (17 mg, 62%). Crystals of [κ4-TitmMe]ZnOC6H4-p-
Br suitable for X-ray diffraction were obtained from slow evaporation from benzene. 1H 
NMR (C6D6): 7.38 [d, J = 1.6 Hz, 3H, p-BrC6H4OZnC(SC3H2N2Me)3], 7.21 [broad, 2H, p-
BrC6H4OZnC(SC3H2N2Me)3], 6.61 [broad, 2H, p-BrC6H4OZnC(SC3H2N2Me)3], 5.74 [s, J = 
1.6 Hz, 3H, p-BrC6H4OZnC(SC3H2N2Me)3], 2.24 [s, 9H, p-BrC6H4OZnC(SC3H2N2Me)3]. 
13C{1H} NMR (C6D6): 151.51 [s, p-BrC6H4OZnC(SC3H2N2Me)3], 132.63 [s, p-
BrC6H4OZnC(SC3H2N2Me)3], 127.42 [s, p-BrC6H4OZnC(SC3H2N2Me)3], 122.66 [s, p-
BrC6H4OZnC(SC3H2N2Me)3], 31.38 [s, p-BrC6H4OZnC(SC3H2N2Me)3], not observed [p-
BrC6H4OZnC(SC3H2N2Me)3]. Anal. calcd. for [TitmMe]ZnOC6H4-p-Br•0.33(C6H6): C, 
41.0%; H, 3.4%; N, 13.7%. Found: C, 41.3%; H, 3.4%; N, 13.4%. IR Data (cm-1) 1576 (m), 
1480 (vs), 1394 (m), 1261 (s), 1162 (m), 1068 (s), 826 (vs), 734 (m), 690 (m), 625 (s). Mass 
spectrum: m/z = 589.0 [M+1]. 
 
1.6.14 Synthesis of [κ4-TitmMe]ZnOC6H4-p-OMe 
A suspension of [κ3-TitmMe]ZnMe (20 mg, 0.046 mmol) in benzene (ca. 2 mL) was treated 
with para-methoxyphenol (5.7 mg, 0.046 mmol), thereby resulting in evolution of 
methane. The mixture was filtered upon cessation of the evolution (ca. 30 minutes), and 
the precipitate obtained was washed with benzene (1 mL) and dried in vacuo to give [κ4- 
TitmMe]ZnOC6H4-p-OMe as a white solid (14 mg, 56%). Crystals of [κ4-TitmMe]ZnOC6H4-
p-OMe suitable for X-ray diffraction were obtained from slow evaporation from 
benzene. 1H NMR (C6D6): 7.62 [d, J = 1.6 Hz, 3H, p-OMeC6H4O(SC3H2N2Me)3], 7.36 [m, 
4H, p-OMeC6H4OZnC(SC3H2N2Me)3], 5.78 [d, J = 1.6 Hz, 3H, p-
OMeC6H4OZnC(SC3H2N2Me)3], 3.64 [s, 3H, p-OMeC6H4OZnC(SC3H2N2Me)3], 2.28 [s, 9H, 
p-OMeC6H4OZnC(SC3H2N2Me)3]. 13C{1H} NMR (C6D6): 152.00 [s, p-
OMeC6H4OZnC(SC3H2N2Me)3], 122.28 [s, p-OMeC6H4OZnC(SC3H2N2Me)3], 119.99 [s, p-
OMeC6H4OZnC(SC3H2N2Me)3], 115.91 [s, p-OMeC6H4OZnC(SC3H2N2Me)3], 56.08 [s, p-
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OMeC6H4OZnC(SC3H2N2Me)3], 31.36 [s, p-OMeC6H4OZnC(SC3H2N2Me)3), not observed 
[s, (p-OMe)PhOZnC(SC3H2N2Me)3]. IR Data (cm-1) 1501 (s), 1460 (m), 1393 (m), 1227 (s), 
1034 (s), 828 (s), 749 (s). 
 
1.6.15 Synthesis of [κ4-TitmMe]ZnOC6H4-p-NO2 
A suspension of [κ3-TitmMe]ZnMe (20 mg, 0.046 mmol) in benzene (ca. 2 mL) was treated 
with para-nitrophenol (6.5 mg, 0.046 mmol), thereby resulting in evolution of methane. 
The mixture was filtered upon cessation of the evolution (ca. 10 minutes) and the 
precipitate obtained was washed with benzene (1 mL) and dried in vacuo to give [κ4-
TitmMe]ZnOC6H4-p-NO2 (23 mg, 90%) as a yellow solid. Crystals of [κ4-TitmMe]ZnOC6H4-
p-NO2 suitable for X-ray diffraction were obtained by slow evaporation of a solution in 
benzene. 1H NMR (C6D6): 8.54 [d, J = 9.3 Hz, 2H, p-NO2C6H4OZnC(SC3H2N2Me)3], 7.26 
[d, J = 1.6 Hz, 3H, p-NO2C6H4OZnC(SC3H2N2Me)3], 6.94 [d, J = 9.3 Hz, 2H, p-
NO2C6H4OZnC(SC3H2N2Me)3], 5.79 [d, J = 1.6 Hz, 3H, p-NO2C6H4OZnC(SC3H2N2Me)3], 
2.27 [s, 9H, p-NO2C6H4OZnC(SC3H2N2Me)3]. 13C{1H} NMR (C6D6): 177.40 [s, p-
NO2C6H4OZnC(SC3H2N2Me)3], 151.52 [s, p-NO2C6H4OZnC(SC3H2N2Me)3], 135.82 [s, p-
NO2C6H4OZnC(SC3H2N2Me)3], 127.61 [s, p-NO2C6H4OZnC(SC3H2N2Me)3], 127.03 [s, p-
NO2C6H4OZnC(SC3H2N2Me)3], 122.72 [s, p-NO2C6H4OZnC(SC3H2N2Me)3], 119.55 [s, p-
NO2C6H4OZnC(SC3H2N2Me)3], 31.40 [s, p-NO2C6H4OZnC(SC3H2N2Me)3], not observed 
[p-NO2C6H4OZnC(SC3H2N2Me)3]. IR Data (cm-1) 3127 (w), 2938 (w), 1582 (s), 1476 (s), 
1392 (m), 1298 (vs), 1152 (m), 1108 (s), 954 (m), 851 (m), 735 (s), 702 (s), 682 (s), 646 (s). 
Mass spectrum: m/z = 554.1 [M+1]. 
 
1.6.16 Synthesis of [κ4-TitmMe]ZnSPh  
A suspension of [κ3-TitmMe]ZnMe (20 mg, 0.046 mmol) in benzene (ca. 2 mL) was treated 
with PhSH (0.005 mL, 0.049 mmol), thereby resulting in evolution of methane. The 
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solution was decanted after cessation of the evolution (ca. 10 minutes) to give [κ4-
TitmMe]ZnSPh as a white solid that was dried in vacuo (15 mg, 62%). Crystals of [κ4-
TitmMe]ZnSPh suitable for X-ray diffraction were obtained by slow evaporation of a 
solution in benzene. 1H NMR (C6D6): ¹H NMR (C6D6): 8.09 [d, J = 7.7 Hz, 2H, 
PhSZnC(SC3H2N2Me)3], 7.64 [d, J = 1.6 Hz, 2H, PhSZnC(SC3H2N2Me)3], 7.41 [m, 1H, 
PhSZnC(SC3H2N2Me)3], 7.02 [m, 2H, PhSZnC(SC3H2N2Me)3], 5.75 [d, 1.6 Hz, 3H, 
PhSZnC(SC3H2N2Me)3], 2.29 [s, 9H, PhSZnC(SC3H2N2Me)3]. Mass spectrum: m/z = 525.1 
[M+1]. 
 
1.6.17 Synthesis of κ⁴-[TitmMe]ZnSePh 
A suspension of [κ³-TitmMe]ZnMe (20 mg, 0.046 mmol) in benzene (ca. 2 mL) was treated 
with PhSeH (0.005 mL, 0.047 mmol), thereby resulting in evolution of methane. The 
solution was decanted after cessation of the evolution (ca. 10 minutes) to give [κ⁴-
TitmMe]ZnSePh as a white solid that was dried in vacuo (16 mg, 60%). Crystals of [κ⁴-
TitmMe]ZnSePh suitable for X-ray diffraction were obtained by slow evaporation of a 
solution in benzene. 1H NMR (C6D6): 8.06 [bs, 3H, PhSeZnC(SC3H2N2Me)3], 7.02 - 7.51 
[m, 5H, PhSeZnC(SC3H2N2Me)3], 6.25 [bs, 3H, PhSeZnC(SC3H2N2Me)3], 2.11 [s, 9H, 
PhSeZnC(SC3H2N2Me)3]. Mass spectrum: m/z = 572.8 [M+1].  
 
1.6.18 Synthesis of [TitmMe]ZnOC(O)Ph A suspension of [κ3-TitmMe]ZnMe (11 mg, 
0.025 mmol) in benzene (ca. 2 mL) was treated with benzoic acid (3.1 mg, 0.025 mmol), 
thereby resulting in evolution of methane. The mixture was filtered after cessation of 
the evolution (ca. 10 minutes) and the precipitate was washed with benzene (1 mL) to 
give [κ4-TitmMe]ZnOCOPh as a yellow solid which was dried in vacuo (12 mg, 88%). 
Crystals of [κ4-TitmMe]ZnOC(O)Ph suitable for X-ray diffraction were obtained by slow 
evaporation from a solution in benzene. 1H NMR (C6D6): 9.0 [bs, 2H, 
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PhOC(O)ZnC(SC3H2N2Me)3], 7.88 [d, J = 1.5 Hz, 2H, PhOC(O)ZnC(SC3H2N2Me)3], 7.43 
(m, 2H, PhOC(O)ZnC(SC3H2N2Me)3], 7.34 [m, 1H, PhOC(O)ZnC(SC3H2N2Me)3], 5.85 [d, 
J = 1.6 Hz, 3H, PhOC(O)ZnC(SC3H2N2Me)3], 2.30 [s, 9H, PhOC(O)ZnC(SC3H2N2Me)3]. IR 
Data (cm-1): 3123 (w), 3092 (w), 2939 (w), 1610 (m), 1571 (m), 1458 (m), 1369 (s), 1281 (m), 
1234 (w), 1150 (m), 953 (m), 810 (m), 723 (s), 680 (s). 
 
1.6.19 Synthesis of [κ4-TitmMe]ZnNCO 
A suspension of [κ4-Titm]ZnOSiMe3 (2.5 mg, 0.005 mmol) in C6D6 (ca. 0.5 mL) in an 
NMR tube equipped with a J. Young valve was treated with Me3SiNCO (0.7 µL, 0.005 
mmol). The reaction was monitored by NMR spectroscopy, thereby demonstrating the 
conversion to [κ4-TitmMe]ZnNCO over a period of 10 min at room temperature.  
1.6.20 Synthesis of [TitmMe]ZnH  
A suspension of [κ4-TitmMe]ZnOSiMe3 (20 mg, 0.04 mmol) in benzene (ca. 2 mL) was 
treated with an excess of PhSiH3. The mixture was allowed to react for 30 min, then the 
mother liquor was decanted, and the white solid was lyophilized (11mg, 66%). 1H NMR 
(C6D6): 5.94 [d, J = 1.6, 3H, HZnC(SC3H2N2Me)3], 5.52 [s, 1H, HZnC(SC3H2N2Me)3], 2.38 
[s, 9H, HZnC(SC3H2N2Me)3]. 13C{1H} NMR (C6D6): not observed [HZnC(SC3H2N2Me)3], 
127.1 [s, HZnC(SC3H2N2Me)3], 121.9 [s, HZnC(SC3H2N2Me)3], 31.9 [s, 
HZnC(SC3H2N2Me)3], not observed [HZnC(SC3H2N2Me)3]. 
 
1.6.21 Methanolysis of PhSiH3 catalyzed by [κ4-TitmMe]ZnOSiMe3  
A suspension of [κ4-TitmMe]ZnOSiMe3 (0.5 mg, 0.001 mmol, 0.007 mol% per Si-H bond) 
in C6D6 (ca. 5 mL) was treated with PhSiH3 (500 mg, 4.63 mmol). The reaction was 
stirred for 10 min, after which MeOH (0.57 mL, 14 mmol) was added and the rapid 
evolution of hydrogen was measured volumetrically via displacement of water from an 
inverted measuring cylinder. After 58 seconds, 95% of the Si-H bond reacted (TOF = 
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8.21 × 105 h-1). After 5 min, the reaction was complete (TOF = 1.67 × 105 h-1 for the overall 
reaction). 
 
1.6.22 Synthesis of 1-isopropyl-1,3-dihydrobenzimidazole-2-thione  
A solution of 1-isopropylbenzimidazole (1.35 g, 8.4 mmol) in THF (20 mL) was cooled 
down to -78°C and was treated with n-BuLi (5,25 mL, 1.6 M in hexanes). The mixture 
was stirred for 1h at -78°C, and then sulfur powder (400mg, 12.5 mmol) was added at 
low temperature. The solution was allowed to warm up to room temperature and was 
stirred for 3h. The reaction was quenched with H2O, and the organic phase was 
extracted in CH2Cl2 (50 mL). The organic phase was washed with an NH4Cl saturated 
aqueous solution (3x50 mL), and then dried with MgSO4 and the solvents were 
evacuated in vacuo. The oily residue was redissolved in 10 mL of acetone, and 50 mL of 
hexanes was added. The supernatant was isolated and allowed to stand for 2 days, 
during which the compound crystallized. The crystals were filtered and washed with 
hexanes to afford 1-isopropyl-1,3-dihydrobenzimidazole-2-thione (1g, 62%) as 
yellow/orange crystals. 1H NMR: 1.61 [d, J = 7.1 Hz, 6H, C6H4NCH(CH3)2NHCS], 5.59 
[sept, J = 7.1 Hz, 1H, C6H4NCH(CH3)2NHCS], 7.2 [m, 3H, C6H4NCH(CH3)2NHCS], 7.42 
[m, 1H, C6H4NCH(CH3)2NHCS], 10.21 [s, 1H, C6H4NCH(CH3)2NHCS]. 
 
1.6.23 Synthesis of [TitmPri,benzo]H  
A brown solution of 1-isopropyl-1,3-dihydrobenzimidazole-2-thione (7.8 g, 40 mmol) in 
THF (40 mL) was slowly added to a cold (0°C) suspension of NaH (1.16 g, 48 mmol) in 
THF (40 mL). Once the evolution of H2 was over, the mixture was allowed to warm up 
to room temperature and stirred for an additional hour. The suspension was cooled 
back down to 0°C, and then CHI3 (5.25 g, 13.3 mmol) was slowly added. A large amount 
of white solid precipitates out in a few minutes, and the reaction was left stirring for 1h 
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at room temperature. 10 mL of methanol were added slowly to quench the unreacted 
NaH. The solution was washed with a saturated ammonium chloride solution, and 
extracted in dichloromethane. The organic phase was dried over NaSO4 and the solvent 
was evaporated in vacuo. The remaining brown oil was triturated with 10 mL of THF. A 
white precipitate quickly formed, which was isolated by filtration and washed with 
cold THF. The solid was dried in vacuo for 12h to give pure [TitmPri,benzo]H (1.9 g, 24% 
yield). A second batch of crystals was isolated after a week of evaporation at room 
temperature from the previous mother liquor (450 mg, total yield 30%). X-ray quality 
crystals were obtained by recrystallization from THF. 1H NMR (C6D6, 400 MHz): 1.61 [d, 
J = 7.0 Hz, 18H, (C6H4N2CH(CH3)2CS)3CH], 4.94 [sept, J = 7.0 Hz, 3H, 
(C6H4N2CH(CH3)2CS)3CH], 7.22 [dd, J = 6.1, 3.2 Hz, (C6H4N2CH(CH3)2CS)3CH], 7.50 [m, 
3H, (C6H4N2CH(CH3)2CS)3CH], 7.58 [s,1H , (C6H4N2CH(CH3)2CS)3CH], 7.69 [bm, 3H, 
(C6H4N2CH(CH3)2CS)3CH]. Anal. calc. for [TitmPri,benzo]H : C, 63.5%; H, 5.8%; N, 14.3%. 
Found: C, 63.4%; H, 5.8%; N, 14.1%. 
 
1.6.24 Synthesis of [κ3-TitmPri,benzo]ZnMe  
A suspension of [TitmPri,benzo]H (500 mg, 0.84 mmol) in toluene (ca. 10 mL) was treated 
with ZnMe2 (126 mg, 1.26 mmol). The white mixture was stirred until the evolution of 
methane was over and was allowed to stand at -17°C overnight. The resulting 
suspension was filtered, and the white solid was washed with pentane, then dried in 
vacuo to give [κ3-TitmPri,benzo]ZnMe (558 mg, 99%). Crystals of [κ3-TitmPri,benzo]ZnMe 
suitable for X-ray diffraction were obtained by slow evaporation of a saturated benzene 
solution. 1H NMR (C6D6) 0.55 [s, 3H, (C6H4N2CH(CH3)2CS)3CZnCH3], 0.87 [bs, 18H, 
(C6H4N2CH(CH3)2CS)3CZnCH3], 4.06 [bs, 3H, (C6H4N2CH(CH3)2CS)3CZnCH3], 6.93 [bs, 
6H, (C6H4N2CH(CH3)2CS)3CZnCH3], 8.08 [bs, 3H, (C6H4N2CH(CH3)2CS)3CZnCH3]. 1H 
NMR (Tol-d8, 330K): 0.26 [m, 3H, (C6H4N2CH(CH3)2CS)3CZnCH3], 1.00 [d, J = 6.6 Hz, 
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18H, (C6H4N2CH(CH3)2CS)3CZnCH3], 4.13 [sept, J = 6.7 Hz, 3H, 
(C6H4N2CH(CH3)2CS)3CZnCH3], 6.96 [m, 6H, (C6H4N2CH(CH3)2CS)3CZnCH3], 7.09 [m, 
6H, (C6H4N2CH(CH3)2CS)3CZnCH3], 7.94 [m, 3H, (C6H4N2CH(CH3)2CS)3CZnCH3]. 13C 
NMR (Tol-d8, 330K): -15.74 [1C, C6H4N2CH(CH3)2CS)3CZnCH3], 49.42 [3C, 
C6H4N2CH(CH3)2CS)3CZnCH3], 111.14 [3C, C6H4N2CH(CH3)2CS)3CZnCH3], 117.77 [3C, 
C6H4N2CH(CH3)2CS)3CZnCH3], 121.52 [3C, C6H4N2CH(CH3)2CS)3CZnCH3], 122.32 [3C, 
C6H4N2CH(CH3)2CS)3CZnCH3], 136.09 [3C, C6H4N2CH(CH3)2CS)3CZnCH3]. Anal. calc. 
for [κ3-TitmPri,benzo]ZnMe•0.33C6H6 : C, 59.0%; H, 5.5%; N, 12.1%. Found: C, 59.3%; H, 
5.5%; N, 12.5%. 
 
1.6.25 Synthesis of [κ4-TitmPri,benzo]ZnO-p-C6H4Br  
para-Bromophenol (13 mg, 0.075) was added to a suspension of [κ3-TitmPri,benzo]ZnMe (50 
mg, 0.075 mmol) in toluene (ca. 2 mL). Instantaneous evolution of methane was 
observed, the mixture was shaken until it became homogeneous. The mixture was 
filtered and was allowed to stand at -17°C overnight, while the compound crystallized. 
The mother liquor was decanted and the white crystals were washed with pentane and 
dried in vacuo to afford [κ4-TitmPri,benzo]ZnO-p-C6H4Br (37 mg, 60 %). Crystals of [κ4-
TitmPri,benzo]ZnO-p-C6H4Br suitable for X-ray diffraction were obtained by vapor 
diffusion of pentane into a saturated benzene solution. 1H NMR (C6D6): 0.90 [d, J = 6.9 
Hz, 18H, (C6H4N2CH(CH3)2CS)3CZnOC6H4Br], 4.12 [sept, J = 6.9 Hz, 3H, 
(C6H4N2CH(CH3)2CS)3CZnOC6H4Br], 6.77 [m, 6H, (C6H4N2CH(CH3)2CS)3CZnOC6H4Br], 
7.03 [d, J = 7.95 Hz, 2H, (C6H4N2CH(CH3)2CS)3CZnOC6H4Br], 7.10 [m, 6H, 




1.6.26 Synthesis of [κ3-TitmPri,benzo]ZnH 
 para-Bromophenol (100 mg, 0.58 mmol) was added to a suspension of [κ3-
TitmPri,benzo]ZnMe (315 mg, 0.47 mmol) in toluene (ca. 3 mL). Instantaneous evolution of 
methane was observed. The mixture was shaken until it became homogeneous, and was 
stirred until the bubbling was over. Phenylsilane (30 mg, 0.27 mmol) was added under 
vigorous stirring, resulting in the quick precipitation of a white solid. The suspension 
was allowed to stand at -17°C overnight and filtered. The white solid was washed with 
benzene (ca. 1 mL) and dried in vacuo to afford [κ3-TitmPri,benzo]ZnH (140 mg, 44%). 
Crystals suitable for X-ray. 1H NMR (C6D6): 0.90 [bs, 18H, (C6H4N2CH(CH3)2CS)3CZnH], 
4.05 [bs, 3H, (C6H4N2CH(CH3)2CS)3CZnH], 5.77 [s, 1H, (C6H4N2CH(CH3)2CS)3CZnH], 
6.94 [bs, 6H, (C6H4N2CH(CH3)2CS)3CZnH], 7.12 [m, 3H, (C6H4N2CH(CH3)2CS)3CZnH], 
8.10 [d, J = 8 Hz, 3H, (C6H4N2CH(CH3)2CS)3CZnH]. 1H NMR (Tol-d8, 330K): 0.98 [d, J = 
6.9 Hz, 18H, (C6H4N2CH(CH3)2CS)3CZnH], 4.09 [sept, J = 7.0 Hz, 3H, 
(C6H4N2CH(CH3)2CS)3CZnH], 5.44 [s, 1H, (C6H4N2CH(CH3)2CS)3CZnH], 6.95 [m, 9H, 
(C6H4N2CH(CH3)2CS)3CZnH], 7.96 [d, J = 8.1 Hz, 3H, (C6H4N2CH(CH3)2CS)3CZnH]. 13C 
NMR (Tol-d8, 330K): 49.46 [3C, C6H4N2CH(CH3)2CS)3CZnH], 111.12 [3C, 
C6H4N2CH(CH3)2CS)3CZnH], 117.99 [3C, C6H4N2CH(CH3)2CS)3CZnH], 121.56 [3C, 
C6H4N2CH(CH3)2CS)3CZnH], 122.38 [3C, C6H4N2CH(CH3)2CS)3CZnH], 135.95 [3C, 
C6H4N2CH(CH3)2CS)3CZnH]. Anal. calc. for [κ3-TitmPri,benzo]ZnH•1.17C6H6 : C, 61.4%; H, 
5.6%; N, 11.3%. Found: C, 61.3%; H, 5.4%; N, 11.1%. 
 
 
1.6.27 Synthesis of [κ4-TitmPri,benzo]ZnOC(O)H  
A suspension of [κ3-TitmPri,benzo]ZnH (10 mg, 0.02 mmol) in C6D6 (ca. 0.5 mL) in an NMR 
tube equipped with a J. Young valve was treated with CO2 (1 atm) resulting in the 
dissolution of the [κ3-TitmPri,benzo]ZnH. After 10 minutes, a white solid precipitated from 
the clear solution. The solid was filtered and washed with pentane (ca. 0.5 mL) and 
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dried in vacuo to afford [κ4-TitmPri,benzo]ZnOC(O)H (5.2 mg, 37%) as a white solid. 1H 
NMR (C6D6, 320 K): 0.93 [d, J = 6.9 Hz, 18H, (C6H4N2CH(CH3)2CS)3CZnOC(O)H], 4.10 
[sept, J = 7.0 Hz, 3H, (C6H4N2CH(CH3)2CS)3CZnOC(O)H], 6.92 [bs, 6H, 
(C6H4N2CH(CH3)2CS)3CZnOC(O)H], 8.78 [bs, 3H, (C6H4N2CH(CH3)2CS)3CZnOC(O)H], 
9.12 [s, 1H, (C6H4N2CH(CH3)2CS)3CZnOC(O)H]. 13C NMR (C6D6, 320K): 20.40 [6C, 
C6H4N2CH(CH3)2CS)3CZnOC(O)H], 49.20 [6C, C6H4N2CH(CH3)2CS)3CZnOC(O)H], 
111.10 [3C, C6H4N2CH(CH3)2CS)3CZnOC(O)H], 119.32 [3C, 
C6H4N2CH(CH3)2CS)3CZnOC(O)H], 122.05 [3C, C6H4N2CH(CH3)2CS)3CZnOC(O)H], 
122.94 [3C, C6H4N2CH(CH3)2CS)3CZnOC(O)H], 124.88 [3C, 
C6H4N2CH(CH3)2CS)3CZnOC(O)H], 136.10 [3C, C6H4N2CH(CH3)2CS)3CZnOC(O)H], 
170.12 [1C, C6H4N2CH(CH3)2CS)3CZnOC(O)H]. IR Data (cm-1): 2980 (w), 2935 (w) 2791 
(w), 1618 (s), 1445 (s), 1408 (s), 1354 (s), 1286 (s), 1135 (m), 1066 (w), 1014 (w), 927 (w), 
745 (vs), 640 (w). 
 
1.6.28 Synthesis of [κ4-TitmPri,benzo]Zn(HB(C6F5)3) 
B(C6F5)3 (15 mg, 0.03 mmol) was added to a suspension of [κ3-TitmPri,benzo]ZnH (20 mg, 
0.03 mmol) in benzene (ca. 2 mL). The mixture was stirred until it became 
homogeneous, and was allowed to sit overnight. During this period, the compound 
crystallized out of the solution as white crystals. The mother liquor was removed and 
the crystals were washed with pentane to afford pure [κ4-TitmPri,benzo]Zn(HB(C6F5)3) (33 
mg, 94%). The crystals as obtained from the reaction were suitable for X-Ray diffraction. 
1H NMR (CD2Cl2) 1.62 [d, J = 6.9 Hz, 18H, (C6H4N2CH(CH3)2CS)3CZnHB(C6F5)3], 4.54 
[sept, J = 6.9 Hz, 3H, (C6H4N2CH(CH3)2CS)3CZnHB(C6F5)3], 7.33 [m, 3H, 
(C6H4N2CH(CH3)2CS)3CZnHB(C6F5)3], 7.43 [m, 3H, (C6H4N2CH(CH3)2CS)3CZnHB(C6F5)3], 
7.55 [d, J = 8.2 Hz, 3H (C6H4N2CH(CH3)2CS)3CZnHB(C6F5)3], 7.76 [d, J = 8 Hz, 3H, 
(C6H4N2CH(CH3)2CS)3CZnHB(C6F5)3] 13C NMR (CD2Cl2) 20.33 [6C, 
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(C6H4N2CH(CH3)2CS)3CZnHB(C6F5)3], 50.86 [3C, (C6H4N2CH(CH3)2CS)3CZnHB(C6F5)3], 
112.33 [3C, (C6H4N2CH(CH3)2CS)3CZnHB(C6F5)3], 115.25 [3C, 
(C6H4N2CH(CH3)2CS)3CZnHB(C6F5)3], 123.56 [3C, (C6H4N2CH(CH3)2CS)3CZnHB(C6F5)3], 
124.13 [3C, (C6H4N2CH(CH3)2CS)3CZnHB(C6F5)3], 134.96 [3C, 
(C6H4N2CH(CH3)2CS)3CZnHB(C6F5)3],  
138.35 [3C, (C6H4N2CH(CH3)2CS)3CZnHB(C6F5)3], 160.86 [3C, 
(C6H4N2CH(CH3)2CS)3CZnHB(C6F5)3] . 19F NMR (CD2Cl2) -167.82 [m, 
(C6H4N2CH(CH3)2CS)3CZnHB(C6F5)3], -164.99 [m, (C6H4N2CH(CH3)2CS)3CZnHB(C6F5)3], 
-134.05 [m, (C6H4N2CH(CH3)2CS)3CZnHB(C6F5)3]. 11B NMR (CD2Cl2) -25.47 [d, J = 92.2 
Hz, (C6H4N2CH(CH3)2CS)3CZnHB(C6F5)3]. Anal. calc. for [κ4-
TitmPri,benzo]Zn(HB(C6F5)3)•1.5 C6H6: C, 54.4%; H, 3.4%; N, 6.6%. Found: C, 54.1%; H, 
3.1%; N, 6.4%. 
 
1.6.29 Synthesis of [κ4-S3-TitmPri,benzo]HgPh 
[TitmPri,benzo]H (50 mg, 0.084 mmol) was suspended in benzene (ca. 1mL) in an NMR tube 
equipped with a J Young valve. HgPh2 (44.6 mg, 0.13 mmol) was added and the 
suspension was heated under reflux for 5 days at 80°C, during which crystals started to 
deposit. The mixture was allowed to cool down to room temperature and sit for one 
day, leading to the formation of more crystalline product. The mixture was decanted 
and the crystals were washed with benzene (2 x 2ml) and pentane (2 mL), then dried in 
vacuo to afford 27 mg (37% yield) of [κ4-S3-TitmPri,benzo]HgPh. 1H NMR (CD2Cl2): 7.61 (d, J 
= 8 Hz, 3H, PhHgC(NCNSCH(CH3)2C6H4)3), 7.44 (m, 2H, 
PhHgC(NCNSCH(CH3)2C6H4)3), 7.26 (t, J = 8 Hz, 2H, PhHgC(NCNSCH(CH3)2C6H4)3), 
7.22 (m, 3H, PhHgC(NCNSCH(CH3)2C6H4)3), 7.11 (m, 1H, 
PhHgC(NCNSCH(CH3)2C6H4)3), 6.82 (ddd, J = 9 Hz, J = 7 Hz, J = 1 Hz, 3H, 
PhHgC(NCNSCH(CH3)2C6H4)3), 5.77 (d, J = 8 Hz, PhHgC(NCNSCH(CH3)2C6H4)3), 5.67 
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(bm, 3H, PhHgC(NCNSCH(CH3)2C6H4)3), 1.69 (d, J = 7 Hz, 
PhHgC(NCNSCH(CH3)2C6H4)3), 1.55 (d, J = 7 Hz, PhHgC(NCNSCH(CH3)2C6H4)3). 13C 
NMR (CD2Cl2) 20.0 (s, 6C, PhHgC(NCNSCH(CH3)2C6H4)3), 50.5 (s, 3C, 
PhHgC(NCNSCH(CH3)2C6H4)3), 111.4 (s, 3C, PhHgC(NCNSCH(CH3)2C6H4)3), 112.0 (s, 
2C, PhHgC(NCNSCH(CH3)2C6H4)3), 123.4 (s, 3C, PhHgC(NCNSCH(CH3)2C6H4)3), 123.6 
(s, 3C, PhHgC(NCNSCH(CH3)2C6H4)3), 126.7 (s, 2C, PhHgC(NCNSCH(CH3)2C6H4)3), 
128.1 (s, 2C, PhHgC(NCNSCH(CH3)2C6H4)3), 130.7 (s, 1C, 
PhHgC(NCNSCH(CH3)2C6H4)3), 133.12 (s, 3C, PhHgC(NCNSCH(CH3)2C6H4)3), 137.19 (s, 
3C, PhHgC(NCNSCH(CH3)2C6H4)3), 165.3 (s, 1C, PhHgC(NCNSCH(CH3)2C6H4)3), 168.8 
(s, 3C, PhHgC(NCNSCH(CH3)2C6H4)3). Anal. calc. for [κ4-S3-TitmPri,benzo]HgPh.0.5C6H6 : C, 




1.6.30 Crystallographic data 





lattice Monoclinic Triclinic 
formula C14H18N6S3Zn C14H15N7OS3Zn 
formula weight 431.89 458.88 
space group P21/c P-1 
a/Å 11.6690(11) 11.307(4) 
b/Å 12.4246(12) 13.657(4) 
c/Å 12.6995(13) 13.962(4) 
α/˚ 90 68.636(4) 
β/˚ 100.3420(10) 69.584(5) 
γ/˚ 90 70.758(5) 
V/Å3 1811.3(3) 1830.5(10) 
Z 4 4 
temperature (K) 150(2) 200(2) 
radiation (λ, Å) 0.71073 0.71073 
ρ (calcd.) g cm-3 1.584 1.665 
µ (Mo Kα), mm-1 1.711 1.704 
θ max, deg. 30.565 26.37 
no. of data collected 5553 22285 
no. of data used 5553 7484 
no. of parameters 222 475 
R1 [I > 2σ(I)] 0.0366 0.0513 
wR2 [I > 2σ(I)] 0.0854 0.0759 
R1 [all data] 0.0548 0.1234 
wR2 [all data] 0.0926 0.0933 
GOF 1.174 1.001 
Rint 0.0410 0.0997 
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lattice Triclinic Monoclinic 
formula C35H39Cl2N12S6Zn2 C13H15BrN6S3Zn 
formula weight 1021.78 496.77 
space group P-1 P21/n 
a/Å 12.8684(12) 9.4115(6) 
b/Å 13.0973(12) 13.1229(9) 
c/Å 15.5044(14) 14.5918(10) 
α/˚ 72.5060(10) 90 
β/˚ 85.1020(10) 98.2220(10) 
γ/˚ 62.5590(10) 90 
V/Å3 2207.5(4) 1783.7(2) 
Z 2 4 
temperature (K) 170(2) 150(2) 
radiation (λ, Å) 0.71073 0.71073 
ρ (calcd.) g cm-3 1.537 1.850 
µ (Mo Kα), mm-1 1.534 3.977 
θ max, deg. 30.655 30.746 
no. of data collected 36021 28417 
no. of data used 13575 5526 
no. of parameters 496 220 
R1 [I > 2σ(I)] 0.0492 0.0319 
wR2 [I > 2σ(I)] 0.1263 0.0755 
R1 [all data] 0.0944 0.0484 
wR2 [all data] 0.1449 0.0822 
GOF 1.104 1.019 










lattice Monoclinic Monoclinic 
formula C13H15IN6S3Zn C16H24N6OS3SiZn 
formula weight 543.76 506.05 
space group P21/n C2/c 
a/Å 9.603(2) 24.036(2) 
b/Å 12.978(3) 12.8658(12) 
c/Å 14.646(4) 18.2274(17) 
α/˚ 90 90 
β/˚ 98.568(4) 129.7258(14) 
γ/˚ 90 90 
V/Å3 1804.9(8) 4335.2(7) 
Z 4 8 
temperature (K) 150(2) 150(2) 
radiation (λ, Å) 0.71073 0.71073 
ρ (calcd.) g cm-3 2.001 1.551 
µ (Mo Kα), mm-1 3.427 1.498 
θ max, deg. 30.679 30.565 
no. of data collected 28866 6648 
no. of data used 5566 6648 
no. of parameters 220 259 
R1 [I > 2σ(I)] 0.0594 0.0586 
wR2 [I > 2σ(I)] 0.0797 0.1351 
R1 [all data] 0.1506 0.1017 
wR2 [all data] 0.0997 0.1514 
GOF 1.011 1.046 









lattice Monoclinic Monoclinic 
formula C19H20N6OS3Zn C20H22N6OS3Zn 
formula weight 509.96 523.98 
space group P21/c P21/c 
a/Å 13.576(4) 10.137(2) 
b/Å 8.775(2) 11.868(3) 
c/Å 18.498(5) 18.978(4) 
α/˚ 90 90 
β/˚ 101.232(4) 99.563(3) 
γ/˚ 90 90 
V/Å3 2161.3(10) 2251.5(8) 
Z 4 4 
temperature (K) 150(2) 150(2) 
radiation (λ, Å) 0.71073 0.71073 
ρ (calcd.) g cm-3 1.567 1.546 
µ (Mo Kα), mm-1 1.450 1.395 
θ max, deg. 32.760 30.609 
no. of data collected 36571 35705 
no. of data used 7633 6917 
no. of parameters 274 284 
R1 [I > 2σ(I)] 0.0371 0.0372 
wR2 [I > 2σ(I)] 0.0965 0.0794 
R1 [all data] 0.0538 0.0643 
wR2 [all data] 0.1033 0.0900 
GOF 1.216 1.027 









lattice Triclinic Monoclinic 
formula C27H30N6O2S3Zn C19H19BrN6OS3Zn 
formula weight 632.12 588.86 
space group P-1 P21/c 
a/Å 9.9890(19) 15.339(2) 
b/Å 11.211(2) 8.7461(11) 
c/Å 13.316(3) 17.822(2) 
α/˚ 87.303(3) 90 
β/˚ 75.592(3) 103.034(2) 
γ/˚ 77.986(3) 90 
V/Å3 1412.7(5) 2329.4(5) 
Z 2 4 
temperature (K) 150(2) 150(2) 
radiation (λ, Å) 0.71073 0.71073 
ρ (calcd.) g cm-3 1.486 1.679 
µ (Mo Kα), mm-1 1.128 3.063 
θ max, deg. 30.856 30.746 
no. of data collected 23268 36991 
no. of data used 8784 7244 
no. of parameters 361 283 
R1 [I > 2σ(I)] 0.0435 0.0487 
wR2 [I > 2σ(I)] 0.0957 0.0972 
R1 [all data] 0.0716 0.1109 
wR2 [all data] 0.1063 0.1180 
GOF 1.058 1.045 




Table 2: Crystallographic data 
 [κ4-TitmMe]ZnOC6H4-p-OMe  [κ4-TitmMe]ZnOC6H4-p-
NO2 
lattice Monoclinic Triclinic 
formula C20H22N6O2S3Zn C19H19N7O3S3Zn 
formula weight 539.98 1109.92 
space group P21/n P-1 
a/Å 14.933(2) 12.867(3) 
b/Å 10.2002(16) 13.368(3) 
c/Å 15.577(3) 14.404(4) 
α/˚ 90 79.320(4) 
β/˚ 106.158(2) 69.456(4) 
γ/˚ 90 75.417(4) 
V/Å3 2279.1(6) 2232.3(10) 
Z 4 4 
temperature (K) 150(2) 150(2) 
radiation (λ, Å) 0.71073 0.71073 
ρ (calcd.) g cm-3 1.574 1.651 
µ (Mo Kα), mm-1 1.383 1.419 
θ max, deg. 30.755 30.721 
no. of data collected 36277 13634 
no. of data used 7080 13634 
no. of parameters 293 602 
R1 [I > 2σ(I)] 0.0401 0.0645 
wR2 [I > 2σ(I)] 0.0870 0.1239 
R1 [all data] 0.0688 0.1282 
wR2 [all data] 0.0986 0.147 









lattice Triclinic Triclinic 
formula C19H20N6S4Zn C19H20N6S3SeZn 
formula weight 526.02 572.92 
space group P-1 P-1 
a/Å 9.429(2) 9.616(5) 
b/Å 11.149(3) 11.126(5) 
c/Å 13.582(3) 13.498(6) 
α/˚ 95.951(4) 95.167(7) 
β/˚ 106.456(4) 106.067(7) 
γ/˚ 96.721(4) 97.479(7) 
V/Å3 1345.8(5) 1363.8(11) 
Z 2 2 
temperature (K) 150(2) 150(2) 
radiation (λ, Å) 0.71073 0.71073 
ρ (calcd.) g cm-3 1.298 1.395 
µ (Mo Kα), mm-1 1.239 2.480 
θ max, deg. 30.898 32.698 
no. of data collected 22036 23538 
no. of data used 8393 9271 
no. of parameters 317 269 
R1 [I > 2σ(I)] 0.0382 0.0482 
wR2 [I > 2σ(I)] 0.0877 0.1333 
R1 [all data] 0.0572 0.0788 
wR2 [all data] 0.0935 0.1426 
GOF 1.027 1.058 










lattice Triclinic Triclinic 
formula C23H23N6O2S3Zn C40H41HgN6S3 
formula weight 577.02 902.56 
space group P-1 P-1 
a/Å 9.113(3) 11.336(2) 
b/Å 9.909(3) 12.347(3) 
c/Å 14.006(4) 14.905(3) 
α/˚ 100.325(4) 80.725(3) 
β/˚ 95.142(5) 67.951(3) 
γ/˚ 95.111(5) 83.225(3) 
V/Å3 1232.1(6) 1904.6(7) 
Z 2 2 
temperature (K) 150(2) 130(2) 
radiation (λ, Å) 0.71073 0.71073 
ρ (calcd.) g cm-3 1.555 1.574 
µ (Mo Kα), mm-1 1.285 4.242 
θ max, deg. 31.452 30.679 
no. of data collected 20516 31262 
no. of data used 7983 11720 
no. of parameters 319 457 
R1 [I > 2σ(I)] 0.0638 0.0276 
wR2 [I > 2σ(I)] 0.1601 0.0311 
R1 [all data] 0.1129 0.0684 
wR2 [all data] 0.1872 0.0703 
GOF 1.045 1.031 









lattice Monoclinic Monoclinic 
formula C35H42N6OS3 C32H36N6S3Zn 
formula weight 658.93 666.22 
space group P21/c P21/n 
a/Å 17.8204(16) 9.900(2) 
b/Å 10.5378(10) 18.629(4) 
c/Å 19.8241(18) 18.879(4) 
α/˚ 90 90 
β/˚ 116.7150(10) 101.498(3) 
γ/˚ 90 90 
V/Å3 3325.3(5) 3412.2(12) 
Z 4 4 
temperature (K) 130(2) 130(2) 
radiation (λ, Å) 0.71073 0.71073 
ρ (calcd.) g cm-3 1.316 1.297 
µ (Mo Kα), mm-1 0.262 0.934 
θ max, deg. 30.61 31.083 
no. of data collected 53390 54856 
no. of data used 10443 10700 
no. of parameters 413 387 
R1 [I > 2σ(I)] 0.0585 0.0577 
wR2 [I > 2σ(I)] 0.0919 0.1265 
R1 [all data] 0.1413 0.0970 
wR2 [all data] 0.1618 0.1393 
GOF 1.019 1.015 










lattice Triclinic Monoclinic 
formula C46H46BrN6OS3Zn C49H52N6S3Zn 
formula weight 940.35 886.52 
space group P-1 P21/c 
a/Å 12.1639(6) 10.0680(14) 
b/Å 13.0868(7) 16.009(2) 
c/Å 14.7500(8) 28.568(4) 
α/˚ 106.5030(10) 90 
β/˚ 96.1200(10) 100.127(2) 
γ/˚ 92.0080(10) 90 
V/Å3 2233.2(2) 4532.9(11) 
Z 2 4 
temperature (K) 130(2) 130(2) 
radiation (λ, Å) 0.71073 0.71073 
ρ (calcd.) g cm-3 1.398 1.299 
µ (Mo Kα), mm-1 1.627 0.721 
θ max, deg. 30.63 30.67 
no. of data collected 36460 72108 
no. of data used 13681 13981 
no. of parameters 530 524 
R1 [I > 2σ(I)] 0.0346 0.0635 
wR2 [I > 2σ(I)] 0.0467 0.1574 
R1 [all data] 0.0895 0.1171 
wR2 [all data] 0.0952 0.1452 
GOF 1.067 1.025 











lattice Monoclinic Triclinic 
formula C38H40N6O2S3Zn C67H52BF15N6S3Zn 
formula weight 774.31 1398.51 
space group P21 P-1 
a/Å 9.0793(14) 16.282(3) 
b/Å 13.332(2) 16.622(3) 
c/Å 14.914(2) 26.644(4) 
α/˚ 90 92.556(2) 
β/˚ 102.137(2) 94.097(2) 
γ/˚ 90 118.952(2) 
V/Å3 1765.0(5) 6267.7(17) 
Z 2 4 
temperature (K) 130(2) 130(2) 
radiation (λ, Å) 0.71073 0.71073 
ρ (calcd.) g cm-3 1.457 1.482 
µ (Mo Kα), mm-1 0.918 0.584 
θ max, deg. 30.63 30.92 
no. of data collected 28067 101882 
no. of data used 10503 38976 
no. of parameters 456 1659 
R1 [I > 2σ(I)] 0.0596 0.0698 
wR2 [I > 2σ(I)] 0.1022 0.1346 
R1 [all data] 0.1182 0.1602 
wR2 [all data] 0.1376 0.1883 
GOF 1.003 1.011 
Rint 0.0930 0.0601 
 65 
 
1.6.31 Computational data 
Table 3. Cartesian Coordinates for Geometry Optimized Structures. 
[κ4-TitmMe]ZnCl 
-2553.77166988271 
atom x y z 
Zn 6.356849942 4.169327151 -1.03300132 
Cl 6.5316484 4.663238796 -3.330322567 
S 5.173963764 4.923396998 2.299992653 
S 7.837581094 3.575137351 2.213860537 
S 5.350510457 2.006464662 1.686315832 
N 10.16895234 4.0135477 0.820016152 
N 4.109104046 7.117271943 1.025872473 
N 4.49009091 0.416818936 -0.387951386 
N 5.406983387 2.300405103 -1.081067554 
N 8.372952454 4.166685997 -0.452693243 
N 5.210667558 5.785458276 -0.345811205 
C 6.157476225 3.604072669 1.588836581 
C 5.084237932 1.583171071 -0.013729378 
C 8.810271926 3.937358435 0.777583771 
C 4.831880008 5.969170678 0.91113234 
C 4.717408151 6.851319626 -1.07715234 
H 4.903077475 6.915988282 -2.138962966 
C 5.009639402 1.575720375 -2.190808191 
H 5.172876648 1.966824424 -3.183995764 







atom x y z 
Zn 0.036570184 -0.002523824 0.181762954 
C 0.030741991 -0.003576539 2.467108811 
H 3.506187491 8.610088129 -0.416188465 
C 9.485743611 4.40275843 -1.240260291 
H 9.373144151 4.614701878 -2.293115651 
C 4.440473177 0.407976305 -1.779872882 
H 4.010555761 -0.419439797 -2.322523709 
C 3.529595311 7.646745298 2.250604096 
H 4.309235536 7.84082775 2.993269129 
H 2.806941175 6.941969432 2.672588973 
H 3.019204666 8.582550458 2.018999716 
C 4.003969932 -0.623062782 0.5055736 
H 3.229177022 -0.229543483 1.170189764 
H 4.821433197 -1.022327994 1.113274275 
H 3.580610994 -1.42976117 -0.094300852 
C 11.00239997 3.828464071 1.99779321 
H 10.83981134 2.837767978 2.432287837 
H 10.77844242 4.587150319 2.753697911 
H 12.04875653 3.91877856 1.702869629 
C 10.60521538 4.312011429 -0.468627925 
H 11.65375532 4.426376645 -0.695612111 
 67 
Cl 0.042199928 -0.00405584 -2.223424575 
S -0.699733058 -1.556082373 3.059291409 
S 1.736664072 0.137049116 3.06455058 
S -0.947764131 1.406807393 3.058714191 
N -0.963876165 -1.948586691 0.373913332 
C -1.202651803 -2.434308381 1.598729561 
C -1.859783531 -3.663337943 1.789790687 
H -2.040492252 -4.025933584 2.796419446 
C -2.266381623 -4.383606872 0.679108458 
H -2.777202285 -5.334275733 0.804899554 
C -2.015383398 -3.873793479 -0.600936118 
H -2.319090579 -4.406598338 -1.495120254 
C -1.363513723 -2.65639773 -0.706090305 
H -1.134150315 -2.196730433 -1.662885625 
N 2.211747615 0.173848566 0.379604882 
C 2.747646628 0.221323022 1.605719175 
C 4.135566904 0.339681279 1.800189117 
H 4.536202399 0.375692617 2.807963501 
C 4.962035621 0.407988606 0.691211461 
H 6.036986454 0.499752387 0.81932465 
C 4.399240856 0.357888991 -0.590283929 
H 5.012076145 0.408370814 -1.483287067 
C 3.023773348 0.241069404 -0.698967946 
H 2.514199674 0.196575634 -1.656881549 
N -1.240427239 1.773777617 0.372327159 
C -1.556799151 2.213241781 1.597041571 
C -2.385219587 3.33420403 1.787248687 
 
 68 
H -2.623582345 3.662482732 2.793656361 
C -2.881866102 3.99456009 0.675881797 
H -3.524410809 4.861779147 0.80109121 
C -2.549760585 3.532955483 -0.603933659 
H -2.919240644 4.021632279 -1.498573245 
C -1.728836076 2.422507422 -0.708251393 




atom x y z 
Zn 0.064105741 0.397535015 0 
Cl -0.282714142 -1.781197806 0 
C 0.373713314 2.379526747 0 
H -0.583723586 2.908425519 0 
H 0.938503863 2.672519699 -0.889563747 





atom x y z 
Zn -2.792731564 -6.177845244 -1.264776524 
O -4.417433227 -4.835383692 -1.206171607 
O -4.893660565 -7.004390948 -1.270508487 
S 0.111013182 -5.539079008 0.234798494 
 69 
S -1.257842304 -3.318867903 -1.267303858 
S 0.117397759 -5.547860372 -2.754878897 
N -2.162167721 -7.065118328 0.527126176 
N -0.70335583 -7.307374252 2.209106116 
N 1.463027709 -3.169299694 -1.310805696 
N 0.477273879 -1.139121288 -1.466622865 
N -2.218963046 -6.967825749 -3.123496895 
N -0.777076386 -7.109226252 -4.831060883 
C -0.831124639 -5.065190698 -1.260928212 
C -5.248713035 -5.794513857 -1.22995898 
H -6.324323049 -5.548444537 -1.214844683 
C -0.98491044 -6.691373382 1.011911854 
C -2.702820385 -7.967274312 1.435555192 
C -3.921103413 -8.652145685 1.412182752 
H -4.616121287 -8.500798707 0.592857499 
C -4.19289376 -9.505494791 2.477719709 
H -5.129698543 -10.05466537 2.494243378 
C -3.282857733 -9.671267911 3.536966914 
H -3.529752757 -10.34575972 4.351651134 
C -2.069101731 -8.987424396 3.569471622 
H -1.378056632 -9.122718815 4.395287964 
C -1.796527491 -8.13271275 2.499471826 
C 0.464342477 -7.133193602 3.102871548 
C 0.521063822 -5.715006345 3.686487288 
H -0.421031027 -5.462380269 4.181745434 
H 0.714903862 -4.967063497 2.913470681 
H 1.325773347 -5.655350455 4.426127167 
 
 70 
C 1.77348459 -7.570323067 2.433907426 
H 1.690104217 -8.589802242 2.046376181 
H 2.581710765 -7.547324579 3.171697263 
H 2.051175601 -6.910179617 1.608675897 
C 0.32570477 -2.511849773 -1.343451227 
C 2.446622474 -2.199473567 -1.42285305 
C 3.838870436 -2.33190843 -1.450174561 
C 4.604160247 -1.176267473 -1.578520889 
H 5.687753675 -1.250150278 -1.603894194 
C 4.001891284 0.091555481 -1.678106526 
H 4.628247758 0.973504297 -1.779263002 
C 2.616490998 0.243065599 -1.65162422 
H 2.165466335 1.227718563 -1.73157526 
C 1.853645378 -0.919525744 -1.52246126 
C -0.545509086 -0.077300489 -1.555395915 
C -1.369292404 -0.18616575 -2.846216729 
H -0.714169131 -0.199335314 -3.722252527 
H -2.039764674 0.675422317 -2.929965542 
H -1.979941886 -1.092901341 -2.860081799 
C -1.41218076 -0.007565379 -0.290646462 
H -2.041017047 -0.894758044 -0.176804864 
H -2.070304642 0.86578702 -0.345242354 
H -0.787233514 0.087324978 0.602222388 
C -1.037099194 -6.591163925 -3.587993298 
C -2.785604031 -7.779801267 -4.100978222 
C -4.326183436 -9.19484829 -5.241600627 
H -5.277097448 -9.71752263 -5.289163792 
 71 
C -4.020900785 -8.432493954 -4.117464314 
H -4.702012508 -8.328047757 -3.279215563 
C -3.429842146 -9.302259685 -6.319314796 
H -3.700908027 -9.906288938 -7.180472709 
C -2.197879142 -8.650053721 -6.312734765 
H -1.519931149 -8.743113087 -7.153117361 
C -1.889348251 -7.884711569 -5.184592464 
C 0.428203684 -6.833288199 -5.638964126 
C 1.237989701 -8.11281274 -5.882477551 
H 0.687279842 -8.835832825 -6.49062961 
H 1.497927915 -8.591907762 -4.934268946 
H 2.165844239 -7.866550497 -6.408176313 
C 0.066763229 -6.080873754 -6.926560421 
H -0.547310902 -6.687869413 -7.597455889 
H 0.981270792 -5.805938589 -7.461201214 
H -0.48363471 -5.164412241 -6.695573661 
H 1.036367788 -6.164201666 -5.024070569 
H 0.033615928 0.848743682 -1.608074291 
H 0.269779846 -7.824545134 3.926745858 





atom x y z 
Zn 2.047732818 3.198982402 3.193180617 
 
 72 
S 0.302302661 2.924400102 6.103659124 
S -0.104888915 0.715188851 4.115705391 
S -1.340516926 3.328138747 3.629426875 
N 2.681722732 3.883577733 5.126839751 
N 2.461085485 4.14633362 7.343508222 
N 2.518061269 1.050561107 3.391385487 
N 1.834450207 -1.089782517 3.377310803 
N 0.698420482 4.836461231 2.583767701 
N -1.3512522 5.502638903 1.947146159 
C 0.109485911 2.503911597 4.337915518 
C 3.337411494 3.35075737 1.015246236 
C 1.899475289 3.686466381 6.171303234 
C 3.828049906 4.504862858 5.602953303 
C 4.970727539 4.930935352 4.918698141 
H 5.047513165 4.786625174 3.846177574 
C 5.976438529 5.530943936 5.6707316 
H 6.879208056 5.874937861 5.174253614 
C 5.852196811 5.702587736 7.061588557 
H 6.658723971 6.175243812 7.614728567 
C 4.717007281 5.279648698 7.750447738 
H 4.635690047 5.418044076 8.823990559 
C 3.708095745 4.678120806 6.995391726 
C 1.932906211 4.099574433 8.724340539 
H 2.715008629 4.57494815 9.321903309 
C 1.77647836 2.658029061 9.227944552 
H 2.716908737 2.108571761 9.126027025 
H 1.001930685 2.117980994 8.677454891 
 73 
H 1.496644923 2.668450037 10.28639238 
C 0.658732936 4.940185916 8.878847192 
H 0.824236181 5.962432598 8.526687937 
H 0.373910056 4.981103167 9.935064971 
H -0.178226235 4.515904908 8.318631894 
C 1.510865106 0.227915099 3.594438656 
C 3.586109576 0.251393548 3.001751567 
C 4.891167748 0.612177478 2.656862745 
H 5.184872667 1.656461324 2.6580607 
C 5.768325275 -0.407818107 2.29984915 
H 6.789389644 -0.16152933 2.023284551 
C 5.358723364 -1.752504552 2.284389862 
H 6.068799853 -2.523100827 1.99818445 
C 4.059173213 -2.124119295 2.624914354 
H 3.759868994 -3.165706368 2.602863196 
C 3.17870569 -1.100478889 2.985640645 
C 0.908697795 -2.233244462 3.486538328 
H -0.038255309 -1.803146202 3.825645912 
C 1.374478256 -3.227847635 4.558043623 
H 1.507590867 -2.725026426 5.520197882 
H 2.320348342 -3.705821357 4.289530581 
H 0.623143355 -4.014179903 4.682232203 
C 0.665126089 -2.880490723 2.11644029 
H 0.297355987 -2.140334633 1.400188719 
H -0.084531196 -3.672986825 2.208635593 
H 1.577978681 -3.323972111 1.709144022 
C -0.595402622 4.611927968 2.670540554 
 
 74 
C 0.834802802 5.935491943 1.743674591 
C 1.99092798 6.587943918 1.308540679 
H 2.966562715 6.231372411 1.620963973 
C 1.833846361 7.677905181 0.457177686 
H 2.712495309 8.205670788 0.097726219 
C 0.559813915 8.108476706 0.047485363 
H 0.473821275 8.961267485 -0.619896792 
C -0.600689565 7.465074457 0.4746837 
H -1.574953468 7.808262464 0.145813266 
C -0.443044908 6.371797781 1.330865724 
C -2.819886069 5.469076691 1.808025177 
H -3.14843837 4.64180316 2.44386093 
C -3.230831084 5.140382367 0.366345728 
H -2.778979382 4.19865055 0.042175975 
H -2.923763238 5.923668234 -0.332219379 
H -4.319222328 5.039344408 0.305162312 
C -3.462212884 6.752598312 2.349601046 
H -4.552482202 6.660088887 2.318008144 
H -3.181809472 7.630251886 1.760973831 
H -3.162112547 6.927247205 3.386731849 
O 3.811587459 3.814086542 2.108384798 
O 2.218129454 2.798087921 0.932491331 
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2.1  Bioinorganic chemistry of zinc 
Zinc plays an essential role in living organisms, as illustrated by its presence in more 
than 300 enzymes.1 Even though the metal has been identified in almost every enzyme 
class, the main reactions involving zinc enzymes are hydrolysis, principally because of 
the strong Lewis acidity and redox inactivity of zinc. Fundamental reactions such as the 
cleavage of peptide bonds, cleavage of phosphates and hydration of CO2 are catalyzed 
by zinc hydrolases.2 In this regard, a clear understanding of the role of zinc center in 
zinc enzymes is vital, as it can help the design of efficient treatments when these 
enzymes malfunction. The coordination geometry of zinc inside the active site of the 
hydrolases is usually tetrahedral, with one water molecule and three coordinating 
groups from amino acid residues such as histidines, glutamates, aspartates and 
cysteines bound to the zinc center.3 The variety of coordination environments around 
the zinc in metalloenzymes has inspired the design of many synthetic analogues of 
these active sites, as they allow for the study of the enzymatic mechanism without 
having to isolate and purify the actual enzyme.4 We decided to investigate the [TitmMe] 
and [TitmPri,benzo] zinc complexes presented in Chapter 1 as potential synthetic analogues 
for the active sites of important zinc enzymes. In the first part, we discuss the 
application of zinc complexes to study the binding between the enzyme carbonic 
anhydrase (CA) and known CA inhibitors, while in the second part, we describe zinc 
complexes to model the binding of antibiotics to zinc metallo-β-lactamases. 
 
2.2 Models for Carbonic Anhydrase  
2.2.1 Introduction 
CA is a zinc enzyme present in almost all living organisms and was the first 
metalloenzyme to be identified.5 Its fundamental role is to catalyze the reversible 
hydrolysis of carbon dioxide to bicarbonate, making it essential for CO2 transport and 
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pH control in the organism.6 The active site is typical of zinc hydrolases, with a zinc 
center bound to three histidine residues and a water molecule, which, upon 
deprotonation, forms a nucleophilic hydroxide that can attack CO2 to form a zinc 
bicarbonate species (Figure 1). Twelve catalytically active isoforms (I to XIV) were 
identified in humans, each one showing various degree of activity.7 Because of its 
ubiquity, deregulation or accumulation of the enzyme can lead to several pathological 
effects such as glaucoma8 or epilepsy.9 Recently, isoforms IX and XII were observed in 
tumor cells, where they are believed to be involved in cell proliferation mechanisms,10 
making them important targets in antitumor research.11 In that regard, inhibitors of CA 
have become very attractive drug targets, as they could diminish the activity of the 
enzyme. 







Figure 1: Mechanism of carbonic anhydrase 
 
Although inhibitors have been successfully developed and used clinically for decades 
as antiglaucoma agents, new generations of drugs are under current investigation for 
potential antitumor activity.12 The most important and widely used family of inhibitors 
is composed of derivatives of primary sulfonamides.13 Crystallographic studies of 
adducts between the enzyme and various inhibitors revealed that a deprotonated 
sulfonamide binds to the zinc via the nitrogen, displacing the zinc bound hydroxide 
(Figure 2). Secondary interactions play an important role in the binding of the inhibitors 
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as they help lock the drug in position via a hydrogen bonding network between both 
the N-H and the S=O of the sulfonamide and amino acid residues in the periphery of 















Figure 2: Schematic representation of the H-bonding pattern in adducts between 
sulfonamides and CA 
 
Following the elucidation of the molecular structure of CA, a variety of ligands were 
designed to mimic the environment around the zinc in the active site of the enzyme, 
with the purpose of investigating the mechanism of action of the enzyme.4,15,16,17 In that 
regard, synthetic analogues of all the intermediates in the catalytic cycle of the enzyme 
have been successfully isolated and structurally characterized.18,19,20 However, only a 
few report the use of synthetic analogues to study the binding of the inhibitors to the 
zinc center.21 In fact, there has been only one structural analog of CA bound to a 
primary sulfonamide, namely the complex [TpCumyl,Me]Zn(acetazolamide), reported in 
the CSD.21a We therefore decided to investigate [TitmMe] zinc complexes as synthetic 
analogues for CA, and focused on their reactivity with known inhibitors of CA.  
 
2.2.2 Binding of a CA inhibitor to a CA synthetic analogue 
[TitmMe] zinc complexes structurally resemble the active site of CA, as they contain a 
zinc center coordinated by three imidazole groups. The formation of [TitmMe] zinc 
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complexes featuring known CA inhibitors such as primary sulfonamides could 
therefore improve understanding of the interactions between the active site in CA and 
these inhibitors, and provide information for the design of more efficient CA inhibitors. 
As a model system, we decided to use para-toluenesulfonamide as a simple primary 
sulfonamide substrate to include in [TitmMe] zinc complexes. 
 
The synthesis of [κ4-TitmMe]ZnNHSO2C6H4-p-Me was achieved by reacting [κ3-
TitmMe]ZnMe and para-toluenesulfonamide in benzene (Scheme 1). The molecular 
structure of [κ4-TitmMe]ZnNHSO2C6H4-p-Me was determined by X-ray diffraction and 
revealed a dimeric structure where two [κ4-TitmMe]ZnNHSO2C6H4-p-Me units are 
connected to each other via a hydrogen bonding interaction between the N-H and the 
S=O groups of both complexes, forming a R22(8) pattern according to the graphset 



























It is significant that the hydrogen bonding interaction observed in the molecular 
structure is very similar to the one observed in structurally characterized adducts 
between the enzyme and primary sulfonamide inhibitors. In these enzyme/inhibitors 
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adducts, hydrogen bonding is clearly observed between the N–H of the sulfonamide 
and the OH of Thr199 and the S=O and the N–H of the same Thr199. The fact that [κ4-
TitmMe]ZnNHSO2C6H4-p-Me participates in a similar hydrogen bonding pattern in the 
solid state not only confirms the propensity of the sulfonamide to form this type of 
hydrogen bonding network, but it also stresses the importance of the Thr199 residue in 
the inhibition mechanism, as it acts as the hydrogen bonding partner in the enzyme 
active site (Figure 2).  
 




2.3 Models for Metallo-β-lactamases  
CA has been one of the most studied zinc enzymes, and has inspired the design of 
many small molecule mimics. In comparison, little attention has been paid to other zinc 
enzymes such as metallo-β-lactamases (MBLs), despite their involvement in pressing 
issue such as antibiotic resistance. In the following part, we used [TitmPri,benzo] zinc 
complexes as synthetic analogues of MBLs, and we report structural information 
pertaining to the interaction between MBLs and β-lactams antibiotics relevant to 
antibiotic resistance. 
 
2.3.1 Antibiotic resistance 
The discovery of penicillin by Alexander Fleming in 1929 was undeniably a turning 
point in medical history.23 The small natural product excreted by the fungus Penicillium 
Rubens was found to prevent the spread of several bacterial strains responsible for 
common infections, as well as major epidemic diseases, such as tuberculosis. As a 
result, penicillin directly led to a decrease in childhood mortality and an increase in life 
expectancy. Furthermore, the ability of penicillin to prevent infectious bacterial strains 
allowed for widespread use of many surgical procedures for disease treatment. Its low 
toxicity to humans led to a global effort to produce the drug and a variety of its 
derivatives at a global scale. However, concurrently with the development of processes 
for the mass production of penicillin in the early 1940s, studies showed that strains of 
microbes that were previously affected by antibiotics were no longer sensitive to the 
drugs.24 This phenomenon was found to not be limited to one type of drugs; in fact, 
every time a new antibiotic was introduced, a fraction of the bacterial population 




Major resistance mechanisms rely on the ability of bacteria to express enzymes that 
specifically target and neutralize different types of antibiotics drugs.25 The fast 
reproductive cycle of bacteria is crucial in this process, as it allows the rapid emergence 
of genes coding for resistant properties through random genetic mutations. 
Additionally, overuse of antibiotics induces a natural selection of the more resistant 
strains, which over time spread to completely replace the original species. The result is 
that all antibiotics are inevitably condemned to become obsolete after a period of time, 
depending on the rate of apparition of resistant genes and the spreading of the genetic 
material of the resistant strain through the bacterial population.  
 
The foreseeable emergence of new types of antibiotic resistance in microbes stresses the 
need for constant renewal of the arsenal of antibiotic drugs in order to curtail the risk of 
resurgence of previously treatable infections.26 Recently, systematic overuse of 
antimicrobial treatments in humans and animal livestock has accelerated the 
appearance of new resistant bacterial strains, at the point of outpacing the development 
of new antibiotics, therefore causing serious concern in global health organizations.27 
The United Nations World Health Organization published a report in 2014 urging 
governments to limit the use of antibiotics and boost research on new drugs. Because of 
this market failure, drug discovery in antibiotics has noticeably transitioned from 
pharmaceutical companies with superior resources to academic centers with lower 
means.28 Unfortunately, the consequences of antibiotic resistance are already 
observable, as illustrated by the increasing number of global outbreaks of “superbugs”. 
The production of new antibiotics, as well as a clear understanding of bacterial 
resistance mechanisms, is therefore urgently required to prevent the further spreading 





β-lactam antibiotics such as penicillins,29,30 cephalosporins31 and penems,32 represent the 
largest group of antimicrobial drugs commercially available (Figure 4).33 The mode of 
action of β-lactam antibiotics involves irreversible binding to transpeptidase penicillin-
binding proteins (PBP) that are vital for building the bacterial cell wall.34 PBPs use a 
serine residue in their active site to catalyze the cross-linking between glycopeptides 
building blocks to form the bacterial cell wall. The β-lactam functionality in β-lactam 
antibiotics reacts with active site serine residues of PBPs to form stable acyl compounds, 
which thereby disrupts the cross-linking reactions, ultimately leading to the breakdown 
of the cell wall and the death of the bacteria.35 Since β-lactam antibiotics attach to PBPs 
via the β-lactam functionality, it is not surprising that the most common type of 
resistance observed in bacteria involves the deactivation of the β-lactam.36 Specifically, 
microbes have evolved to produce β-lactamase enzymes that catalyze the hydrolysis of 
the 4-membered lactam ring to yield an inactive carboxylic acid (Scheme 2). Several 
classes of β-lactamases have been identified,37,38,39,40 each with a specific mechanism. For 
example, class A β-lactamases use a serine residue similar to that observed in PBPs to 
attack the carbonyl of the β-lactam. On the other hand, class B β-lactamases use 
mononuclear41 or binuclear zinc42,43,44,45 active sites to catalyze the hydrolysis of β-
lactams antibiotics (Figure 5). The active site consists of a zinc bound hydroxide 
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Class B β-lactamase enzymes, also called MBLs, have emerged as one of the more recent 
microbial defense mechanisms,47 as illustrated by the recent discovery of the New-Dehli 
MBL (NDM-1).48 MBLs have quickly become a cause of concern among organizations 
that monitor antibiotic resistance surveillance, such as the World Health Organization, 
because MBLs are active against a much broader spectrum of β-lactams antibiotics than 
are other classes (A, C, D) of β-lactamases. In particular, MBLs hydrolyze carbapenems, 
which are often cited as “last resort” drugs.48,49, In addition, no inhibitor for MBLs has 
yet passed clinical trials, although several compounds showed promising results.50 The 
NDM-1 resistance is particularly worrisome because the gene coding for the enzyme is 
located on a plasmid that easily spreads out to the bacterial population.51 Several 
outbreaks of NDM-1 have been reported in India and an increased numbers of cases 

















2.3.3 Mechanism of MBLs 
Even though two zinc centers are present in the active site of most MBLs, only the zinc 
in the tris histidine environment is involved in the catalysis, while the other zinc serves 
as an anchor, locking the drug in the right position.53 The first step of the proposed 
mechanism for the hydrolysis of β-lactam antibiotics consists of the binding of the β-
lactam to the zinc centers via the oxygen from the lactam carbonyl, therefore activating 
the functionality for further nucleophilic attack (Figure 6).54 Once activated, the 
carbonyl is attacked by the hydroxide to form a tetrahedral intermediate that breaks 
down to the corresponding carboxylic acid and amine. The strength of the binding 
between the β-lactam group and the metal center is a pivotal factor in the high 
efficiency of MBLs, as illustrated by the broad spectrum of antibiotics hydrolyzed by 
these enzymes55,56 and the fact that the MBL apoenzymes do not bind antibiotics.57 
Unfortunately, because of the high reactivity of the enzyme, it is very difficult to probe 
the strength of the binding between the β-lactam group and the metal center as well as 




























































































Figure 6: Schematic representation of the mechanism of action of dinuclear MBLs. 
 
2.3.4 Synthetic analogues of MBLs 
Knowledge of the structure of MBLs has led to the design of several synthetic analogues 
to reproduce the structural features of the active site (Figure 7).58,59,60,61 However, the 
main focus of most studies involving mimics of MBLs has been to reproduce the 
catalytic activity of the enzyme and obtain kinetic data, in order to elucidate the 
mechanism of action of MBLs. While these goals have been achieved successfully, there 
have been very few reports that aim to characterize the binding interaction with β-
lactams.62,63,64,65 Specifically, there are only 4 examples of β-lactams binding to a zinc 
center in the CSD.66 The complexes [(3,5-bis(R2NCH2)pyrazolyl]Zn2(lactamide)](ClO4)2 
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(R = CH2CH2Py, Et, CH2Im) provide an example of a β-lactam binding to a dinuclear 
zinc complex. (Figure 8) However, the azetidinone ligand in these complexes appears as 
a deprotonated bridging lactamido species.62,64 On the other hand, the complex [(3,5-
bis(RN(Me)CH2)pyrazolyl]Zn2(2-oxazetidinylacetato)](ClO4)2 features a bridging 2-
oxazetidinylacetato ligand, in which the carbonyl from the β-lactam binds to a zinc 
center (Figure 8).64 However, there are no examples of a simple, non-bridging β-lactam 




























Figure 7: Examples of synthetic analogues for MBLs used for the determination of the 
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Figure 8: Structurally characterized examples of β-lactams binding to a zinc center [(3,5-
bis(R2NCH2)pyrazolyl]Zn2(lactamide)](ClO4)2 (R = CH2CH2Py (A), Et (B), CH2Im (C)) 
and [(3,5-bis(RN(Me)CH2)pyrazolyl]Zn2(2-oxazetidinylacetato)](ClO4)2 (D) 67 
 
The tris(1-Pribenzimidazol-2-ylthio)methyl ligand, [TitmPri,benzo], provides a similar tris 
imidazole coordination environment as that observed for the catalytically active zinc 
center in MBLs, and could therefore be used as a synthetic analogue for MBLs. The 
carbanion present in [TitmPri,benzo] zinc complexes fills the role of the hydroxide ligand in 
the active site of MBLs, as it acts as an X ligand. These structural similarities between 
[TitmPri,benzo] zinc complexes and the catalytically active zinc center in MBLs led us to 
investigate [TitmPri,benzo] zinc complexes as synthetic models for MBLs. In this chapter, 
we report the complete structural and thermodynamic characterization of the binding 
interactions between [TitmPri,benzo] zinc complexes and both simple β-lactams and more 
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elaborate antibiotic analogues. Secondary interactions previously ignored have been 
identified, and might explain the high affinity of MBLs towards β-lactam antibiotics. In 
addition, the synthetic models were used to test a number of ligands as potential 
inhibitors for MBLs.  
 
2.3.5 Synthesis of novel MBL synthetic analogues based on the [TitmPri,benzo] ligand 
The [TitmPri,benzo] zinc complexes used as synthetic analogues of MBLs used herein are 
ion pairs [κ4-TitmPri,benzo]ZnX, where X represents a bulky, non coordinating anion, such 
as the MeB(C6F5)3 or BPh4 anions. The {[κ4-TitmPri,benzo]Zn}+ cationic moiety of [κ4-
TitmPri,benzo]ZnX therefore presents an empty Lewis acidic site which allows for for the 
binding of a variety of different Lewis bases to the zinc center, such as, for example, the 
carbonyl group of a β-lactam. The benefits of using {[κ4-TitmPri,benzo]Zn}+ cationic species 
are that both the structure of the adducts between various ligands and the {[κ4-
TitmPri,benzo]Zn}+ cation, and the binding constant for the formation of these adducts can 
be determined by X-ray diffraction and NMR spectroscopy, respectively. Both data can 
help draw in unprecedented detail as picture of the binding interaction between a 
specific ligand and the {[κ4-TitmPri,benzo]Zn}+ cation, and help understand the factors 
affecting this binding interaction. In the case of biologically relevant ligands such as β-
lactams, information on the binding interaction can not only help understand the 
selectivity of MBLs towards β-lactams, but also help towards the design of inhibitors 
and new antibiotics. 
 
Treatment of [κ3-TitmPri,benzo]ZnMe with either [PhNMe2H]BPh4 or B(C6F5)3 yields the 
cationic species [κ4-TitmPri,benzo]ZnX (X = BPh4, MeB(C6F5)3) (Scheme 3). The molecular 
structure of [κ4-TitmPri,benzo]ZnMeB(C6F5)3 has been determined by X-ray diffraction, 
which shows the formation of a metallocarbatrane68,69 motif with a quasi trigonal 
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pyramidal geometry70 (Figure 9). The Zn-C bond length in [κ4-TitmPri,benzo]ZnMeB(C6F5)3 
is 2.107(2) Å, which is closer to the values observed for [κ4-Tptm]ZnX [2.11 – 2.22 Å]71 
than for [κ4-TitmMe]ZnX [2.44 – 2.68 Å] and is also close to the average Zn-C value in the 
CSD [2.01 Å]. The Zn-C bonding interaction in [κ4-TitmPri,benzo]ZnMeB(C6F5)3 is therefore 
more accurately described as a covalent Zn-C interaction, as opposed to a zwitterionic 

































Figure 9: Molecular structure of [κ4-TitmPri,benzo]ZnMeB(C6F5)3 
 
As several examples of weak coordination of MeB(C6F5)3 and BPh4 to a metal center 
were reported in the literature,72,73,74 the non-coordinating nature of these two counter 
ions was investigated in the case of [κ4-TitmPri,benzo]Zn+ cations. The distance between the 
Zn center and the closest hydrogen from the CH3 moiety of the MeB(C6F5)3 counterion 
in [κ4-TitmPri,benzo]ZnMeB(C6F5)3 is 4.721 Å, which is well beyond the sum of the van der 
Waals radii (3.2 Å),75 suggesting that the [MeB(C6F5)3]– anion is non-coordinating in this 
system. The 11B NMR spectra for [κ4-TitmPri,benzo]Zn(MeB(C6F5)3) and [κ4-
TitmPri,benzo]Zn(BPh4) show peaks at -14.99 and -6.51 ppm, which are characteristic of free 
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MeB(C6F5)3 and BPh4 counterions. 76,77 In addition, 1H NMR pulse gradient spin echo 
(PGSE) experiments78,79 indicate that the {[κ4-TitmPri,benzo]Zn} moiety of [κ4-
TitmPri,benzo]ZnMeB(C6F5)3 has the same diffusion constant and therefore the same size as 
[κ3-TitmPri,benzo]ZnMe, providing further evidence of the non-coordinating nature of the 
MeB(C6F5)3 counterion.  
 
2.3.6 Synthesis of an adduct between a MBL synthetic analogue and a β-lactam 
The expected high Lewis acidity of the zinc center and the non-coordinating nature of 
the counterions allow for the binding of biologically relevant Lewis bases to the cationic 
center. Thus, addition of 1 equivalent of 4-phenylazetidin-2-one to [κ4-
TitmPri,benzo]Zn(BPh4) leads to the formation of the 1:1 adduct [κ4-TitmPri,benzo]Zn(4-
phenylazetidin-2-one)(BPh4) (Scheme 4). The molecular structure of the adduct has been 
determined by X-ray diffraction, showing a distorted trigonal bipyramidal coordination 
of the zinc center,80 in which the β-lactam binds via the oxygen from the amide carbonyl 
in the axial position that is trans to the carbanion. The adduct [κ4-TitmPri,benzo]Zn(4-
phenylazetidin-2-one)(BPh4) represents the first structurally characterized example of 
simple, non-bridging β-lactam binding to a zinc center. The Zn-C distance in the [κ4-
TitmPri,benzo]Zn moiety increases significantly upon coordination of the azetidinone, 
elongating from 2.107(2) Å in the naked cation to 2.281(7) Å in the β-lactam adduct. 
Such a variation is not surprising, since the energetic profile of the Zn-C in related 
[TitmMe] zinc compounds is very shallow, and large variations in the Zn-C bond length 
lead to small changes in the energy of the [TitmMe]Zn compound (see Chapter 1). The 
C=O bond length in the coordinated β-lactam is 1.234(8) Å, which is very much 
identical to the C=O bond length in the free β-lactam [1.222 Å], and longer than the 
average C=O bonds in β-lactams [1.209 Å] reported in the CSD.66 However, the IR 
stretching frequency of the C=O bond decreases from 1757 cm-1 in the free lactam81 to 
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1709 cm-1 in the [κ4-TitmPri,benzo]Zn(4-phenylazetidin-2-one)(BPh4) adduct, implying a 
weakening of the lactam C=O bond upon binding to the {[κ4-TitmPri,benzo]Zn+} cation. 
These observations provide direct evidence for the activation of the carbonyl group 
from the β-lactam by the zinc center, as proposed in the first step of the hydrolysis 

























Figure 10: Molecular structure of [κ4-TitmPri,benzo]Zn(4-phenylazetidin-2-one)(BPh4). The 




To further investigate the binding of ligands to the {[κ4-TitmPri,benzo]Zn+} cation, we 
decided to study the difference between how β-lactams and acyclic amides bind to the 
{[κ4-TitmPri,benzo]Zn+} cation, as it has been proposed that acyclic amides are stronger 
donors than β-lactams.82 It is therefore interesting to investigate if such differences in 
donor ability of various amide substrate translate into different structures of their 
adducts with the {[κ4-TitmPri,benzo]Zn+} cation. In that regard, the adduct [κ4-
TitmPri,benzo]Zn(N-benzylacetamide)(BPh4) was synthesized by addition of one equivalent 
of N-benzylacetamide to [κ4-TitmPri,benzo]Zn(BPh4) (Scheme 4) and characterized by X-ray 
crystallography. The molecular structure shows the amide binding to the zinc cation via 
the oxygen from the carbonyl group in a way similar to that in the 4-phenylazetidin-2-
one adduct (Figure 11). The C=O bond is also elongated upon binding to the zinc center, 
increasing from 1.233(1) Å in the free compound83 to 1.256(2) Å in the [κ4-
TitmPri,benzo]Zn(N-benzylacetamide)(BPh4) adduct. However, several other differences 
can be observed between [κ4-TitmPri,benzo]Zn(N-benzylacetamide)(BPh4) and [κ4-
TitmPri,benzo]Zn(4-phenylazetidin-2-one)(BPh4). First, the Zn-O bond is shorter in [κ4-
TitmPri,benzo]Zn(N-benzylacetamide)(BPh4) [2.070(1) Å] than in [κ4-TitmPri,benzo]Zn(4-
phenylazetidin-2-one)(BPh4) [2.097(5) Å], which supports the proposition that acyclic 
amides are stronger donors than β-lactams. Additionally, the largest N-Zn-N angle 
between two benzimidazole arms is larger in [κ4-TitmPri,benzo]Zn(N-
benzylacetamide)(BPh4) [141.76°] than in [κ4-TitmPri,benzo]Zn(4-phenylazetidin-2-
one)(BPh4) [133.71°], showing that the [TitmPri,benzo] ligand scaffold is more distorted in 
the case of the N-benzylacetamide than with the 4-phenylazetidin-2-one adduct (Figure 
12).84 Such distortions of the [TitmPri,benzo] ligand scaffold might weaken the interaction 




























Figure 11: Molecular structure of [κ4-TitmPri,benzo]Zn(N-benzylacetamide)(BPh4). The BPh4 















Figure 12: Schematic representation of the largest N-Zn-N angle α. As α deviates from 
the ideal value of 120°, the [TitmPri,benzo] ligand becomes increasingly distorted 
 
2.3.7 Determination of binding constants between MBLs synthetic analogues and 
lactams  
The ability for the {[κ4-TitmPri,benzo]Zn+} cation to form a well defined 1:1 adduct with β-
lactams allows for the determination of the binding constant by using 1H NMR titration 
experiments.85,68a The signal of {[κ4-TitmPri,benzo]Zn+} is measured in the presence of 
different concentrations of β-lactam (Figure 13) and analysis of the variation of the 
chemical shift as a function of N-benzylazetidin-2-one86 concentration indicates that the 
equilibrium constant is 200 (± 11) M-1 for the formation of the [κ4-TitmPri,benzo]Zn(N-
benzylazetidin-2-one)(B(C6F5)3) adduct (see experimental section). For comparison, the 

































Figure 13: Binding equilibrium between the {[κ4-TitmPri,benzo]Zn} cation and N-
benzylazetidin-2-one. The signal of the hydrogens was followed by 1H NMR 






Figure 14: (top) variation of the 1H NMR chemical shift of the {[κ4-TitmPri,benzo]Zn} cation 
as a function of the concentration of N-benzylazetidin-2-one. (bottom) Scott plot for the 
determination of the binding constant between the {[κ4-TitmPri,benzo]Zn} cation and N-
benzylazetidin-2-one (Δδ = δ0-δ, where δ0 is the chemical shift of the free {[κ4-
TitmPri,benzo]Zn} cation). For the extraction of the binding constant from the Scott plot, see 




The binding of β-lactams was compared to that of acyclic amides, as it has been shown 
that acyclic amides have better donor abilities than β-lactams. The binding constant 
between N,N-benzylmethylacetamide and the {[κ4-TitmPri,benzo]Zn+} cation was found to 
be smaller than N-benzylazetidin-2-one (79 (± 10) M-1 and 200 (± 11) M-1 respectively, see 
Table 1). This result is contradictory with the expected donor abilities of β-lactams and 
acyclic amides, and suggests that other factors such as steric effects, more specifically 
the distortions of the [TitmPri,benzo] scaffold observed in [κ4-TitmPri,benzo]Zn(N-
benzylacetamide)(BPh4), may play a significant role in determining the binding constant 
between a ligand and {[κ4-TitmPri,benzo]Zn+} cation.  


















79 (± 10) 
Table 1: Binding constants between various cyclic and linear amides and the {[κ4-
TitmPri,benzo]Zn+} cation. 
 
The binding ability of β-lactams was also compared to that of 5-membered and 6-
membered ring lactams. 1H NMR titration experiments show that the binding of N-
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benzyl-2-pyrrolidinone and N-benzyl-2-pipieridinone is 117 (± 11) M-1 and 113 (± 10) M-1 
respectively (Table 1), suggesting that donor ability for cyclic lactam decreases in the 
order β-lactam > γ-butyrolactam ≈ δ-valerolactam. Although the reverse order has been 
reported in other systems,87 the binding constants are very similar in magnitude, such 
that no clear conclusion can be drawn from the observed binding constants of the 
different ring size lactams. Interestingly, 5 and 6-membered ring antibiotics have been 
proposed as possible alternative to 4-membered ring containing drugs, as their 
synthesis is less tedious than β-lactams, but their lower activity hindered further 
development.88 Based on these observations, we suggest than larger lactam rings 
antibiotics should be explored again as potential replacements for β-lactam antibiotics, 
not only because their hydrolysis rates are slower, but also their binding constants are 
smaller. 
 
2.3.8 Adducts between MBL synthetic analogues and potential MBL inhibitors 
2.3.8.1 Inhibitors of MBLs  
As soon as β-lactamases were identified, many studies were conducted to find 
inhibitors that can bind to the enzymes and disrupt their activity, allowing the 
antibiotics to serve their purpose without being hydrolyzed. Indeed, to find compounds 
that inhibit the action of a specific enzyme is easier than finding a completely new type 
of antibiotics. Compounds such as clavulanic acid, sulbactam and tazobactam have 
been found to inhibit the activity of most serine based β-lactamases (Scheme 6).89 They 
are currently used in commercial increased-spectrum antibiotic treatments, in which 
both the antibiotic and the inhibitor are co-formulated, for example clavulanic acid with 





















Clavulanic acid Sulbactam Tazobactam  
Scheme 6: Inhibitors of β-lactamases  
 
However, the search for MBL inhibitors has proven to be much more difficult, mainly 
because MBLs bear many structural resemblances with vital zinc enzymes.91 Chelating 
agents have been used with variable success, their limit being the extent by which they 
affect other important metalloenzymes.92 Moreover, because of their different mode of 
action, MBLs are unaffected by β-lactamases inhibitors effective against other classes (A, 
C,) of β-lactamases.93 As a result, no MBL inhibitor has yet passed clinical trial.50 
However, many small molecules have been screened and several have shown 
promising results (Table 2). 












































































































NDM-1 4 100b 
Table 2: Inhibitors for MBLs 
 
Although the structures of the inhibitors are relatively different, they usually include 
several binding groups such as amides, amines, nitrogen-containing heterocycles and 
thiols. Moreover, these groups are usually in close vicinity to each other, which could 
suggest potential chelating interactions. Because chelating interactions tend to be 
stronger than monodentate binding, it is reasonable to consider potentially chelating 
groups in inhibitors, as it would guarantee high affinity for the metal center. Several of 
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the inhibitors listed above have been isolated in adducts with the enzyme and 
structurally characterized by protein crystallography.107 However, only picolinic acid 
has been show to bind the zinc in a bidentate manner.104 We decided to react several 
small bidentate ligands possessing structural similarities with the existing inhibitors 
with the {[κ4-TitmPri,benzo]Zn+} cation in the hope of finding ligands with high binding 
constants, which would explain their use as inhibitors. The binding mode was analyzed 
by X-ray diffraction and the binding constants were determined via 1H NMR 
spectroscopy. 
 
2.3.8.2 Structure of adducts between MBL synthetic analogues and potential MBL 
inhibitors 
The first substrate investigated was the 2-aminoacetamide group, such as in 3,3-
dethylglycinamide, which consists of an amide with an amine in the α position, and has 
the potential to chelate the metal center. The reaction between 3,3-dethylglycinamide 
and [κ4-TitmPri,benzo]Zn(BPh4) yielded the adduct [κ4-TitmPri,benzo]Zn(3,3-
dethylglycinamide)(BPh4) (Scheme 7). The molecular structure of the adduct was 
determined by X-ray crystallography, showing that the glycinamide binds only through 
the amide group (Figure 15). The diethylamine group is involved in an intramolecular 
hydrogen bonding interaction with the hydrogen on the nitrogen from the amide 































Figure 15: Molecular structure of [κ4-TitmPri,benzo]Zn(3,3-dethylglycinamide)(BPh4). The 
BPh4 counterion has been omitted for clarity. 
 
Picolinamide was then investigated as another bidentate ligand, as it has been shown 
that the closely related compound picolinic acid binds the zinc center inside a MBL in a 
bidentate manner.104 The reaction between picolinamide and [κ4-TitmPri,benzo]Zn(BPh4) 
yielded the adduct [κ4-TitmPri,benzo]Zn(picolinamide)(BPh4) (Scheme 8). The molecular 
structure of the adduct was determined by X-ray crystallography, showing that 
picolinamide binds in a bidentate manner, with coordination of both the carbonyl from 
the amide and the pyridine to the zinc center (Figure 16). It is important to note that free 
picolinamide exhibits intramolecular hydrogen bonding between the pyridine and the 
 
 113 
amido group in the solid state, but this interaction is disrupted upon binding to the {[κ4-
TitmPri,benzo]Zn+} cation. The coordination geometry around the zinc is distorted 
octahedral, and the Zn-Npico distance of 2.313(3) Å is only slightly longer than the 




























Figure 16: Molecular structure of [κ4-TitmPri,benzo]Zn(picolinamide)(BPh4). The BPh4 




Some of the functionalities recurrently appearing in inhibitors are two carbonyl groups 
in the β or γ position relative to each other, such that the two oxygens could potentially 
chelate the zinc center. Therefore, dialkylpiperazine-2,3-diones were selected to test the 
binding of such functionalities. Not only are they able to chelate metals via their two 
carbonyl groups,108 but they also lack unwanted additional intramolecular hydrogen 
bonding interactions seen in oxalamides, succinimides, and polypeptides. The reaction 
between dimethylpiperazine-2,3-dione (DMDP) with [κ4-TitmPri,benzo]Zn(BPh4) yielded 
the adduct [κ4-TitmPri,benzo]Zn(DMDP)(BPh4) (Scheme 9). The molecular structure of the 
adduct was determined by X-ray crystallography, showing that the DMDP ligand binds 
in a bidentate fashion to the zinc center (Figure 17). Although the Zn-O bond cis to the 
carbanion bond is longer than the other Zn-O bond (2.347(2) Å and 2.154(2) Å 
respectively), it is still within the range of Zn-O bonds reported in the CSD, such that 



























Scheme 9  
Figure 17: Molecular structure of [κ4-TitmPri,benzo]Zn(DMDP)(BPh4). The BPh4 counterion 
has been omitted for clarity. 
 
2.3.9 Determination of binding constants between MBL synthetic analogues and 
potential MBL inhibitors 
The binding constants between 3,3-dethylglycinamide, picolinamide, and 
diethylpiperazine-2,3-dione (DEDP)109 and the {[κ4-TitmPri,benzo]Zn+} cation were 
determined by using 1H NMR spectroscopy, and are reported in Table 3. The goal of 
this study is to correlate structural features of the adducts between these three ligands 
and the {[κ4-TitmPri,benzo]Zn+} cation, with the magnitude of the binding interaction in 
these adducts, in hope of finding substrates with high binding constants towards the 
{[κ4-TitmPri,benzo]Zn+} cation. The binding constant between 3,3-dethylglycinamide and 
the {[κ4-TitmPri,benzo]Zn+} cation was determined to be 37 (±6) M-1 (Figure 18), whereas 
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that of picolinamide is 73 (±14) M-1 (Figure 19). The binding constant between 
diethylpiperazine-2,3-dione (DEDP)110 and the {[κ4-TitmPri,benzo]Zn+} cation as measured 
by 1H NMR spectroscopy is 176 (± 20) M-1 (Figure 20), a value very similar to that of N-
benzylazetidin-2-one (200 (± 11) M-1) (Table 3). 
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Figure 18: Scott plot for the determination of the binding constant between the {[κ4-




Figure 19: Scott plot for the determination of the binding constant between the {[κ4-




Figure 20: Scott plot for the determination of the binding constant between the {[κ4-
TitmPri,benzo]Zn} cation and DEDP 
 
Notably, none of the three ligands exhibit a higher binding constant than that of N-
benzylazetidin-2-one (200 (± 11) M-1). We hypothesize that several factors influence the 
strength of the binding interaction between ligands and the {[κ4-TitmPri,benzo]Zn+} cation, 
namely the donor ability of the ligand, the presence of chelating groups and the extent 
to which the ligand distorts the [TitmPri,benzo] scaffold when bound. However, in the case 
of 3,3-dethylglycinamide, picolinamide, and DMDP, structural evidences seem to point 
to distortions of the [TitmPri,benzo] scaffold as the reason for the low binding constants for 




The common structural difference between the {[κ4-TitmPri,benzo]Zn+} cation and 3,3-
dethylglycinamide, picolinamide, and DMDP adducts is that they feature a highly 
distorted [TitmPri,benzo] scaffold in comparison to the β-lactam [κ4-TitmPri,benzo]Zn(4-
phenylazetidin-2-one)(BPh4) adduct. The distortion of the [TitmPri,benzo] scaffold can be 
correlated to the value of the largest N-Zn-N angle between two benzimidazole arms in 
the [TitmPri,benzo] ligand, and how far it deviates from the ideal value of 120° (Figure 12). 
Whereas this angle is 133.71° in [κ4-TitmPri,benzo]Zn(4-phenylazetidin-2-one)(BPh4), it is 
141.66° in [κ4-TitmPri,benzo]Zn(3,3-dethylglycinamide)(BPh4), 157.1° in [κ4-
TitmPri,benzo]Zn(picolinamide)(BPh4), and 158.9° in [κ4-TitmPri,benzo]Zn(DMDP)(BPh4). 
Therefore, 3,3-dethylglycinamide, picolinamide, and DMDP have a much higher 
propensity to distort the [TitmPri,benzo] ligand upon binding to the the {[κ4-TitmPri,benzo]Zn+} 
cation than the β-lactam 4-phenylazetidin-2-one, which could explain their lower 
binding constant. Interestingly, the chelation observed in the [κ4-
TitmPri,benzo]Zn(picolinamide)(BPh4) and [κ4-TitmPri,benzo]Zn(DMDP)(BPh4) adducts 
increases the distortion of the [TitmPri,benzo] scaffold in these adducts, as the coordination 
around the zinc is forced into an octahedral geometry. It is important to note that 
distortions observed in the [TitmPri,benzo] scaffold can not be necessarily extrapolated to 
distortions of the ligand environment in the actual active site of MBLs. However, in the 
general context of a rigid enzyme active site, ligands that require a consequent 
reorganization of the coordination around the metal center upon binding will exhibit 
lower binding constants.  
 
2.3.10 Structural characterization of adducts between MBL synthetic analogues and 
other relevant ligands 
Preliminary results for the binding of several other monodentate and bidentate ligands 
were obtained. Although succinamides could potentially bind the metal in a bidentate 
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manner, the molecular structure of the adduct [κ4-TitmPri,benzo]Zn(N,N’-
dibutylsuccinamide)(BPh4) as determined by X-ray crystallography showed only 
monodentate binding with one of the amide groups, while the other amide is involved 




























Figure 21: (top) formation of [κ4-TitmPri,benzo]Zn(N,N’-dibutylsuccanimide)(BPh4). 
(bottom) Molecular structure of [κ4-TitmPri,benzo]Zn(N,N’-dibutylsuccanimide)(BPh4). The 
BPh4 counterion has been omitted for clarity. 
Interestingly, the switch to N,N,N’,N’-tetraethylsuccinamide did not promote bidentate 
binding, but instead generated the dinuclear compound ([κ4-TitmPri,benzo]Zn)2(N,N,N’,N’-
tetrabutylsuccinamide)(BPh4)2 where the N,N,N’,N’-tetrabutylsuccinamide bridges 







































Figure 22: (top) formation of ([κ4-TitmPri,benzo]Zn)2(N,N,N’,N’-
tetrabutylsuccinamide)(BPh4)2 (bottom) Molecular structure of ([κ4-
TitmPri,benzo]Zn)2(N,N,N’,N’-tetrabutylsuccinamide)(BPh4)2. The BPh4 counterions have 
been omitted for clarity. 
 
A variety of ligands were tested (Figure 23). Unfortunately, they neither produce 
crystals suitable for X-ray diffraction studies, nor had the appropriate solubility to 











































N,N'-dibenzylphthalic diamide 2,2'-bipyridyl N-benzylthiophene-2-carboxamide
Penicillin G benzyl ester adenine  
Figure 23: Ligands tested with the {[κ4-TitmPri,benzo]Zn+} cation. On the top line are listed 
potentially bidentate ligands. On the middle line are listed monodentate ligands. On the 
bottom line are listed biologically relevant ligands. 
Of all the ligands tested, acetylphthalimide, oxanilide, N,N’-dibenzylphthalic diamide, 
N-benzylthiophene-2-carboxamide, ureas, thioureas, penicillin G benzyl ester and 
adenine were not sufficiently soluble in benzene to observe significant binding with the 
{[κ4-TitmPri,benzo]Zn+} cation. However, simple structural modifications of the compounds 
to include more solubilizing groups could overcome this issue. 2,2’-bipyridyl, 
benzimidazoles, and guanidines showed promising results by 1H NMR spectroscopy, 
but did not provide any crystals to confirm the binding mode of these ligands. Future 
directions for this project include the synthesis of more soluble ligands as well as the 
extension of the library of functionalities capable of binding the {[κ4-TitmPri,benzo]Zn+} 
cation. Extending the list of binding functionalities could lead to the identification of 
functionalities with high binding constants that could ultimately be used to design 




2.3.11 Identification of secondary interactions in the binding between MBL synthetic 
models and analogues of antibiotics 
Since no potential inhibitor showed satisfactory results, we decided to focus on the 
binding of β-lactam substrates to the {[κ4-TitmPri,benzo]Zn+} cation. Specifically, β-lactam 
antibiotics are structurally more elaborate than the simple 4-phenylazetidin-2-one used 
in our binding studies, and contain several functional groups capable of interacting 
with a metal center in addition to the carbonyl from the β-lactam (Figure 4). Such 
interactions, even secondary, might result in an increased affinity between the enzymes 
and the drug, thereby playing a determinant role in the selectivity of MBLs.111 However, 
any additional secondary interactions involving the zinc center and other functionalities 
present in β-lactams antibiotics will not be observed if the binding studies are limited to 
simple β-lactams. We therefore decided to investigate substrates structurally closer to β-
lactam antibiotics. Of particular interest, almost all β-lactam antibiotics possess an 
amide group in the 3 position of the β-lactam (Scheme 10),112 which could possibly 
interact with the zinc center in MBLs active site. This amide group is not involved in the 
mechanism of action of β-lactam drugs since the main functionality that interacts with 
the target enzymes for these drugs is the β-lactam core. However, this amide group has 
been observed to be involved in hydrogen bonding in the crystal structures of adducts 
between antibiotics and penicillin binding proteins.113,114 The presence of this amide 
group originates from the fact that the synthetic starting materials for most β-lactam 
antibiotics are amines such as 6-aminopenicillanic acid, which can be acylated with 
































1-benzyl-3-acetamidoazetidin-2-one possesses a structure closer to commercially 
available antibiotics than 4-phenylazetidin-2-one (Scheme 10), as it contains an amide 
group in the 3 position of the β-lactam. Therefore, we investigated its binding towards 
the {[κ4-TitmPri,benzo]Zn} cation to probe for additional secondary interactions between 
the amide group and the zinc center. 
 
The synthesis of 1-benzyl-3-acetamidoazetidin-2-one was inspired from a known 
procedure involving a [2+2] addition between a ketene and a formimide equivalent.116 
Phthaloyl ketene, which is obtained by reaction between phthalimidoacetyl chloride 
and triethylamine at low temperature, was reacted with a mixture of 1,3,5-tribenzyl-
1,3,5-triazacyclohexane and boron trifuoride diethyletherate to give 1-benzyl-3-
phthaloylazetidin-2-one. The phthaloyl group was easily removed by reaction with 
methylamine, and the remaining 1-benzyl-3-aminoazetidin-2-one was acylated with 
acetic anhydride (Figure 24).117 Reaction with [κ4-TitmPri,benzo]Zn(BPh4) leads to the 
immediate formation of the 1:1 adduct [κ4-TitmPri,benzo]Zn(1-benzyl-3-acetamidoazetidin-
2-one)(BPh4) (Scheme 11). The molecular structure of the adduct was determined by X-
ray crystallography, and shows the ligand binding to the zinc center via the carbonyl 
from the β-lactam (Figure 25). The Zn-C distance in the adduct is 2.212 Å, which is 
similar to that observed in [κ4-TitmPri,benzo]Zn(4-phenylazetidin-2-one)(BPh4) [2.281(7) Å]. 
The C=O bond in the β-lactam in [κ4-TitmPri,benzo]Zn(1-benzyl-3-acetamidoazetidin-2-
one)(BPh4) [1.242(2) Å] is slightly longer than in the free 1-benzyl-3-acetamidoazetidin-

































R = Me, C2H4Ph
 
































Figure 25: Molecular structure of [κ4-TitmPri,benzo]Zn(1-benzyl-3-acetamidoazetidin-2-
one)(BPh4). The BPh4 counterion has been omitted for clarity. 
 
Interestingly, the acetamide group of 1-benzyl-3-acetamidoazetidin-2-one takes part in a 
weak interaction with the zinc center. Indeed the geometry around the zinc center in 
[κ4-TitmPri,benzo]Zn(1-benzyl-3-acetamidoazetidin-2-one)(BPh4) approaches a square 
pyramidal geometry characterized by τ5 = 0.34, 118 clearly deviating from the distorted 
trigonal bipyramidal geometry in [κ4-TitmPri,benzo]Zn(4-phenylazetidin-2-one)(BPh4). The 
Zn-O2 bond length of 3.042 Å, although being clearly longer than the sum of the 
covalent radii for Zn and O [1.81 – 1.88 Å],119 is significantly smaller than the sum of the 
respective van der waals radii [3.65 Å].120 Furthermore, the 1-benzyl-3-
acetamidoazetidin-2-one undergoes structural change upon binding to the {[κ4-
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TitmPri,benzo]Zn+} cation, as illustrated by the overlay between the structures of free 1-
benzyl-3-acetamidoazetidin-2-one and coordinated 1-benzyl-3-acetamidoazetidin-2-one 
shown in Figure 26. Specifically, the O1-C1-C2-O2 torsion angle, θ, between the β-lactam 
carbonyl and the acetamide carbonyl (Figure 27) varies from -88.19° in the free 1-benzyl-
3-acetamidoazetidin-2-one to 49.22° for the coordinated compound in [κ4-
TitmPri,benzo]Zn(1-benzyl-3-acetamidoazetidin-2-one)(BPh4). Notably, the average torsion 
angle θ  for compounds possessing a 3-acetamidoazetidin-2-one motif reported in the 
CSD is -86.88°, and 1% of these compounds have θ between 50° and -50°. Therefore, the 
value of θ of 49.22° in the coordinated 1-benzyl-3-acetamidoazetidin-2-one substrate is 
unusual, and most likely results from a secondary interaction between the amide 
carbonyl and the zinc center in the {[κ4-TitmPri,benzo]Zn+} cation. 
 
Figure 26: Overlay between the structures of 1-benzyl-3-acetamidoazetidin-2-one when 









Figure 27: Definition of the torsion angle θ.   
 
Moreover, DFT calculations on 1-benzyl-3-acetamidoazetidin-2-one with various O-C-
C-O torsion angle show that the conformation of the free 1-benzyl-3-acetamidoazetidin-
2-one with a θ of -88.19 is 2.3 kcal mol-1 lower in energy than the conformation observed 
in [κ4-TitmPri,benzo]Zn(1-benzyl-3-acetamidoazetidin-2-one)(BPh4) with a θ of 49.22°. 
However, DFT calculations on [κ4-TitmPri,benzo]Zn(1-benzyl-3-acetamidoazetidin-2-
one)(BPh4) with various θ in the 1-benzyl-3-acetamidoazetidin-2-one show that the 
conformation with a θ of 49.22° is lower in energy by 0.2 kcal mol-1 than with a θ of -
88.19°. Overall, theses changes prove that the 1-benzyl-3-acetamidoazetidin-2-one 
ligand undergoes severe structural distortions upon binding to promote secondary 
interaction between the acetamide group and the zinc center. The energetic penalty to 
access the energetically unfavorable conformation of 1-benzyl-3-acetamidoazetidin-2-
one observed in [κ4-TitmPri,benzo]Zn(1-benzyl-3-acetamidoazetidin-2-one)(BPh4) is 
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counterbalanced by the binding interaction between the zinc center and the amido 
carbonyl group.  
 
2.3.12 Determination of the binding constant between a MBL synthetic model and an 
analogue of antibiotics 
1H NMR spectroscopy provides a binding constant between 1-benzyl-3-
acetamidoazetidin-2-one and the {[κ4-TitmPri,benzo]Zn} cation of 94 (± 21) M-1 (Figure 28). 
Although this value is lower than N-benzylazetidin-2-one [200 (± 11) M-1] , it is in the 
range of binding constants observed for the other ligands reported in this chapter. The 
difference in binding constants between N-benzylazetidin-2-one and 1-benzyl-3-
acetamidoazetidin-2-one probably originates from the constraints imposed on the 
[TitmPri,benzo] ligand upon binding of 1-benzyl-3-acetamidoazetidin-2-one to the {[κ4-
TitmPri,benzo]Zn} cation. The largest N-Zn-N angle between two benzimidazole arms in 
the [TitmPri,benzo] ligand is 146.95° in the [κ4-TitmPri,benzo]Zn(1-benzyl-3-acetamidoazetidin-
2-one)(BPh4) adduct, which is significantly larger than that observed in the [κ4-
TitmPri,benzo]Zn(4-phenylazetidin-2-one)(BPh4) [133.71°]. Interestingly, the value of 
146.95° for this angle is close to the value observed in [κ4-TitmPri,benzo]Zn(N-
benzylacetamide)(BPh4) [141.8°]. In that regard, the distortions on the [TitmPri,benzo] 
scaffold are comparable in the two adducts. The binding constant for the closely related 





Figure 28: Scott plot for the determination of the binding constant between the {[κ4-
TitmPri,benzo]Zn} cation and 1-benzyl-3-acetamidoazetidin-2-one. 
 
2.3.13 Binding between MBL synthetic models and carbapenems 
One of the reasons why MBLs are a cause of great concern is their ability to hydrolyze 
“last resort” drugs like carbapenems. Interestingly, carbapenems also possess a binding 
alcohol group in the 3 position of the β-lactam (Figure 4), which could provide a similar 
secondary chelating interaction. We therefore synthesized a synthetic analogue of 
carbapenems to test whether the alcohol group binds to the zinc in addition to the 
carbonyl from the β-lactam, which would justify the enhanced activity of MBLs towards 
these drugs. The target compound is 1-benzyl-3-(hydroxy(phenyl)methyl)azetidin-2-
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one (Scheme 12), and was synthesized by using the same strategy as 1-benzyl-3-
acetamidoazetidin-2-one. The lactam was produced via a [2+2] addition between benzyl 
formimide and the ketene derived from 3-((tert-butyldimethylsilyl)oxy)-3-
phenylpropanoyl chloride. Deprotection of the TBS group with tetrabutylammonium 
fluoride generated the desired compound (Scheme 12). Preliminary results show that 
the addition of the lactam to [κ4-TitmPri,benzo]Zn(BPh4) generates the adduct; however, we 
could not confirm the binding mode by X-ray diffraction. Further efforts are underway 







2) TBSCl, imidazole, DCM
3) LiOH, H2O
4) Oxalyl chloride, 


















In conclusion, [TitmMe] zinc complexes were investigated as models for CA. In 
particular, [κ4-TitmMe]ZnNHSO2C6H4-p-Me provides a rare example of a zinc center 
bound to a primary sulfonamide, which are known inhibitors of CA. In the solid state, 
[κ4-TitmMe]ZnNHSO2C6H4-p-Me exists as a hydrogen bonded dimer, in which the N–H 
from the sulfonamide interacts with a sulfone oxygen. This type of hydrogen bonding 
pattern has been observed in adducts between CA and sulfonamide inhibitors, thereby 
highlighting the importance of secondary interactions in the binding between enzymes 
and inhibitors. 
 
Then, the bulky [TitmPri,benzo] ligand was used to access to novel cationic zinc compounds 
[κ4-TitmPri,benzo]ZnX (X = MeB(C6F5)3, BPh4). The protective pocket provided by the benzo 
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groups from the ligand allows for the binding of 4-phenylazetidin-2-one to provide the 
1:1 adduct [κ4-TitmPri,benzo]Zn(4-phenylazetidin-2-one)(BPh4). This unprecedented adduct 
shows binding of the β-lactam to the zinc center via the oxygen from the carbonyl, as 
proposed in the mode of action of MBLs. The binding constant for the N-
benzylazetidin-2-one was measured by 1H NMR spectroscopy and was determined to 
be higher than that of linear amide, as well as cyclic amides with larger ring size. This 
work provides structural evidence for the first step of the mechanism of antibiotic 
hydrolysis by MBLs. It also highlights the roles of both the donor abilities of the ligand 
binding, as well as the constraints imposed on the [TitmPri,benzo] ligand scaffold upon 
binding as two important factors influencing the strength of the binding to the {[κ4-
TitmPri,benzo]Zn+} cation. 
 
Notably, after testing the binding of several other neutral monodentate and bidentate 
ligands including 3,3-dethylglycinamide, picolinamide, and DMDP, the functionality 
exhibiting the highest binding constant towards the {[κ4-TitmPri,benzo]Zn+} cation remains 
N-benzylazetidin-2-one, as it is electronically a good donor, and it generates very few 
constraints on the [TitmPri,benzo] ligand scaffold upon binding. However, the binding 
studies on these ligands provided important information pertaining to the different 
factors that affect the binding constant, such as the electronics of the ligand, the 
presence of intramolecular hydrogen bonding in the ligand and the amount of 
constraints imposed on the [TitmPri,benzo] scaffold upon binding of the ligand. With that 
in mind, extending the library of functionalities capable of binding the {[κ4-
TitmPri,benzo]Zn+} cation could allow to identifiy ligands with higher binding than β-
lactams, and facilitate the design of new inhibitors for MBLs. 
 
The adduct of the cationic zinc complex [κ4-TitmPri,benzo]Zn(BPh4) and the simple mimic 
of β-lactam antibiotics, 1-benzyl-3-acetamidoazetidin-2-one, which possesses a β-lactam 
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core and an acetamide group in the 3 position, was characterized. In addition to the 
expected coordination from the β-lactam to the zinc center, we also identified a 
secondary interaction between the acetamide group and the metal. This observation is 
of great importance because secondary interactions can greatly affect the binding of a 
substrate to an enzyme. The fact that this amide group is present in almost all 
commercially available β-lactam antibiotics can therefore explain the broad spectrum 
for MBLs, especially since the binding affinity to the zinc center has been shown to be 
an important factor in the activity of these enzymes. The proposed non-innocence of the 
side amide group also offers easily accessible solutions for the design of new antibiotics, 
as the modification or suppression of this specific group could greatly reduce binding to 




2.5 Experimental Section 
2.5.1 General Considerations 
All manipulations were performed using a combination of glovebox, high vacuum, and 
Schlenk techniques under a nitrogen or argon atmosphere.121 Solvents were purified and 
degassed by standard procedures. 1H NMR spectra were measured on Bruker 300 DRX, 
Bruker 400 DRX, and Bruker Avance 500 DMX spectrometers. 1H NMR chemical shifts 
are reported in ppm relative to SiMe4 (δ = 0) and were referenced internally with respect 
to the protio solvent impurity (δ 7.16 for C6D5H, 1.72 for THF-d7, 5.32 for CDHCl2).122 13C 
NMR spectra are reported in ppm relative to SiMe4 (δ = 0) and were referenced 
internally with respect to the solvent (δ 128.06 for C6D6, 67.21 for THF-d8, 53.84 for 
CD2Cl2). Coupling constants are given in hertz.122 11B NMR are reported in ppm relative 
to BF3•Et2O (δ = 0) and were obtained by using the Ξ/100% value of 32.083974.123 19F 
NMR chemical shifts are reported in ppm relative to CFCl3 (δ = 0.0) and were obtained 
by using the Ξ/100% value of 94.094011. Infrared spectra were recorded on Nicolet 
Avatar 370 DTGS spectrometer and are reported in cm-1. 4-phenylazetidin-2-one,124 N-
benzylpyrrolidone,125 N-benzylpiperidone,125 1,4-dimethylpiperazine-2,3-dione 
(DMDP),126 3,3-dethylglycinamide,127 N,N,N’,N’-tetraethylsuccinimide,128 
acetylphthalimide,129 N,N’-dibenzylphthalic diamide,130 N-benzylthiophene-2-
carboxamide,131 dibenzyl thiourea,132 penicillin G benzyl ester,133 and 1-benzyl-3-
phthalimidoazetidin-2-one134 were obtained by literature method. 
 
2.5.2 X-ray Structure Determinations 
X-ray diffraction data were collected on a Bruker Apex II diffractometer. Crystal data, 
data collection and refinement parameters are summarized in Table 4. The structures 
were solved using direct methods and standard difference map techniques, and were 
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refined by full-matrix least-squares procedures on F2 with SHELXTL (Version 
2014/7).135 
 
2.5.3 Computational Details 
Calculations were carried out using DFT as implemented in the Jaguar 7.5 (release 207) 
suite of ab initio quantum chemistry programs.136 Geometry optimizations were 
performed with the B3LYP density functional137 using the 6-31G** (C, H, N, O, S) and 
LAV3P (Zn) basis sets.138  
 
2.5.4 Synthesis of [κ4-TitmMe]ZnNHS(O)2Tol 
A mixture of [κ3-TitmMe]ZnMe (20 mg, 0.046 mmol) and para-toluenesulfonamide (8 mg, 
0.047 mmol) was treated with benzene (ca. 2 mL). After the evolution of methane was 
finished, the solution was filtered. The off white solid was washed with THF (1 mL) and 
dried in vacuo to give [κ4-TitmMe]ZnNHS(O)2Tol (23 mg, 90%). Crystals of [κ4-
TitmMe]ZnNHS(O)2Tol suitable for X-ray diffraction were obtained from slow 
evaporation from benzene. 1H NMR (C6D6): 8.51 [d, J = 8 Hz, 2H, 
CH3C6H4O2SNHZnC(SC3H2N2Me)3], 7.88 [d, J = 1.7 Hz, 3H, 
CH3C6H4O2SNHZnC(SC3H2N2Me)3], 7.05 [d, J = 8.0 Hz, 2H, 
CH3C6H4O2SNHZnC(SC3H2N2Me)3], 5.85 [d, J = 1.6 Hz, 3H, 
CH3C6H4O2SNHZnC(SC3H2N2Me)3], 2.28 [s, 9H, (CH3C6H4O2SNHOZnC(SC3H2N2Me)3], 
2.07 [s, 9H, CH3C6H4O2SNHPhOZnC(SC3H2N2Me)3]. 1H NMR (THF-d8): 7.9 [d, J = 8 Hz, 
2H, CH3C6H4O2SNHZnC(SC3H2N2Me)3], 7.56 [s, 3H, 
CH3C6H4O2SNHZnC(SC3H2N2Me)3], 7.17 [d, J = 7.8 Hz, 2H, 
CH3C6H4O2SNHZnC(SC3H2N2Me)3], 6.85 [d, 3H, CH3C6H4O2SNHZnC(SC3H2N2Me)3], 
3.34 [s, 9H, (CH3C6H4O2SNHOZnC(SC3H2N2Me)3], 2.35 [s, 9H, 
CH3C6H4O2SNHPhOZnC(SC3H2N2Me)3]. 13C{1H} NMR (THF-d8): 128.9 [s, 2C, 
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CH3C6H4O2SNHZnC(SC3H2N2Me)3], 128.1 [s, 3C, CH3C6H4O2SNHZnC(SC3H2N2Me)3], 
126.6 [s, 2C, CH3C6H4O2SNHZnC(SC3H2N2Me)3], 122.7 [s, 3C, 
CH3C6H4O2SNHZnC(SC3H2N2Me)3], 32.1 [s, 3C, (CH3C6H4O2SNHOZnC(SC3H2N2Me)3], 
21.1 [s, 1C, CH3C6H4O2SNHPhOZnC(SC3H2N2Me)3]. 
 
2.5.5 Synthesis of [κ4-TitmPri,benzo]Zn(MeB(C6F5)3)  
a) B(C6F5)3 (76 mg, 0.15 mmol) was added to a suspension of [κ3-TitmPri,benzo]ZnMe (100 
mg, 0.15 mmol) in benzene (ca. 2 mL). The mixture was stirred until it became 
homogeneous, and was allowed to sit overnight. During this period, the compound 
crystallized out of the solution as white crystals. The mother liquor was removed and 
the crystals were washed with pentane to afford pure [κ4-TitmPri,benzo]Zn(MeB(C6F5)3 (157 
mg, 89%). The crystals as obtained from the reaction were suitable for X-Ray diffraction. 
b) B(C6F5)3 (114 mg, 0.22 mmol) was added to a suspension of [κ3-TitmPri,benzo]ZnMe (150 
mg, 0.23 mmol) in toluene (ca. 2 mL). The mixture was stirred until it became 
homogeneous, and was allowed to sit overnight. During this period, the compound 
precipitated out of the solution as a white solid. The mother liquor was removed and 
the solid was washed with pentane to afford pure [κ4-TitmPri,benzo]Zn(MeB(C6F5)3 (170 
mg, 65%). The solid was used for the binding experiments. 1H NMR (CD2Cl2) 0.49 [s, 
3H, (C6H4N2CH(CH3)2CS)3CZnCH3B(C6F5)3], 1.62 [d, J = 7 Hz, 18H, 
(C6H4N2CH(CH3)2CS)3CZnCH3B(C6F5)3], 4.54 [sept, J = 6.9 Hz, 3H, 
(C6H4N2CH(CH3)2CS)3CZnCH3B(C6F5)3], 7.36 [m, 3H, 
(C6H4N2CH(CH3)2CS)3CZnCH3B(C6F5)3], 7.44 [m, 3H, 
(C6H4N2CH(CH3)2CS)3CZnCH3B(C6F5)3], 7.57 [d, J = 8.2 Hz, 3H 
(C6H4N2CH(CH3)2CS)3CZnCH3B(C6F5)3], 7.78 [d, J = 8 Hz, 3H 
(C6H4N2CH(CH3)2CS)3CZnCH3B(C6F5)3]. 13C NMR (CD2Cl2) 10.52 [s, 1C, 
(C6H4N2CH(CH3)2CS)3CZnH3B(C6F5)3],20.97 [s, 6C, 
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(C6H4N2CH(CH3)2CS)3CZnCH3B(C6F5)3], 51.51 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZnCH3B(C6F5)3], 112.96 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZnCH3B(C6F5)3], 115.91 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZnCH3B(C6F5)3], 124.20 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZnCH3B(C6F5)3], 124.78 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZnCH3B(C6F5)3], 135.63 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZnCH3B(C6F5)3], 139.02 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZnCH3B(C6F5)3], 161.52 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZnCH3B(C6F5)3]. 19F NMR (CD2Cl2) -133.25 [d, J = 24.4 Hz, 
(C6H4N2CH(CH3)2CS)3CZnCH3B(C6F5)3], -165.51 [t, J = 20.2 Hz, 
(C6H4N2CH(CH3)2CS)3CZnCH3B(C6F5)3], -168.06 [m, 
(C6H4N2CH(CH3)2CS)3CZnCH3B(C6F5)3]. 11B NMR (CD2Cl2) -14.98 [s, 
(C6H4N2CH(CH3)2CS)3CZnCH3B(C6F5)3]. Anal. Calc. for [κ4-
TitmPri,benzo]Zn(MeB(C6F5)3)•0.5 C6H6: C, 52.3%; H, 3.2%; N, 6.9%. Found: C, 52.1%; H, 
3.1%; N, 6.8%. 
 
2.5.6 Self diffusion constant 
The self-diffusion constant for [κ4-TitmPri,benzo]ZnMeB(C6F5)3 were determined by pulsed 
gradient spin-echo (PGSE) diffusion NMR spectroscopic experiments employing the 
Bruker stebpg1s pulse sequence. 
 
2.5.7 Synthesis of [κ4-TitmPri,benzo]Zn(BPh4)  
A suspension of [κ3-TitmPri,benzo]ZnMe (90 mg, 0.14 mmol) in benzene (ca. 2 mL) was 
treated with [PhNMe2H](BPh4) (60 mg, 0.14 mmol) and stirred for 30 min. The solution 
turned clear and a white precipitate appeared after 10 min. The solid was filtered, 
washed with pentane and dried in vacuo to afford [κ4-TitmPri,benzo]Zn(BPh4) (68 mg, 50%). 
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1H NMR (THF-d8): 1.55 [d, J = 6.8 Hz, 18H, (C6H4N2CH(CH3)2CS)3CZnB(Ph)4], 4.57 [sept, 
J = 6.9 Hz, 3H, (C6H4N2CH(CH3)2CS)3CZnB(Ph)4], 6.68 [t, J = 7.2 Hz, 4H, 
(C6H4N2CH(CH3)2CS)3CZnB(Ph)4], 6.84 [t, J = 7.4, 8H, (C6H4N2CH(CH3)2CS)3CZnB(Ph)4], 
7.31 [m, 11H, (C6H4N2CH(CH3)2CS)3CZnB(Ph)4], 7.38 [t, J = 7.8 Hz, 3H, 
(C6H4N2CH(CH3)2CS)3CZnB(Ph)4], 7.66 [d, J = 8.2 Hz, 3H, 
(C6H4N2CH(CH3)2CS)3CZnB(Ph)4], 8.08 [d, J = 8.1 Hz, 3H, 
(C6H4N2CH(CH3)2CS)3CZnB(Ph)4]. 13C NMR (THF-d8): 20.50 [s, 6C, 
(C6H4N2CH(CH3)2CS)3CZnB(Ph)4], 51.40 [s, 3C (C6H4N2CH(CH3)2CS)3CZnB(Ph)4], 113.17 
[s, 3C, (C6H4N2CH(CH3)2CS)3CZnB(Ph)4], 116.56 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZnB(Ph)4], 121.49 [s, 4C, (C6H4N2CH(CH3)2CS)3CZnB(Ph)4], 
124.08 [s, 3C, (C6H4N2CH(CH3)2CS)3CZnB(Ph)4], 124.49 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZnB(Ph)4], 125.42 [q, J = 2.9 Hz, 8C, 
(C6H4N2CH(CH3)2CS)3CZnB(Ph)4], 136.30 [s, 3C, (C6H4N2CH(CH3)2CS)3CZnB(Ph)4], 
137.08 [s, 8C, (C6H4N2CH(CH3)2CS)3CZnB(Ph)4], 139.89 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZnB(Ph)4], 161.32 [s, 3C, (C6H4N2CH(CH3)2CS)3CZnB(Ph)4], 
165.12 [q, J = 50 Hz ,4C, (C6H4N2CH(CH3)2CS)3CZnB(Ph)4]. 11B NMR (THF-d8): - 6.51 [p, J 
= 2.4 Hz, (C6H4N2CH(CH3)2CS)3CZnB(Ph)4].  
 
2.5.8 Synthesis of [κ4-TitmPri,benzo]Zn(4-phenylazetidin-2-one)(BPh4)  
4-Phenylazetidin-2-one (1.9 mg, 0.01 mmol) was added to a suspension of [κ4-
TitmPri,benzo]Zn(BPh4) (10 mg, 0.01 mmol) in benzene (ca. 0.5 mL). The mixture was 
shaken until all solids dissolved, after which the solution was filtered and was allowed 
to stand for a period of 1 day, during which white crystals deposited. The mother liquor 
was decanted and the cystals were washed with hexanes (0.5 mL) and dried in vacuo to 
afford [κ4-TitmPri,benzo]Zn(4-phenylazetidin-2-one)(BPh4)•C6H6 (11 mg, 89%). The crystals 
as obtained from the reaction were suitable for X-Ray diffraction. 1H NMR (C6D6): 0.92 
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[d, J = 6.9 Hz, 18H, (C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 1.87 [d, J = 
15.1 Hz, 1H, (C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 2.53 [d, J = 14 Hz, 
1H, (C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 2.96 [s, 1H, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 4.02 [sept, J = 6.9 Hz, 3H, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 5.00 [s, 1H, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 6.24 [d, J = 7.6 Hz, 2H, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 6.80 [d, J = 8.2 Hz, 3H 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 6.83 [t, J = 7.7 Hz, 2H 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 6.91 [t, J = 8.2 Hz, 3H 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 7.04 [t, J = 7.2 Hz, 4H 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 7.23 [m, 8H, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 7.97 [m, 8H, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 8.27 [d, J = 8.2 Hz, 3H, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4]. 1H NMR (CD2Cl2): 1.59 [d, J = 6.9 
Hz, 18H, (C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 2.72 [d, J = 15.0 Hz, 1H, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 3.29 [m, 1H, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 4.53 [sept, J = 6.9 Hz, 3H, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 6.18 [s, 1H, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 6.85 [d, J = 8.2 Hz, 3H 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 7.00 [t, J = 7.4 Hz, 4H 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 7.11 [t, J = 7.7 Hz, 2H 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 7.29 [m, 16H, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 7.34 [s, J = 7.7 Hz, 3H 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 7.41 [t, J = 7.5 Hz, 3H 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 7.53 [m, 3H, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 7.87 [d, J = 8.1 Hz, 3H, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4]. 13C NMR (CD2Cl2): 21.01 [s, 6C, 
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(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 48.01 [s, 1C, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 51.04 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 51.37 [s, 1C, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 112.80 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 116.39 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 119.7 [s, 1C, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 122.08 [s, 4C, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 123.91 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 124.43 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 125.98 [q, J = 2.7 Hz, 8C, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 128.71 [s, 2C, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 129.13 [s, 2C, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 135.89 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 136.31 [s, 8C, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4], 139.51 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4]. 11B NMR (CD2Cl2): -6.61 [s, 
(C6H4N2CH(CH3)2CS)3CZn(HNC(O)CH2CHPh)B(Ph)4]. IR Data (cm-1): 3426.3 (w), 2983 
(w), 2939 (w), 1709.4 (s), 1640.7 (w), 1510.9 (s), 1441.1 (vs), 1358.5 (s), 1286.5 (s), 1267.8 
(s), 1075.1 (vs), 933.3 (s), 831.4 (m), 742.9 (s), 679.3(m). 
 
2.5.9 Synthesis of [κ4-TitmPri,benzo]Zn(N-benzylacetamide)(BPh4)  
N-Benzylacetamide (1.9 mg, 0.01 mmol) was added to a suspension of [κ4-
TitmPri,benzo]Zn(BPh4) (10 mg, 0.01 mmol) in benzene (ca. 0.5 mL). The mixture was 
shaken until all solids dissolved, after which the solution was filtered and was allowed 
to stand for a period of 1 day, during which white crystals deposited. The mother liquor 
was decanted and the crystals were washed with hexanes (0.5 mL) and dried in vacuo to 
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afford [κ4-TitmPri,benzo]Zn(N-benzylacetamide)BPh4•4(C6H6) (9.1 mg, 62%). The crystals 
as obtained from the reaction were suitable for X-Ray diffraction. 1H NMR (CD2Cl2): 
1.59 [d, J = 6.9 Hz, 18H, (C6H4N2CH(CH3)2CS)3CZn(PhCH2NHC(O)CH3)B(Ph)4], 1.70 [s, 
3H, (C6H4N2CH(CH3)2CS)3CZn(PhCH2NHC(O)CH3)B(Ph)4], 4.53 [sept, J = 7 Hz, 3H, 
(C6H4N2CH(CH3)2CS)3CZn(PhCH2NHC(O)CH3)B(Ph)4], 4.68 [s, 2H, 
(C6H4N2CH(CH3)2CS)3CZn(PhCH2NHC(O)CH3)B(Ph)4], 6.17 [s, 1H, 
(C6H4N2CH(CH3)2CS)3CZn(PhCH2NHC(O)CH3)B(Ph)4], 6.84 [t, J = 7.2 Hz, 3H 
(C6H4N2CH(CH3)2CS)3CZn(PhCH2NHC(O)CH3)B(Ph)4], 6.99 [t, J = 7.4 Hz, 8H 
(C6H4N2CH(CH3)2CS)3CZn(PhCH2NHC(O)CH3)B(Ph)4], 7.37 [m, 21H, 
(C6H4N2CH(CH3)2CS)3CZn(PhCH2NHC(O)CH3)B(Ph)4], 7.81 [s, 3H, 
(C6H4N2CH(CH3)2CS)3CZn(PhCH2NHC(O)CH3)B(Ph)4]. 13C NMR (CD2Cl2): 21.00 [s, 6C, 
(C6H4N2CH(CH3)2CS)3CZn(PhCH2NHC(O)CH3)B(Ph)4], 44.72 [s, 1C 
(C6H4N2CH(CH3)2CS)3CZn(PhCH2NHC(O)CH3)B(Ph)4], 50.56 [s, 3C 
(C6H4N2CH(CH3)2CS)3CZn(PhCH2NHC(O)CH3)B(Ph)4], 112.50 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn(PhCH2NHC(O)CH3)B(Ph)4], 116.69 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn(PhCH2NHC(O)CH3)B(Ph)4], 122.09 [s, 4C, 
(C6H4N2CH(CH3)2CS)3CZn(PhCH2NHC(O)CH3)B(Ph)4], 123.46 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn(PhCH2NHC(O)CH3)B(Ph)4], 123.86 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn(PhCH2NHC(O)CH3)B(Ph)4], 126.01 [q, J = 2.5 Hz, 8C, 
(C6H4N2CH(CH3)2CS)3CZn(PhCH2NHC(O)CH3)B(Ph)4], 128.07 [s, 2C, 
(C6H4N2CH(CH3)2CS)3CZn(PhCH2NHC(O)CH3)B(Ph)4], 128.34 [s, 1C, 
(C6H4N2CH(CH3)2CS)3CZn(PhCH2NHC(O)CH3)B(Ph)4], 129.35 [s, 2C, 
(C6H4N2CH(CH3)2CS)3CZn(PhCH2NHC(O)CH3)B(Ph)4], 134.53 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn(PhCH2NHC(O)CH3)B(Ph)4], 136.00 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn(PhCH2NHC(O)CH3)B(Ph)4], 136.28 [s, 8C, 
(C6H4N2CH(CH3)2CS)3CZn(PhCH2NHC(O)CH3)B(Ph)4]. 11B NMR (CD2Cl2): - 6.64 [s, 
(C6H4N2CH(CH3)2CS)3CZn(PhCH2NHC(O)CH3)B(Ph)4]. Anal. calc. for [κ4-
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TitmPri,benzo]Zn(N-benzylacetamide)BPh4: C, 68.7%; H, 5.8%; N, 8.8%. Found: C, 67.8%; H, 
5.7%; N, 8.3%. IR Data (cm-1): 3361.5 (w), 3338.2 (w), 3051 (w), 2982.2 (w) 2930.7 (w), 
1599.8 (m), 1429.5 (m), 1408.0 (m), 1354.2 (m), 1283.4 (m), 1137.6 (w), 1067.7 (m), 931.9 
(w) 846.5 (w), 734.4 (s), 702.1 (s), 609.2 (m). 
 
2.5.10 Synthesis of [κ4-TitmPri,benzo]Zn(DMDP)(BPh4)  
DMDP (1.5 mg, 0.01 mmol) was added to a suspension of [κ4-TitmPri,benzo]Zn(BPh4) (10 
mg, 0.01 mmol) in benzene (ca. 0.5 mL). The mixture was shaken until all solids 
dissolved after 2 minutes, after which the solution was filtered and lyophilized. The 
solid was recrystallized from benzene (0.2 mL) and the crystals were washed with 
pentane (0.5 mL) and dried in vacuo to afford [κ4-TitmPri,benzo]Zn(DMDP)(BPh4) (9.5 mg, 
83%). Crystals of [κ4-TitmPri,benzo]Zn(DMDP)(BPh4)•C7H9 suitable for X-ray diffraction 
were obtained by vapor diffusion of pentane into a toluene solution. 1H NMR (C6D6): 
0.91 [d, J = 6.9 Hz, 18H, (C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4], 1.81 [bs, 4H, 
(C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4], 2.26 [bs, 6H, 
(C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4], 4.02 [sept, J = 6.9 Hz, 3H, 
(C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4], 6.83 [d, J = 8.2 Hz, 3H 
(C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4], 6.91 [t, J = 7.7 Hz, 3H 
(C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4], 7.07 [m, 4H 
(C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4], 7.22 [t, J = 7.7 Hz, 3H 
(C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4], 7.29 [t, J = 7.4 Hz, 8H 
(C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4], 8.01 [bs, 3H, 
(C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4], 8.06 [d, J = 8.2 Hz, 8H, 
(C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4]. 13C NMR (C6D6): 20.74 [s, 6C, 
(C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4], 35.22 [s, 2C, 
(C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4], 45.27 [s, 2C, 
 
 144 
(C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4], 49.66 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4], 112.25 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4], 117.52 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4], 122.75 [s, 4C, 
(C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4], 123.16 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4], 123.56 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4], 126.70 [m, 8C, 
(C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4], 136.31 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4], 137.60 [s, 8C, 
(C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4], 140.98 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4], 158.06 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4], 165.47 [q, J = 49.2 Hz, 4C, 
(C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4]. 11B NMR (C6D6): -5.88 [m, 
(C6H4N2CH(CH3)2CS)3CZn((CH2NMeCO)2)B(Ph)4]. Anal. calc. for [κ4-
TitmPri,benzo]Zn(DMDP)(BPh4) )•C6H6: C, 67.6%; H, 5.8%; N, 9.4%. Found: C, 67.2%; H, 3.8 
%; N, 9.0%. IR Data (cm-1): 3057.3 (w), 2979.2 (w), 1649.0 (m), 1407.3 (m), 1355.3 (m), 
1285.5 (m), 1136.7 (w), 1065.6 (w), 929.9 (w), 844.0 (w), 743.5 (s), 702.7 (s), 678.8 (s) 611.8 
(m). 
 
2.5.11 Synthesis of [κ4-TitmPri,benzo]Zn(picolinamide)(BPh4) Picolinamide (1.3 mg, 0.01 
mmol) was added to a suspension of [κ4-TitmPri,benzo]Zn(BPh4) (10 mg, 0.01 mmol) in 
benzene (ca. 0.5 mL). The mixture was shaken until all solids dissolved, after which the 
solution was filtered and was allowed to stand for a period of 2h, during which a white 
solid precipitated. The mother liquor was decanted and the solid was washed with 
hexanes (0.5 mL) and dried in vacuo to afford [κ4-TitmPri,benzo]Zn(picolinamide)BPh4 (8.3 
mg, 76%). Crystals of [κ4-TitmPri,benzo]Zn(Picolinamide)BPh4•2(C7H9) were obtained from 
vapor diffusion of pentane into a toluene solution.1H NMR (C6D6): 1.57 [d, J = 6.9 Hz, 
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18H, (C6H4N2CH(CH3)2CS)3CZn(C5H4NC(O)NH2)B(Ph)4], 4.51 [s, J = 6.9 Hz, 3H, 
(C6H4N2CH(CH3)2CS)3CZn(C5H4NC(O)NH2)B(Ph)4], 5.50 [s, 1H, 
(C6H4N2CH(CH3)2CS)3CZn(C5H4NC(O)NH2)B(Ph)4], 6.32 [s, 1H, 
(C6H4N2CH(CH3)2CS)3CZn(C5H4NC(O)NH2)B(Ph)4], 6.88 [t, J = 7.2 Hz, 4H, 
(C6H4N2CH(CH3)2CS)3CZn(C5H4NC(O)NH2)B(Ph)4], 7.04 [t, J = 7.3 Hz, 8H, 
(C6H4N2CH(CH3)2CS)3CZn(C5H4NC(O)NH2)B(Ph)4], 7.33 [m, 16H, 
(C6H4N2CH(CH3)2CS)3CZn(C5H4NC(O)NH2)B(Ph)4], 7.48 [d, J = 8.2 Hz, 3H, 
(C6H4N2CH(CH3)2CS)3CZn(C5H4NC(O)NH2)B(Ph)4], 7.61 [m, 1H, 
(C6H4N2CH(CH3)2CS)3CZn(C5H4NC(O)NH2)B(Ph)4], 7.84 [d, J = 8 Hz, 3H, 
(C6H4N2CH(CH3)2CS)3CZn(C5H4NC(O)NH2)B(Ph)4], 8.64 [d, J = 4.8 Hz, 1H, 
(C6H4N2CH(CH3)2CS)3CZn(C5H4NC(O)NH2)B(Ph)4]. 13C NMR (CD2Cl2): 21.03 [s, 6C, 
(C6H4N2CH(CH3)2CS)3CZn(C5H4NC(O)NH2)B(Ph)4], 50.71 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn(C5H4NC(O)NH2)B(Ph)4], 112.47 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn(C5H4NC(O)NH2)B(Ph)4], 116.62 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn(C5H4NC(O)NH2)B(Ph)4], 122.21 [s, 8C, 
(C6H4N2CH(CH3)2CS)3CZn(C5H4NC(O)NH2)B(Ph)4], 123.52 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn(C5H4NC(O)NH2)B(Ph)4], 124.09 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn(C5H4NC(O)NH2)B(Ph)4], 126.13 [q, J = 2.77 Hz, 8C, 
(C6H4N2CH(CH3)2CS)3CZn(C5H4NC(O)NH2)B(Ph)4], 128.71 [s, 2C, 
(C6H4N2CH(CH3)2CS)3CZn(C5H4NC(O)NH2)B(Ph)4], 135.76 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn(C5H4NC(O)NH2)B(Ph)4], 136.34 [s, 4C, 
(C6H4N2CH(CH3)2CS)3CZn(C5H4NC(O)NH2)B(Ph)4], 148.07 [s, 1C, 
(C6H4N2CH(CH3)2CS)3CZn(C5H4NC(O)NH2)B(Ph)4], 159.55 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn(C5H4NC(O)NH2)B(Ph)4], 164.50 [q, J = 49.3 Hz, 4C, 
(C6H4N2CH(CH3)2CS)3CZn(C5H4NC(O)NH2)B(Ph)4]. 11B NMR (CD2Cl2): -6.56 [m, 
(C6H4N2CH(CH3)2CS)3CZn(C5H4NC(O)NH2)B(Ph)4]. Anal. calc. for [κ4-
TitmPri,benzo]Zn(picolinamide)BPh4: C, 67.1%; H, 5.4%; N, 10.3%. Found: C, 66.3%; H, 
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4.4%; N, 9.2%. IR Data (cm-1): 3436.0 (w), 3342.3 (w), 3053.4 (w), 2979.2 (w), 1657.4 (m), 
1566.1 (w), 1406.1 (m), 1356.1 (m), 1292.1 (m), 1135.5 (w), 1067.0 (m), 734.3 (s), 704.3 (s), 
606.0 (m). 
 
2.5.12 Synthesis of [κ4-TitmPri,benzo]Zn(3,3-dethylglycinamide)(BPh4) 3,3-
dethylglycinamide (1.3 mg, 0.01 mmol) was added to a suspension of [κ4-
TitmPri,benzo]Zn(BPh4) (10 mg, 0.01 mmol) in benzene (ca. 0.5 mL). The mixture was 
shaken until all solids dissolved after 2 minutes, after which the solution was filtered 
and lyophilized. The solid was recrystallized by vapor diffusion of pentane into a 
benzene solution and the crystals were washed with pentane (0.5 mL) and dried in 
vacuo to afford [κ4-TitmPri,benzo]Zn(3,3-dethylglycinamide)(BPh4)•6(C6H6) (6.1 mg, 38%). 
The crystals as obtained from the recrystallization were suitable for X-Ray diffraction. 
1H NMR (C6D6): 0.18 [t, J = 7.1 Hz, 6H, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 0.91 [d, J = 6.9 Hz, 18H, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 1.58 [q, J = 7.2 Hz, 4H, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 2.28 [s, 2H, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 4.04 [sept, J = 7 Hz, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 5.44 [s, 1H, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 6.54 [s, 1H, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 6.80 [d, J = 8.3 Hz, 3H, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 6.88 [m, 3H, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 7.21 [m, 4H, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 7.31 [m, 3H, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 7.44 [t, J = 7.4 Hz, 8H, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 8.22 [bs, 3H 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 8.30 [m, 8H, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4]. 13C NMR (C6D6): 10.52 [s, 
 
 147 
2C, (C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 20.27 [s, 6C, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 47.20 [s, 2C, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 49.50 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 55.74 [s, 1C, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 111.68 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 117.79 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 122.57 [s, 4C, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 123.47 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 124.45 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 126.69 [m, 8C, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 135.86 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 137.35 [s, 8C, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 140.37 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 157.48 [s, 3C, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 165.29 [q, J = 48.9 Hz, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4], 178.41 [s, 1C, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4]. 11B NMR (C6D6): -5.64 [s, 
(C6H4N2CH(CH3)2CS)3CZn((CH3CH2)2NCH2C(O)NH2)B(Ph)4]. Anal. calc. for [κ4-
TitmPri,benzo]Zn(2-(diethylamino)acetamide)(BPh4)•0.5C6H6: C, 67.5%; H, 6.2%; N, 9.8%. 
Found: C, 67.4%; H, 5.7%; N, 10.0%. IR Data (cm-1): 3412.5 (w), 3303.2 (w), 3057.3 (w), 
2983.1 (w), 1644.6 (m), 1444.4 (m), 1405.9 (m), 1356.1 (m), 1284.4 (m), 1134.9 (w), 1067.7 





2.5.13 Synthesis of N,N’-dibutylsuccinimide  
Benzylamine (1mL, 9.1 mmol) and triethylamine (1.27 mL, 9.1 mmol) were mixed in 
DCM (ca. 50 mL). Succinyl chloride (0.5 mL, 4.55 mmol) was added dropwise at 0°C 
under vigorous stirring. The solution was allowed to warm up to room temperature 
and was stirred overnight. The organic solution was washed with 20 mL of aqueous 1M 
HCl solution, and was dried over MgSO4 and the solvent was evaporated in vacuo to 
afford 800 mg of N,N’-dibutylsuccinimide (77%). The 1H NMR spectrum matches the 
one reported in the literature .139 
 
2.5.14 Synthesis of [κ4-TitmPri,benzo]Zn(N,N’-dibutylsuccinimide)(BPh4):  
N,N’-dibutylsuccinimide (2.3 mg, 0.01 mmol) was added to a suspension of [κ4-
TitmPri,benzo]Zn(BPh4) (10 mg, 0.01 mmol) in toluene (ca. 0.5 mL). The mixture was shaken 
until all solids dissolved after 2 minutes, after which the solution was filtered. Crystals 
of [κ4-TitmPri,benzo]Zn(N,N’-dibutylsuccinimide)(BPh4) suitable for X-Ray diffraction were 
obtained from slow diffusion of pentane in the toluene solution. 1H NMR (C6D6): 0.81 [t, 
J = 7.3 Hz, 6H, (C6H4N2CH(CH3)2CS)3CZn(((O)CNH(C4H9)CH2)2)B(Ph)4], 0.89 [t, J = 6.8 
Hz, 6H, (C6H4N2CH(CH3)2CS)3CZn(((O)CNH(C4H9)CH2)2)B(Ph)4], 0.98 [d, J = 7 Hz, 6H, 
(C6H4N2CH(CH3)2CS)3CZn(((O)CNH(C4H9)CH2)2)B(Ph)4], 1.24 [m, 12H, 
(C6H4N2CH(CH3)2CS)3CZn(((O)CNH(C4H9)CH2)2)B(Ph)4], 3.12 [m, 4H, 
(C6H4N2CH(CH3)2CS)3CZn(((O)CNH(C4H9)CH2)2)B(Ph)4], 4.1 [sept, J = 6.9, 3H, 
(C6H4N2CH(CH3)2CS)3CZn(((O)CNH(C4H9)CH2)2)B(Ph)4], 6.9 [m, 
(C6H4N2CH(CH3)2CS)3CZn(((O)CNH(C4H9)CH2)2)B(Ph)4], 7.86 [s, 8H, 





2.5.15 Synthesis of ([κ4-TitmPri,benzo]Zn)2(N,N,N’,N’-tetrabutylsuccinimide)(BPh4)2:  
N,N,N’,N’-tetrabutylsuccinimide (4.6 mg, 0.02 mmol) was added to a suspension of [κ4-
TitmPri,benzo]Zn(BPh4) (10 mg, 0.01 mmol) in toluene (ca. 0.5 mL). The mixture was shaken 
until all solids dissolved after 2 minutes, after which the solution was filtered. Crystals 
of [κ4-TitmPri,benzo]Zn(N,N’-dibutylsuccinimide)(BPh4) suitable for X-Ray diffraction 
formed while the solution was allowed to stand for 2 hours. 1H NMR (C6D6): 0.74 [t, J = 
7 Hz, 6H, ((C6H4N2CH(CH3)2CS)3CZn)2(((O)CN(CH2CH3)2CH2)2)(B(Ph)4)2], 0.96 [m, 48H, 
((C6H4N2CH(CH3)2CS)3CZn)2(((O)CN(CH2CH3)2CH2)2)(B(Ph)4)2], 2.46 [s, 4H, 
((C6H4N2CH(CH3)2CS)3CZn)2(((O)CN(CH2CH3)2CH2)2)(B(Ph)4)2], 2.79 [q, J = 7.3, 6.8 Hz, 
4H, ((C6H4N2CH(CH3)2CS)3CZn)2(((O)CN(CH2CH3)2CH2)2)(B(Ph)4)2], 3.2 [q, J = 7.3, 6.9 
Hz, 4H, ((C6H4N2CH(CH3)2CS)3CZn)2(((O)CN(CH2CH3)2CH2)2)(B(Ph)4)2], 4.09 [sept, J = 7 
Hz, 6H ((C6H4N2CH(CH3)2CS)3CZn)2(((O)CN(CH2CH3)2CH2)2)(B(Ph)4)2], 6.87 [m, 6H, 
((C6H4N2CH(CH3)2CS)3CZn)2(((O)CN(CH2CH3)2CH2)2)(B(Ph)4)2], 7.08 [m, 
((C6H4N2CH(CH3)2CS)3CZn)2(((O)CN(CH2CH3)2CH2)2)(B(Ph)4)2], 7.26 [t, J = 7.3 Hz, 16H, 




2.5.16 Synthesis of 1-benzyl-3-acetamidoazetidin-2-one:  
A solution of 1-benzyl-3-phthalimidoazetidin-2-one (300 mg, 0.98 mmol) in EtOH (10 
mL) was treated with methylamine (1 mL, 33% in EtOH, 9.7 mmol). The mixture was 
stirred for 3h at room temperature, and then the solvents were removed in vacuo. The 
remaining oil was dissolved in EtOAc and filtered, and the solvent was evaporated. The 
procedure was repeated until no solid precipitates out of the EtOAc solution. The 
product was used without further purification.  
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The remaining oil was dissolved in CH2Cl2 (ca. 10 mL) and was treated with NEt3 (0.136 
mL, 0.98 mmol). After the solution was stirred for 10 min at room temperature, acetic 
anhydride (0.092 mL, 0.98 mmol) was added dropwise. The reaction was stirred 
overnight, and then CH2Cl2 (50 mL) was added. The organic phase was washed with a 
NaHCO3 saturated aqueous solution (30 mL), then was dried with MgSO4 and the 
solvent was evaporated. The resulting solid was recrystallized from EtOAc/Hexanes to 
afford yellow crystals of 1-benzyl-3-acetamidoazetidin-2-one (30 mg, 15%). 1H NMR 
(CDCl3): 2.01 [s, 3H, N(CH2Ph)C(O)CH(NHC(O)CH3)CH2], 3.14 [dd, 1H, J = 2.4, 5.7 Hz, 
N(CH2Ph)C(O)CH(NHC(O)CH3)CH2], 3.50 [t, J = 5.4 Hz, 1H, 
N(CH2Ph)C(O)CH(NHC(O)CH3)CH2], 4.39 [m, 2H, 
N(CH2Ph)C(O)CH(NHC(O)CH3)CH2], 4.94 [m, 1H, 
N(CH2Ph)C(O)CH(NHC(O)CH3)CH2], 6.03 [s, 1H, 
N(CH2Ph)C(O)CH(NHC(O)CH3)CH2], 7.35 [m, 5H, 
N(CH2Ph)C(O)CH(NHC(O)CH3)CH2]. IR Data (cm-1): 3278.7 (m), 1721.8 (vs), 1670.2 (vs), 
1553.5 (s), 1419.6 (m), 1367.0 (s), 1298.1 (s), 1225.3 (m), 1030.0 (m), 808.3 (m), 750.9 (m), 
700.3 (vs), 614.0 (m). 
 
2.5.17 Synthesis of [κ4-TitmPri,benzo]Zn(1-benzyl-3-acetamidoazetidin-2-one)(BPh4)  
1-benzyl-3-acetamidoazetidin-2-one (2.2 mg, 0.01 mmol) was added to a suspension of 
[κ4-TitmPri,benzo]Zn(BPh4) (10 mg, 0.01 mmol) in benzene (ca. 0.5 mL). The mixture was 
shaken until all solids dissolved, after which the solution was filtered and was allowed 
to stand for a period of 2h, during which a white solid precipitated. The mother liquor 
was decanted and the solid was washed with pentane (0.5 mL) and dried in vacuo to 
afford [κ4-TitmPri,benzo]Zn(1-benzyl-3-acetamidoazetidin-2-one)(BPh4) (5.3 mg, 38%). 
Crystals of [κ4-TitmPri,benzo]Zn(1-benzyl-3-acetamidoazetidin-2-one)(BPh4)•4(C6H6) 
suitable for X-Ray diffraction were obtained from slow diffusion of pentane in a 
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saturated benzene solution. 1H NMR (C6D6): 0.94 [d, J = 6.9 Hz, 18H, 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 0.94, [s, 3H, 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 2.41 [dd, J1 = 
6.7 Hz, J2 =2.5 Hz, 1H, 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 2.58 [t, J = 
6Hz, 1H, (C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 4.06 
[sept, J = 7 Hz, 3H, 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 4.22 [m, 2H, 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 4.86 [d, J = 7.5 
Hz, 1H, (C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 6.85 
[d, J = 8.21 Hz, 3H 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 6.95 [m, 7H 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 7.19 [m, 15H, 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 7.98 [s, 8H, 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 8.13 [d, J = 8.2 
Hz, 3H, (C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4]. 13C 
NMR (C6D6): 20.27 [6C, 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 22.52 [1C, 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 46.81 [1C, 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 46.98 [1C, 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 49.67 [3C 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 56.01 [1C, 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 111.97 [3C, 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 117.40 [3H, 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 122.36 [4C, 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 123.26 [3C, 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 123.94 [3C, 
 
 152 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 126.39 [8C, 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 128.87 [2C, 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 129.33 [2C, 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 135.18 [1C, 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 135.98 [3C, 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 137.15 [8C, 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 140.39 [3C, 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 158.24 [3C, 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 165.05 [q, J = 
50 Hz ,4C, (C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 
168.93 [1C, (C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4], 
172.76 [1C, (C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4]. 11B 
NMR (C6D6): - 5.93 [s, 
(C6H4N2CH(CH3)2CS)3CZn(N(CH2Ph)C(O)CH(NHC(O)CH3)CH2)B(Ph)4]. Anal. calc. for: 
C, 67.7%; H, 5.7%; N, 9.4%. Found: C, 67.8%; H, 5.7%; N, 9.2%. IR Data (cm-1): 3399.0 
(w), 3050.1 (w), 2980.1 (w), 1704.0 (s), 1444.3 (m), 1407.2 (m), 1360.2 (m), 1286.6 (m), 
1067.9 (m), 736.1 (vs), 704.5 (vs), 608.5 (m). 
 
2.5.18 Synthesis of N-benzylazetidin-2-one:  
Azetidin-2-one (200 mg, 2.8 mmol) was dissolved in THF (ca. 20 mL). Solid KOH (243.6 
mol, 4.2 mmol) and tetrabutylammonium bromide (93 mg, 0.28 mmol) were added, and 
the resulting white mixture was stirred for 30 min. Benzyl bromide (0.33 mL, 2.8 mmol) 
was added dropwise at room temperature. The reaction was allowed to stir overnight, 
after what the solvent was evaporated. The resulting white residue was distilled under 
reduced pressure to afford N-benzylazetidin-2-one (93 mg, 21%). The 1H NMR 




2.5.19 Synthesis of N,N-benzylmethylacetamide:  
Benzylmethylamine (2 mL, 15.5 mmol) and triethylamine (2.15 mL, 15.5 mmol) were 
mixed in DCM (ca. 50 mL). Acetyl chloride (1.1 mL, 15.5 mmol) was added dropwise at 
room temperature and the solution was allowed to stir overnight. The solution was 
washed with a saturated NH4Cl aqueous solution (ca. 20 mL), and the organic phase 
was dried with MgSO4 and the solvent was evaporated in vacuo. The resulting clear 
liquid was distilled, and the cleanest fraction of N,N-benzylmethylacetamide was used 
for the 1H NMR binding studies. The 1H NMR spectrum matches the one reported in the 
literature.141 
 
2.5.20 Binding studies with [κ4-TitmPri,benzo]Zn(MeB(C6F5)3) 
Solutions of [κ4-TitmPri,benzo]Zn(MeB(C6F5)3) in C6D6 were treated with aliquots of 
benzene solutions of trimethylacetonitrile, N-benzylazetidin-2-one, N-
benzylpyrrolidone, N-benzylpiperidone, N,N-benzylmethylacetamide, 4-
Phenylazetidin-2-one, picolinamide, DEDP, 3,3-dethylglycinamide, 1-benzyl-3-
acetamidoazetidin-2-one and were monitored by 1H NMR spectroscopy at 300K. For 
situations in which there is a large excess of ligand such that [ligand] = [ligand]tot (i.e. 
the total concentration of ligand, whether coordinated or uncoordinated), the 
equilibrium constants for coordination of the ligand may be obtained by using the 
relationship [ligand]tot/Δδ = 1/(KΔδmax) + [-ligand]tot/Δδmax, where (i) Δδ = δ{[κ4-
TitmPri,benzo]Zn(MeB(C6F5)3)} - δobs, and (ii) Δδmax is the maximum value of Δδ.142 
Specifically, a plot of [ligand]tot/Δδ versus [ligand]tot over a region in which [ligand]tot > 




2.5.21 Synthesis of 1-benzyl-3-(hydroxy(phenyl)methyl)azetidin-2-one  
To a solution of 3-((tert-butyldimethylsilyl)oxy)-3-phenylpropanoyl chloride (1.8 g, 6 
mmol) in dichloromethane (50 mL) at -50°C was added triethylamine (1.6 mL, 12 mmol) 
dropwise. The resulting yellow mixture was stirred for 1h at -50°C. Meanwhile, in a 
separate vessel, 1,3,5-Tribenzyl-1,3,5-triazacyclohexane and boron trifuoride 
diethyletherate were mixed in dichloromethane at room temperature. The resulting 
solution was stirred for 30 minutes at room temperature, after what the solution was 
transferred via canula to the ketene. The mixture was stirred at -50°C for 1h and was 
allowed to warm up to room temperature. The reaction was quenched with water (ca. 
20 mL), and the organic solution was washed with 1M HCl (20 mL), aq NaHCO3 (ca. 20 
mL), dried with MgSO4 and the solvents were removed in vacuo. The resulting oil was 
dissolved in hexanes (ca. 30 mL), the hexane phase was decanted and evaporated in 
vacuo to afford 1-benzyl-3-(tertbutyldimethylsilyloxy(phenyl)methyl)azetidin-2-one 
(1.22 g, 53 %) , which was used without further purification. 1H NMR (CDCl3): 0.07 [s, 
6H, PhCH2NC(O)CH(CHO(SiMe2tBu)Ph)CH2], 0.89 [s, 9H, 
PhCH2NC(O)CH(CHO(SiMe2tBu)Ph)CH2], 2.93 [t, J = 5.2 Hz, 1H, 
PhCH2NC(O)CH(CHO(SiMe2tBu)Ph)CH2], 3.42 [m, 2H, 
PhCH2NC(O)CH(CHO(SiMe2tBu)Ph)CH2], 4.39 [m, 2H, 
PhCH2NC(O)CH(CHO(SiMe2tBu)Ph)CH2], 5.21 [d, J = 2.6 Hz, 1H, 
PhCH2NC(O)CH(CHO(SiMe2tBu)Ph)CH2], 7.26 [m, 10H, 
PhCH2NC(O)CH(CHO(SiMe2tBu)Ph)CH2]. 
1-benzyl-3-(tertbutyldimethylsilyloxy(phenyl)methyl)azetidin-2-one (500 mg, 1.31 
mmol) was dissolved in THF, and TBAF (2.62 mL, 1M in THF) was added dropwise. 
The solution was stired for 2 hours, after which diethylether was added (50 mL). The 
organic solution was washed with aq NH4Cl (6x30 mL), dried with MgSO4 and 
evaporated in vacuo. The resulting oil was washed with hexanes and purified using 
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column chromatography (Rf = 0.2 in a 3:1 hexane/acetone mixture) to afford 1-benzyl-
3-(hydroxy(phenyl)methyl)azetidin-2-one (190 mg, 54%). 1H NMR (CDCl3): 2.29 [s, 1H, 
PhCH2NC(O)CH(CHOHPh)CH2], 3.05 [t, J = 5.4 Hz, 1H, 
PhCH2NC(O)CH(CHOHPh)CH2], 3.32 [m, 1H, PhCH2NC(O)CH(CHOHPh)CH2], 3.59 
[m, 1H, PhCH2NC(O)CH(CHOHPh)CH2], 4.40 [m, 2H, 
PhCH2NC(O)CH(CHOHPh)CH2], 5.21 [s, 1H, PhCH2NC(O)CH(CHOHPh)CH2], 7.33 
[m, 10H, PhCH2NC(O)CH(CHOHPh)CH2]. 
 
2.5.22 Reaction between [κ4-TitmPri,benzo]Zn(BPh4) and 1-benzyl-3-
(hydroxy(phenyl)methyl)azetidin-2-one  
1-benzyl-3-(hydroxy(phenyl)methyl)azetidin-2-one (2.7 mg, 0.01 mmol) was added to a 
suspension of [κ4-TitmPri,benzo]Zn(BPh4) (10 mg, 0.01 mmol) in benzene (ca. 0.5 mL). The 
mixture was shaken until all solids dissolved, after which the solution was filtered and 
lyophililzed. 1H NMR demonstrated the formation of the adduct [κ4-TitmPri,benzo]Zn(1-
benzyl-3-(hydroxy(phenyl)methyl)azetidin-2-one)(BPh4). 1H NMR (C6D6) 0.91 [d, J = 6.9 
Hz, 18H, (C6H4N2CH(CH3)2CS)3CZn(PhCH2NC(O)CH(CHOHPh)CH2)B(Ph)4], 2.32 [d, J 
= 5.5 Hz, 1H, (C6H4N2CH(CH3)2CS)3CZn(PhCH2NC(O)CH(CHOHPh)CH2)B(Ph)4],2.56 
[d, J = 4.5, 1H, (C6H4N2CH(CH3)2CS)3CZn(PhCH2NC(O)CH(CHOHPh)CH2)B(Ph)4],2.85 
[m, 1H, (C6H4N2CH(CH3)2CS)3CZn(PhCH2NC(O)CH(CHOHPh)CH2)B(Ph)4], 2.98 [s, 1H, 
(C6H4N2CH(CH3)2CS)3CZn(PhCH2NC(O)CH(CHOHPh)CH2)B(Ph)4], 3.99 [m, 2H, 
(C6H4N2CH(CH3)2CS)3CZn(PhCH2NC(O)CH(CHOHPh)CH2)B(Ph)4], 4.04 [sept, J = 6.6 
Hz, 3H, (C6H4N2CH(CH3)2CS)3CZn(PhCH2NC(O)CH(CHOHPh)CH2)B(Ph)4], 4.72 [s, 1H, 
(C6H4N2CH(CH3)2CS)3CZn(PhCH2NC(O)CH(CHOHPh)CH2)B(Ph)4], 7.10 [m, 





2.6 Crystallographic data 
Table 4. Crystallographic data 




formula weight 626.12 









temperature (K) 130(2) 
radiation (λ, Å) 0.71073 
ρ (calcd.) g cm-3 1.560 
µ (Mo Kα), mm-1 1.271 
θ max, deg. 32.119 
no. of data collected 23776 
no. of data 9149 
no. of parameters 342 
R1 [I > 2σ(I)] 0.0528 
wR2 [I > 2σ(I)] 0.1070 
R1 [all data] 0.1003 






Table 4. Crystallographic data 
 [κ4-TitmPri,benzo]Zn(4-
phenylazetidin-2-






lattice Monoclinic Triclinic 
formula C76H74BN7OS3Zn C85H85BN7OS3Zn 
formula weight 1273.78 1392.95 
space group Cc P-1 
a/Å 14.422(6) 10.4311(14) 
b/Å 44.475(17) 16.845(2) 
c/Å 10.335(4) 22.275(3) 
α/˚ 90 97.786(2) 
β/˚ 97.969(6) 103.297(2) 
γ/˚ 90 94.888(2) 
V/Å3 6565(4) 3746.3(8) 
Z 4 2 
temperature (K) 130(2) 130(2) 
radiation (λ, Å) 0.71073 0.71073 
ρ (calcd.) g cm-3 1.289 1.235 
µ (Mo Kα), mm-1 0.521 0.462 
θ max, deg. 30.637 30.776 
no. of data collected 53435 62710 
no. of data 19913 23182 
no. of parameters 803 887 
R1 [I > 2σ(I)] 0.0720 0.0446 
wR2 [I > 2σ(I)] 0.2081 0.0615 
R1 [all data] 0.1000 0.1100 
wR2 [all data] 0.1358 0.1186 
GOF 1.072 1.043 











lattice Monoclinic Triclinic 
formula C550H591B8N62O8S24Zn8 C75H75BN8OS3Zn 
formula weight 9576.72 1276.78 
space group C2 P-1 
a/Å 52.292(12) 15.615(6) 
b/Å 15.728(4) 16.021(7) 
c/Å 32.593(8) 16.647(7) 
α/˚ 90 63.388(6) 
β/˚ 109.326(4) 66.048(6) 
γ/˚ 90 84.641(7) 
V/Å3 25296(10) 3383(2) 
Z 16 2 
temperature (K) 130(2) 130(2) 
radiation (λ, Å) 0.71073 0.71073 
ρ (calcd.) g cm-3 1.257 1.254 
µ (Mo Kα), mm-1 0.537 0.506 
θ max, deg. 30.613 30.757 
no. of data collected 209066 56218 
no. of data 77441 20850 
no. of parameters 3057 806 
R1 [I > 2σ(I)] 0.0641 0.0701 
wR2 [I > 2σ(I)] 0.1197 0.1935 
R1 [all data] 0.1283 0.1216 
wR2 [all data] 0.1511 0.1543 
GOF 1.002 1.016 












lattice Monoclinic Triclinic 
formula C68H71BN8O2S3Zn C88H88BN8O2S3Zn 
formula weight 1204.68 1462.02 
space group P21/c P-1 
a/Å 17.220(6) 10.4500(12) 
b/Å 18.197(6) 17.115(2) 
c/Å 19.877(7) 22.015(3) 
α/˚ 90 80.178(2) 
β/˚ 90.209(6) 78.774(2) 
γ/˚ 90 87.230(2) 
V/Å3 6228(4) 3805.0(8) 
Z 4 2 
temperature (K) 130(2) 130(2) 
radiation (λ, Å) 0.71073 0.71073 
ρ (calcd.) g cm-3 1.285 1.276 
µ (Mo Kα), mm-1 0.547 0.460 
θ max, deg. 30.588 30.687 
no. of data collected 101388 63080 
no. of data 19080 23435 
no. of parameters 767 939 
R1 [I > 2σ(I)] 0.0522 0.0545 
wR2 [I > 2σ(I)] 0.1116 0.1066 
R1 [all data] 0.1042 0.0955 
wR2 [all data] 0.1273 0.1101 
GOF 1.008 1.005 










lattice Monoclinic Triclinic 
formula C53H39BF15N6S3Zn C67H77BN8O2S3Zn 
formula weight 1217.26 1198.72 
space group P21/n P-1 
a/Å 14.4346(15) 13.558(2) 
b/Å 18.0772(19) 15.535(3) 
c/Å 20.644(2) 18.145(3) 
α/˚ 90 113.077(3) 
β/˚ 109.1296(15) 105.162(3) 
γ/˚ 90 97.229(3) 
V/Å3 5089.3(9) 3279.4(10) 
Z 4 2 
temperature (K) 130(2) 130(2) 
radiation (λ, Å) 0.71073 0.71073 
ρ (calcd.) g cm-3 1.589 1.214 
µ (Mo Kα), mm-1 0.706 0.519 
θ max, deg. 30.560 30.670 
no. of data collected 82537 54424 
no. of data 15593 20125 
no. of parameters 719 821 
R1 [I > 2σ(I)] 0.0372 0.0741 
wR2 [I > 2σ(I)] 0.0555 0.1448 
R1 [all data] 0.1019 0.1910 
wR2 [all data] 0.0915 0.2136 
GOF 1.035 1.172 











lattice Triclinic Orthorhombic 
formula C137H143B2N14O2S6Zn2 C9H9NO 
formula weight 2362.37 147.17 
space group P-1 Pna21 
a/Å 17.216(11) 8.1423(10) 
b/Å 18.451(12) 15.6733(19) 
c/Å 21.377(14) 5.8793(7) 
α/˚ 86.428(9) 90 
β/˚ 87.920(9) 90 
γ/˚ 76.027(8) 90 
V/Å3 6575(7) 750.30(16) 
Z 2 4 
temperature (K) 130(2) 130(2) 
radiation (λ, Å) 0.71073 0.71073 
ρ (calcd.) g cm-3 1.193 1.303 
µ (Mo Kα), mm-1 0.515 0.086 
θ max, deg. 30.672 30.630 
no. of data collected 98625 8676 
no. of data 40059 2305 
no. of parameters 1469 105 
R1 [I > 2σ(I)] 0.0981 0.0561 
wR2 [I > 2σ(I)] 0.2649 0.0751 
R1 [all data] 0.1703 0.1373 
wR2 [all data] 0.1989 0.1473 
GOF 1.021 1.054 









formula weight 218.25 









temperature (K) 130(2) 
radiation (λ, Å) 0.71073 
ρ (calcd.) g cm-3 1.264 
µ (Mo Kα), mm-1 0.088 
θ max, deg. 26.367 
no. of data collected 12943 
no. of data 2342 
no. of parameters 150 
R1 [I > 2σ(I)] 0.1370 
wR2 [I > 2σ(I)] 0.2878 
R1 [all data] 0.3702 







2.7 Computational data 
[κ4-TitmPri,benzo]Zn(1-benzyl-3-acetamidoazetidin-2-one)(BPh4) 
-3515.57230262543 
atom x y z 
Zn 4.691258739 12.82060196 4.776513429 
S 5.265126511 9.830248857 6.067979181 
S 2.553139753 10.96397716 6.601289002 
S 4.874308871 12.07778232 8.025153107 
O 4.841924517 14.54810703 3.461474804 
O 4.026180288 15.88913065 7.642219981 
N 4.676823109 16.82895139 2.919288825 
N 3.015003838 16.28327404 5.639886962 
N 5.668349982 11.29220258 3.757082513 
N 6.686744241 9.296281224 3.778840187 
N 2.534809816 12.81343445 4.554409947 
N 0.497730872 12.17399113 5.260995425 
N 6.107344702 13.66665777 6.154416459 
N 6.744755146 14.06844745 8.271331028 
C 4.317578933 11.33650358 6.458623396 
C 4.627754915 15.74449069 3.712932031 
C 4.236351742 16.58206033 4.951769035 
H 5.037683961 16.603 5.69305124 
C 4.269583186 17.7935345 3.964114625 
H 3.295989076 18.25403554 3.766715171 
H 5.02213508 18.55777959 4.176255355 
 
 164 
C 5.096886581 17.02160687 1.530806426 
H 4.30217939 17.57180377 1.013603823 
H 5.160466012 16.02384085 1.087694114 
C 6.418651231 17.75605908 1.414523955 
C 6.449318859 19.15510297 1.333492854 
H 5.517934229 19.71735844 1.313430893 
C 7.668647186 19.83473033 1.262477032 
H 7.680380684 20.91873633 1.196602538 
C 8.868847948 19.1191049 1.263484888 
H 9.816320007 19.64605314 1.199731466 
C 8.846387206 17.72280454 1.331654595 
H 9.776400186 17.1617776 1.315572651 
C 7.627371768 17.04539572 1.408863299 
H 7.615950675 15.95894168 1.453670194 
C 2.995966499 15.95936473 6.980549298 
C 1.626614907 15.71952428 7.581561046 
H 1.417781602 16.5199415 8.298602193 
H 1.648005924 14.77847379 8.1369938 
H 0.821990263 15.69157794 6.84185698 
C 5.890865185 10.18183169 4.449826851 
C 6.359675381 11.14802948 2.558943371 
C 6.465837645 12.02427509 1.474459328 
H 5.959562565 12.98377456 1.490951203 
C 7.238435731 11.61511525 0.38971638 
H 7.343126277 12.26754831 -0.471904973 
C 7.887697394 10.36559091 0.386609755 
H 8.482797877 10.07792832 -0.474537471 
 
 165 
C 7.785377855 9.484462014 1.463391005 
H 8.292910575 8.527771344 1.440249103 
C 7.008612347 9.895819096 2.552453547 
C 7.121400038 7.974014 4.289885245 
H 6.651570259 7.884864434 5.27337835 
C 8.640620201 7.933792955 4.493283952 
H 8.968549625 8.749676419 5.144211085 
H 9.184378426 8.009615656 3.547630868 
H 8.919135366 6.986973745 4.965695439 
C 6.582928171 6.838049811 3.412516971 
H 5.495275138 6.903182843 3.314951525 
H 6.827765589 5.876442315 3.873463851 
H 7.018829416 6.849659816 2.40984594 
C 1.853051216 12.05558671 5.405218329 
C 1.574829971 13.45714382 3.771729873 
C 1.720060007 14.32482077 2.681224775 
H 2.702426775 14.56759451 2.297140726 
C 0.562725474 14.82071469 2.081029946 
H 0.646823222 15.48533383 1.226202449 
C -0.71525475 14.45913618 2.545928413 
H -1.596180002 14.8615249 2.0554496 
C -0.875159686 13.57506074 3.61296352 
H -1.866056985 13.28971793 3.944440037 
C 0.287057224 13.07641945 4.212500941 
C -0.521948028 11.44973239 6.059477382 
H 0.052630236 10.8568085 6.776067086 
C -1.394657064 12.42354931 6.860828052 
 
 166 
H -0.778464019 13.07675511 7.485858701 
H -2.061348249 11.85650486 7.517412039 
H -2.016479007 13.05005315 6.215470007 
C -1.323994611 10.47986615 5.183789007 
H -0.658673475 9.795154134 4.649920646 
H -1.940373786 11.00321827 4.447623602 
H -1.989605483 9.885063879 5.81642416 
C 5.947505318 13.34656808 7.433077812 
C 7.088819719 14.65629306 6.136682834 
C 7.684999804 15.32181316 5.059562162 
H 7.412776992 15.0810912 4.038567494 
C 8.652842584 16.28445591 5.343581784 
H 9.129067028 16.81861886 4.527298901 
C 9.028362074 16.57272662 6.668873867 
H 9.785311757 17.32798292 6.856760619 
C 8.458306627 15.90037785 7.749938783 
H 8.767508215 16.127377 8.762979609 
C 7.487735263 14.9343246 7.46286967 
C 6.742207877 13.9795287 9.75155681 
H 6.005027276 13.20536755 9.983111288 
C 8.100127797 13.50227064 10.27978664 
H 8.38799784 12.55276084 9.818690428 
H 8.035388419 13.3514794 11.36169726 
H 8.894085034 14.23025949 10.09109699 
C 6.254652977 15.29102454 10.38002139 
H 5.302471032 15.59833241 9.940041927 
H 6.974584938 16.10272113 10.24106441 
 
 167 
H 6.11915597 15.14639695 11.45657887 




atom x y z 
O 3.318002348 5.236903207 2.624557005 
O 6.709274012 4.928096957 2.610709468 
N 4.129708896 3.561299855 1.164402727 
N 5.715144331 3.476452056 4.045268237 
H 5.666248522 3.139658466 4.993974397 
C 6.655099113 4.422321107 3.724483646 
C 3.904191032 4.215425674 2.350895282 
C 4.668538797 3.096757155 3.133224722 
H 3.974647774 2.440101913 3.663492702 
C 5.039021686 2.54922653 1.71486542 
H 6.086411511 2.719653358 1.450743998 
H 4.747179706 1.515913321 1.501111573 
C 3.926926216 4.012875472 -0.195918296 
H 4.886092623 4.32149857 -0.634195028 
H 3.302714202 4.910747362 -0.118437471 
C 3.267244545 2.9671973 -1.0766343 
C 1.449054181 1.414343965 -1.495564536 
H 0.512550219 0.960851833 -1.182388662 
C 2.059468873 2.371976652 -0.688409658 
H 1.602469648 2.66179678 0.254313544 
 
 168 
C 3.239475549 1.623836927 -3.099816113 
H 3.706555885 1.33321666 -4.03674009 
C 3.850170935 2.581710797 -2.28713347 
H 4.790837267 3.032065297 -2.595645271 
C 7.612682399 4.803045394 4.841220514 
H 7.572018553 4.132762719 5.704385722 
H 8.629438085 4.815183908 4.442542345 
H 7.377325754 5.818705009 5.173678591 
C 2.038007478 1.037149754 -2.70527434 
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As reported in Chapter 1, the tris(2-pyridylthio)methyl [Tptm] ligand has been one of 
the most studied metallacarbatrane ligands. Not only has [Tptm] been used to bind 
various metals,1 but several [Tptm] complexes have also shown remarkable reactivity. 
For example, the monomeric alkyl zinc hydride compound [κ3-Tptm]ZnH,2 is an 
effective catalyst for transformations such as hydrosilylation of aldehydes, ketones and 
carbon dioxide.3,4 The [Tptm] ligand also allows for the isolation of novel structures, 
such as the terminal zinc fluoride [κ4-Tptm]ZnF.5 Even though the chemistry of the 
[Tptm] ligand is mostly unexplored compared to other ligands such as [TpR,R], these 
examples highlight the potential of this ligand to produce new structures and reactivity. 
In this chapter, we investigate some of the previously reported [Tptm] zinc complexes, 
and report their reactivity towards C–F bond formation and their catalytic activity for 
the hydrosilylation of aldehydes and ketones to form alkoxysilanes, as well as the 
hydrosilylation of CO2 to methoxy silanes. 
 
3.2 Synthesis and reactivity of a terminal zinc fluoride 
3.2.1 Introduction 
The special position of fluorine in the periodic table gives this element very unique 
properties compared to the other halogens. In addition to being the most 
electronegative element, its small size and low polarizability has a profound effect on 
how fluorine binds to other elements. Organofluorine compounds have many 
applications ranging from agrochemicals6 to drug discovery,7 as the C–F bonds confer 
uncommon properties on fluorine containing products. However, fluorination of 
organic compounds still remains challenging because of the unique properties of this 
element. Standard procedures for halogenation do not transpose for fluorine, and other 




Similar disparities apply for metal fluoride compounds, such that they are much more 
scarce than other metal halogen compounds. However, because of the particular 
properties of fluorine, metal fluorides tend to exhibit unexpected structures and 
reactivity,9 and have found applications in C-F bond formation10 and cleavage.11 Despite 
promising results, the difficulty in the synthesis of metal fluorides impedes further 
developments of this chemistry, as many compounds tend to come from unexpected 
reactions or decomposition pathways,12 and general methods for fluorination have yet 
to be reported. For example, the chemistry of organozinc fluorides is extremely limited 
compared to the other organozinc halides, because the typical synthesis of such 
compounds via zinc insertion in carbon halogen bonds is unfeasable in the case of 
strong C–F bonds.13 In that regard, zinc fluoride compounds account for only 2.2% of 
the zinc halogen compounds reported in the CSD.14 The proportion of terminal zinc 
fluoride is even smaller, with only 0.14% of the zinc halogen compounds, while there is 
no structurally characterized simple organozinc fluoride compound.  
 
The recent report by Wesley Sattler in the Parkin lab on the synthesis of a terminal 
organozinc fluoride based on the tris(2-pyridylthio)methyl [Tptm] ligand, namely [κ4-
Tptm]ZnF, is therefore of great interest.5 The compound was structurally characterized 
(Figure 1) and preliminary results on its reactivity highlight the interesting Lewis basic 
properties of the fluoride ligand. In the first part of this chapter, we report a new and 
more efficient synthesis for [κ4-Tptm]ZnF, as well as more complete studies of the 




Figure 1: Molecular structure of [κ4-Tptm]ZnF. 
 
3.2.2 Synthesis of [κ 4-Tptm]ZnF 
The synthesis of [κ4-Tptm]ZnF reported by Wesley Sattler involves the reaction between 
[κ4-Tptm]ZnI and tetrabutylammonium fluoride. The product of the reaction is the aqua 
adduct [κ4-Tptm]ZnF•H2O, which was structurally characterized and exhibits a dimeric 
structure with two water molecules bridging two [κ4-Tptm]ZnF moieties. The water is 
not tightly bound, as it can be pumped away in vacuo to afford the anhydrous [κ4-
Tptm]ZnF. This synthesis, however, is relatively inconvenient, as it is conducted in air 
and wet conditions, which lead to the formation of a significant amount of [Tptm]H 
from the protonation of the ligand carbanion.  
 
We therefore sought a more facile synthesis of [κ4-Tptm]ZnF. As mentioned above, the 
synthetic routes for the other zinc halides do not necessarily apply for fluorine. For 
example, [κ4-Tptm]ZnX (X = Cl, Br, I) can be accessed via reaction between [Tptm]Li and 
the corresponding ZnX2 salt, but no reaction is observed in the case of the ZnF2. 
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Similarly, [κ4-Tptm]ZnOSiMe3 undergoes metathesis reactions with Me3SiX (X= Cl, Br, I) 
to afford [κ4-Tptm]ZnX (X = Cl, Br, I), but not with Me3SiF. However, the fluorinating 
agent Me3SnF was found to react with both [κ4-Tptm]ZnOSiMe3 and [κ3-Tptm]ZnH to 
cleanly generate [κ4-Tptm]ZnF (Scheme 1). Although Me3SnF has been previously used 
to access metal fluorides,15 this is the first example of its use with zinc. The reaction is 
particularly convenient, because the byproducts Me3SnH and Me3SnOSiMe3 can be 
either pumped away in vacuo, or washed away with pentane, leading to fewer 































3.2.3 Reactivity of [κ 4-Tptm]ZnF  
The reactivity of [κ4-Tptm]ZnF is dictated by the fluoride ligand (Scheme 2). Metathesis 
reactions between [κ4-Tptm]ZnF and either PhSiH3 or Me3SiX (X = Cl, Br, I) yields [κ3-
Tptm]ZnH or [κ4-Tptm]ZnX (X = Cl, Br, I), respectively, which is in accord with the 
known silaphilicity of fluorine.16 In addition, [κ4-Tptm]ZnF reacts with Me3SnCl to 
generate [κ4-Tptm]ZnCl and Me3SnF, which is the reverse of reactions between [κ4-
Tptm]ZnOSiMe3 or [κ3-Tptm]ZnH with Me3SnF, and also the opposite of what is 
observed in other systems with different metals where the chloride is used as a 
precursor to form the fluoride using Me3SnF.15 The difference in thermodynamics 
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between the zinc system and other metals highlights the importance of considering the 
































[κ4-Tptm]ZnF also reacts with the strong Lewis acid B(C6F5)3 to form [κ4-
Tptm]Zn(FB(C6F5)3) via fluoride abstraction (Scheme 3). The crystal structure, solved by 
Wesley Sattler, showed the FB(C6F5)3 anion coordinating to the cationic [κ4-Tptm]Zn+ 
fragment. We decided to investigate whether this binding interaction was maintained in 
solution or if the compound exists as an ion pair. The size of [κ4-Tptm]ZnFB(C6F5)3 in 
solution was determined using pulsed gradient spin echo (PGSE) diffusion NMR 
spectroscopic measurements.18 These experiments provide the diffusion coefficient of 
species in solution, which can in turn be related to their hydrodynamic radius using the 
Sotkes-Einstein equation. The diffusion constant found for [κ4-Tptm]ZnFB(C6F5)3 
indicates that the compound is much larger than [κ4-Tptm]ZnF, suggesting that the 
adduct is intact in solution and does not separate in a ion pair (Table 1). In fact, the 
diffusion constant of [κ4-Tptm]ZnFB(C6F5)3 indicates that the size of the adduct is very 
close to that of the large covalent compound [κ4-Tptm]ZnOSiPh3. In addition 19F PGSE 
experiments show that the diffusion constant for the FB(C6F5)3 fragment of [κ4-
Tptm]ZnFB(C6F5)3  is the same as the whole molecule, thereby providing more evidence 
that the adduct is intact in solution. In addition, [κ4-Tptm]ZnFB(C6F5)3 does not undergo 
exchange with free B(C6F5)3 in solution, indicating that the transfer is very exoergic, as 
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opposed to the binding of water in [κ4-Tptm]ZnF•H2O, for example. Interestingly, [κ4-
Tptm]ZnCl does not react with B(C6F5)3, highlighting again the uniqueness of fluorine in 
































D/10–10 m2s–1 rH/Åb 
[κ4-Tptm]ZnF 283 7.15 5.08 
[κ4-Tptm]ZnCl 302 7.13 5.13 
[κ4-Tptm]ZnOSiMe3 371 6.88 5.31 
[κ4-Tptm]ZnOSiPh3 500 5.65 6.47 
[κ4-Tptm]ZnFB(C6F5)3 597 5.47 [5.36]c 6.71 
Table 1: Self-Diffusion Constants for [κ4-Tptm]ZnX. (a) Molecular volume as 
determined by using OLEX219 on the molecular structure as obtained by X-ray 
diffraction. (b) Hydrodynamic radius as determined by the Stokes-Einstein relation (rH 
= kBT/6πηD); η = 6.01 × 10-4 kg s-1 m-1, kB =  1.38 × 10-23 J K-1, T = 300 K (c) Value from 19F 
NMR spectroscopy. 
 
The reaction with B(C6F5)3 and water shows that the fluoride ligand of [κ4-Tptm]ZnF can 
both act as a Lewis base and participate in hydrogen bonding interactions. The ability of 
[κ4-Tptm]ZnF to form hydrogen bonds was further investigated and quantified using 
NMR spectroscopy. Indole was used as a model compound for a hydrogen bond donor, 
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as it contains a single hydrogen bond donor site, and no hydrogen bond acceptor 
functionality (Scheme 4).20 The 1:1 stoichiometry of the hydrogen bond adduct between 
[κ4-Tptm]ZnF and indole was confirmed using a Job plot (Figure 2).21 Measurements of 
the variation of the 19F chemical shift of [κ4-Tptm]ZnF in the presence of different 
concentrations of indole provides a value of 85 ±7 M–1 for the binding constant between 
[κ4-Tptm]ZnF and indole in benzene (Figure 3). This number is comparable with the 
other constant previously reported for the hydrogen bonding adduct between 





























Figure 2: Job plot for coordination of indole to [κ4-Tptm]ZnF as measured by 1H NMR 
spectroscopy.  Δδ is the change in chemical shift of the signal at δ 9.69 in pure 
[κ4-Tptm]ZnF, and xindole(init) and x[κ4-Tptm]ZnF(init) are the mole fractions prior to the 




Figure 3:Variation of the 19F NMR chemical shift of [κ4-Tptm]ZnF as a function of indole 
concentration (the line corresponds to the fit by WinEQNMR2). 
 
Additionally, [κ4-Tptm]ZnF can participate in halogen bonding interactions with the 
iodine atom of iodopentafluorobenze (Scheme 5). Halogen bonding interactions have 
been identified only recently but have gained interest in the context of supramolecular 
chemistry and crystallization processes.23 Analysis of the variation of the chemical shift 
of [κ4-Tptm]ZnF with different concentration of iodopentafluorobenze produced a 
binding constant of 9.0 ± 0.5 M-1 in benzene (Figure 4). This number is again comparable 
with the binding constant reported previously for systems such as (R3P)2M(Ar)F (2.4 to 
5.2 M-1), where M = Ni, Pd and Pt.22,24 The observation that the binding constant for 
halogen bonding is an order of magnitude smaller than for hydrogen bonding is not 

































Scheme 5: Halogen bonding between [κ4-Tptm]ZnF and C6F5I 
 
Figure 4: Variation of the 19F NMR chemical shift of [κ4-Tptm]ZnF as a function of C6F5I 
concentration (the line corresponds to the fit by WinEQNMR2). 
 
Finally, [κ4-Tptm]ZnF reacts with one equivalent of Ph3CCl to quantitatively produce 
[κ4-Tptm]ZnCl and Ph3CF at room temperature in less than 5 minutes (Scheme 6). In 
addition to being the first report of such a reaction with a zinc complex, the formation 
of a C–F bond is of great interest, because, as stated above, efficient fluorination 
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methods for organic compounds are scarce and still suffer from many drawbacks. Metal 
fluorides have been investigated as potential sources of fluorides, but most of the 
reports focus on transition metals.11,25 The ability to achieve such a reaction with a 



















Scheme 6: Fluorination of Ph3CCl using [κ4-Tptm]ZnF 
 
In conclusion, we improved the synthesis of [κ4-Tptm]ZnF by using Me3SnF as the 
fluorination agent. The chemistry of [κ4-Tptm]ZnF was found to be dominated by the 
reactivity of the fluoride ligand, which can interact with the strong Lewis acid B(C6F5)3 
to make a [Tptm]ZnFB(C6F5)3 adduct, and can also participate in hydrogen bonding 
with water and indole, as well as halogen bonding with iodopentafluorobenzene. 
Finally, [κ4-Tptm]ZnF reacts with Ph3CCl to form Ph3CF, thus providing the first 
example of C–F bond formation using a zinc fluoride complex as the fluorinating agent.  
 
3.3 Hydrosilylation of carbonyls using zinc hydrides 
3.3.1 Introduction 
The hydrosilylation reaction corresponds to the addition of silicon hydrides across 
multiple bonds such as olefins or carbonyls to form organosilanes or siloxanes. This 
reaction has found many applications in industry, especially in the large scale 
production of silicon rubbers, lubricants, oil and resins.27 Since the report of the highly 
active Karstedt catalyst, a vinyl siloxane platinum(0) complex, the entire hydrosilylation 
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industry has been dominated by platinum compounds.28 Indeed, in addition to being 
highly active so that small catalyst loadings are required, these complexes tend to be 
stable in the presence of moisture, oxygen and heat. However, the main drawback of 
this chemistry is the unsustainability of the process, as it is currently impossible to 
recover the platinum at the end of the catalysis. The high costs of platinum, the 
possibility of exhausting the natural sources of platinum, and the toxicity of the 
platinum nanoparticules formed over the course of the catalysis have stimulated the 
research for new catalysts based on cheaper, available, non-toxic and environmentally 
friendly metals.29  
 
Zinc appears as an ideal candidate as it fulfills all of these requirements, and has 
therefore been investigated as an alternative for catalytic hydrosilylation. In recent 
years, several zinc complexes have been reported to be capable of performing the 
hydrosilylation of carbonyls and imines at high turnover frequencies.30 Common to 
most mechanisms invoked for these transformations is the presence of a zinc hydride as 
the reactive intermediate that reacts with the carbonyl compound to generate a zinc 
alkoxide. It is therefore not surprising that the stable zinc hydride [κ3-Tptm]ZnH acts as 
a catalyst for the hydrosilylation of aldehydes, ketones and CO2. Preliminary results 
show that [κ3-Tptm]ZnH catalyzes the insertion of acetaldehyde and acetone in the 3 Si–
H bonds of PhSiH3 to produce PhSi(OEt)3 and PhSi(OPri)3.3 Interestingly, although 
catalysts for hydrosilylation of carbonyls using phenylsilane as the Si–H source have 
been reported before, the insertion very rarely proceeds to the fully tris substituted 
siloxane.31 Additionally, [κ3-Tptm]ZnH catalyzes the hydrosilylation of CO2 by 













Scheme 7: Proposed catalytic cycle for the hydrosilylation of ketones an aldehydes with 
PhSiH3 catalyzed by [κ3-Tptm]ZnH  
 
In this second part, we extended the scope of ketones and aldehydes substrates for the  
hydrosilylation of carbonyls catalyzed by [κ3-Tptm]ZnH. The use of prochiral ketones 
led to the formation of products that present interesting NMR signals. We also 
investigated the reaction mechanism and identified key intermediates in the catalytic 
process. Finally, we report the improved hydrosilylation of CO2 to methoxysilanes with 
[κ3-Tptm]ZnH as a catalyst. 
 
3.3.2 Hydrosilylation of ketones and aldehydes 
The aldehydes and ketones tested for the hydrosilylation reaction, with PhSiH3 as a Si–
H source and [κ3-Tptm]ZnH as a catalyst (Scheme 8), are listed in Table 2. Insertion in 
all three of the Si–H bonds of phenylsilane is observed when a ratio of 1:3.3 of 
PhSiH3/carbonyl and 3.3 mol% of catalyst are used. The hydrosilylation of aldehydes is 
the fastest, with turnover frequencies (TOFs) ranging from 271 h-1 to greater than 500 h-1. 
In contrast, mono and dialklyl ketones are less reactive, with TOFs ranging from 4 h-1 to 
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77 h-1, the slowest being dialkyl ketones such as 3-pentanone and cyclohexanone. 
Interestingly, the diaryl ketone benzophenone exhibits very high reactivity with a TOF 
higher than 500 h-1.  
 
Scheme 8: Zinc-catalyzed insertion of carbonyl compounds into the Si–H bonds of 
PhSiH3. 
 
Using fewer equivalents of carbonyl lead to mixtures of mono, bis, and tris insertion 
PhSiH2(OR), PhSiH(OR)2 and PhSi(OR)3 products. When a 1:1 ratio of carbonyl and 
phenylsilane is used, the main compound produced is usually the bis insertion product, 
with a small percentage of mono insertion compound. In the case of PhC(O)Me, a 2:1 
ratio of ketone and phenylsilane gives a mixture of bis insertion PhSiH[OCH(Me)Ph]2 
and tris insertion PhSi[OCH(Me)Ph]3 products. The fact that the major product in both 
the 1:1 and 2:1 reactions is the double insertion product shows that the insertion into the 
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Si–H bond of PhSiH2[OCH(Me)Ph] is easier than that of PhSiH3, suggesting that the 
presence of the alkoxy group activates the remaining Si–H bonds.32 However, this 
promotion effect dissipates when going from the double insertion to the tris insertion 
product, as the carbonyl insertion into the Si–H bond of PhSiH[OCH(Me)Ph]2 is much 
slower, possibly because of its larger size. 
 
 PhSiH3:RR’CO Ratio 
 1:1a 1:3.3b 
























































































0:10 600c PhSi[OCH(R)R’]3 
(100 %) 
0:10 542c 
Table 2: [κ3-Tptm]ZnH catalyzed insertion of aldehydes and ketones into the Si–H 
bonds of PhSiH3. (a) 1.0 mol % catalyst based on PhSiH3; TON = 100.0; product mixture 
contains excess PhSiH3.  (b) 3.3 mol% catalyst based on PhSiH3; TON = 90.3.  (c) In view 
of the high activity, these values represent the minimum TOF. 
 
3.3.3 Mechanistic studies 
The hypothetic mechanism proposed by Wesley Sattler for the hydrosilylation of 
carbonyl compounds by silanes catalyzed by [κ3-Tptm]ZnH involves two steps. First, 
the carbonyl group inserts into the Zn–H bond to generate a zinc alkoxy species, then 
the Zn–O bond formed undergoes metathesis with the Si–H bond of the silane to 
regenerate the zinc hydride and produce the desired alkoxy silane species (Figure 5). 
This hypothetical mechanism is based on the independent observations that, on one 
hand, CO2 inserts in the Zn–H bond of [κ3-Tptm]ZnH to form [κ4-Tptm]ZnOC(O)H, and 
on the other hand, [Tptm]ZnOR species react with silanes to produce alkoxy silanes and 
[κ3-Tptm]ZnH. However, the presence of a hydride ligand on the metal complex does 
not necessarily mean that the hydride is involved in the mechanism, as illustrated by 
the catalyst (Tp)(ArN=)Mo(H)(PMe3) (Tp = tri(pyrazolyl)borate, Ar = 2,6-
diisopropylphenyl)31b in which the hydride ligand acts as a spectator. We therefore 
investigated the mechanism further to understand the role of the hydride. 
 
In the case of [κ3-Tptm]ZnH, reaction with a carbonyl group readily forms the 
corresponding [Tptm]ZnOR compound and subsequent treatment with phenylsilane 
regenerates [κ3-Tptm]ZnH. For example, insertion of either benzophenone or 
acetophenone into the Zn–H of [κ3-Tptm]ZnH produces [Tptm]ZnOCHPh2 or 
[Tptm]ZnOCH(Me)Ph, respectively. Both compounds were identified via 1H NMR, the 
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latter showing a singlet at δ 6.28 and the former a quartet at δ 5.41 and a doublet at δ 
1.59. Similarly, reaction with the zinc deuteride isotopologue [κ3-Tptm]ZnD generates 
the deuterated compounds [Tptm]ZnOCDPh2 or [Tptm]ZnOCD(Me)Ph. Interestingly, 
treatment with phenylsilane regenerates the [κ3-Tptm]ZnH and shows complete 
transfer of the deuterated groups to the silane, suggesting that the formation of the zinc 
alkoxide is irreversible and does not dissociate back into [κ3-Tptm]ZnH and the 
corresponding carbonyl. Further evidence of the irreversibility of the carbonyl insertion 
is provided by the reaction between [κ3-Tptm]ZnD and excess benzaldehyde to form 
[Tptm]ZnOCD(H)Ph. Indeed, no deuterium incorporation is observed between the 
deuterated zinc alkoxide and the excess benzaldehyde in the timescale of the reaction. 
 
Figure 5: Mechanism for the zinc-catalyzed insertion of a carbonyl group into Si–H 
bonds as illustrated for PhSiH3 
 
3.3.4 NMR spectroscopy of the hydrosilylation products 
The triple insertion products PhSi(OR)3 obtained from prochiral ketones such as 
PhC(O)Me and EtC(O)Me present interesting spectroscopic features. Indeed, the 
presence of three chiral centers on the three alkoxy groups of the silicon lead to complex 
1H NMR spectra for these compounds. For example, PhSi[OCH(Me)Ph]3, the product of 
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triple insertion of acetophenone PhC(O)Me in PhSiH3 present a 1:1:1:1:1:1:1:1 ratio 
signal for the methyl groups, much different from the commonly observed doublet in 
C(H)Me groups (Figure 6). Wes Sattler reported that the complexity observed in the 
NMR spectrum of PhSi[OCH(Me)Ph]3 can be explained by the presence of different 
diastereomers, namely the RRR/SSS isomers and the RRS/SSR isomers (Figure 7). 
 
Figure 6: 1H NMR spectra (C6D6) of methine (left) and methyl (right) regions for 






Figure 7: Origin of eight signals for the methyl groups of PhSi[OCH(Me)Ph]3 in the 1H 
NMR spectrum, with chemically equivalent methyl groups coded by color.  The methyl 
groups of the RRR isomer are chemically equivalent, whereas the methyl groups of the 
RRS isomer are chemically inequivalent; however, since the RRS isomer is statistically a 
factor of three more prevalent than the RRR isomer, four equally abundant methyl 
groups are observed.  A similar argument pertains to comparison of their enantiomers, 
i.e. SSS and SSR. 
 
We observed that the double insertion product PhSiH[OCH(Me)Ph]2 also present 
unusual spectroscopic features, due to the chirality of the alkoxy groups on the silane. 
Indeed, the 1H NMR spectrum for PhSiH[OCH(Me)Ph]2 shows what appears to be four 
doublets of almost equal intensity, instead of a single doublet (Figure 8). Similar 
analysis than for PhSi[OCH(Me)Ph]3 shows that PhSiH[OCH(Me)Ph]2 exists as several 
diastereomers, namely the RR/SS, the RrS and the RsS isomers, each with different 
NMR signals. Unlike the compound PhSi[OCH(Me)Ph]3 in which the RRS and SSR 
isomers are enantiomers by virtue of the 3 fold symmetry, the RS and SR isomers of 
PhSiH[OCH(Me)Ph]2 are diastereomers, because the silicon is a pseudoasymmetric 
center. Therefore the notation r and s was introduced to distinguish between the two 
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diastereomers of the silicon center. The RR and SS isomers are enantiomers, and 
therefore possess the same 1H NMR signal, making it twice more intense than the RrS 
and the RsS isomers signals. Analysis of the 29Si{1H} NMR (Figure 9) and the SiH region 
of the spectrum (Figure 10) confirms the presence of three compounds in a 2:1.06:0.93 
ratio, close to the expected 2:1:1 statistical ratio.  
 
Figure 8: Methyl region of the 1H NMR spectrum of PhSiH[OCH(Me)Ph]2 illustrating 
four doublets associated with the three RR/SS, RrS (“r”) and RsS (“s”) diastereomers 
(bottom) and two doublets associated with SS-PhSiH[OCH(Me)Ph]2 (top).  Note that of 




Figure 9: 29Si{1H} NMR spectrum illustrating the three RR/SS, RrS and RsS 





Figure 10: Si–H region of the 1H NMR spectrum of PhSiH[OCH(Me)Ph]2 illustrating the 
three RR/SS, RrS and RsS diastereomers (* = PhSiH2[OCH(Me)Ph]).   
 
However, the methyl region of the spectrum of PhSiH[OCH(Me)Ph]2 shows a signal 
that corresponds to four inequivalent methyl groups. The discrepancy can be explained 
by the fact that, although the RR and SS isomers are enantiomers, the two methyl 
groups are chemically inequivalent, due to the absence of a mirror plane. Therefore, two 
of the doublets come from the enantiopure compound, which is nearly twice as 
abundant. The RrS and RsS both possess a mirror plane that makes the two methyl 
groups chemically equivalent, such that each product appears as one doublet with 
similar abundance (Figure 11). The enantiopure (R,R)-PhSiH[OCH(Me)Ph]2 and (S,S)-
PhSiH[OCH(Me)Ph]2 can be synthesized via the reaction between PhSiH3 and two 
equivalents of either (R)-(+)-1-phenylethanol or (S)-(-)-1-phenylethanol. The 1H NMR 
spectrum indeed shows two doublets for the methyl groups that correspond to the ones 




Figure 11: Isomers of PhSiH[OCH(Me)Ph]2, with chemically equivalent methyl groups 
coded by color (the phenyl groups and oxygen atoms attached to the asymmetric 
carbon centers are omitted for clarity).  While the methyl groups of the RR and SS 
isomers are chemically inequivalent, the methyl groups of the RrS and RsS isomers are 
chemically equivalent due to the presence of a mirror plane.  As such, the methyl region 
of the 1H NMR spectrum consists of four doublets in a ratio that reflects the relative 
abundance of the RR/SS, RrS and RsS diastereomers. 
 
Interestingly, the 1:3 ratio of RRR/SSS-PhSi[OCH(Me)Ph]3 and RRS/SSR-
PhSi[OCH(Me)Ph]3 isomers is indistinguishable from the statistical ratio,  whereas the 
ratio of several PhSiH[OCH(Me)Ph]2 diastereomers, namely the RR/SS, the RrS and the 
RsS isomers, deviates from statistical distribution. This deviation represents a kinetic 
bias in the reaction between PhSiH2[OCH(Me)Ph] and [Tptm]Zn(OR*), such that the 
formation of RrS is kinetically slightly favored than that of RsS. The fact that this bias 
disappears in the PhSi[OCH(Me)Ph]3 shows that either the kinetic distribution is 
incidentally the same as the thermodynamic distribution for the third insertion reaction, 
or that the final product undergoes alkoxide exchange to produce a statistical 
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distribution. In that regard, prolonged heating of a mixture of (R,R,R)-
PhSi[OCH(Me)Ph]3 and (S,S,S)-PhSi[OCH(Me)Ph]3 shows no alkoxide redistribution to 
form the RRS and the SSR compounds, with or without a catalytic amount of [κ3-
Tptm]ZnH. The 1:3 ratio of RRR/SSS-PhSi[OCH(Me)Ph]3 and RRS/SSR-
PhSi[OCH(Me)Ph]3 isomers is therefore a kinetic distribution that, incidentally, 
corresponds to the statistical distribution. 
 
3.4 Carbon dioxide functionalization 
3.4.1 Introduction 
In addition to catalyzing the hydrosilylation of ketones and aldehydes, [κ3-Tptm]ZnH 
aslo catalyzes the hydrosilylation of CO2 with (EtO)3SiH to generate the silyl formate 
(EtO)3SiOC(O)H. This reaction is particularly attractive for the prospective to directly 
use CO2 as a C1 fragment for the synthesis of commodity chemicals such as 
polycarbonates, formic acid and formamides.33 Furthermore, the constantly increasing 
concentration of CO2 in the atmosphere caused by human activities plays a major part 
in the climate change observed over the past century on earth. In that regard, CO2 
capture and recycling has become a major field of research lately and has already found 
applications at industrial scale.34 
 
The hydrosilylation of CO2 is an interesting alternative to hydrogenation for the 
reduction of CO2 to formates, as the reaction is more favorable thermodynamically.3 
Many catalysts have shown remarkable activity for this reaction; however, the majority 
of them consist of precious metal complexes such as ruthenium and iridium.35 The 
prospective that similar reactivity can be obtained with a cheap, abundant and non-
toxic metal such as zinc is therefore attractive.36 Wesley Sattler reported that [κ3-
Tptm]ZnH catalyzes the hydrosilylation of CO2 with (EtO)3SiH at 100°C with catalyst 
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loading as low as 0.1%. The reaction consists of the insertion of CO2 into the Zn–H bond 
to from a zinc formate, followed by metathesis with the silane to regenerate the zinc 
hydride and produce the desired silyl formate (Scheme 9).3,37 This reaction can be done 











Scheme 9: Hydrosilylation of CO2 catalyzed by [κ3-Tptm]ZnH  
 
The further reduction of CO2 to methanol is even more desirable, as methanol has 
emerged as a serious candidate for the replacement of fossil fuel in transports and 
electricity generation.38 Methanol can either be used as a way to chemically store 
hydrogen, or as a fuel by itself. Indeed, methanol is a good substituent for gasoline in 
combustion engines, because of both its high octane rating and the fact that its 
combustion is cleaner than regular gasoline.39 Methanol can also be used in fuel cells, 
and as a precursor for chemicals usually obtained from fossil fuel sources. The direct 
hydrogenation of methanol requires an external source of power, which could be 
provided by renewable sources.40 For example, the George Olah plant in Iceland 
successfully produces methanol from CO2 and water using geothermal energy. 
Hydrosilylation of CO2 is an alternative way to access methanol (Scheme 10), and 
homogeneous catalysts have been shown to perform hydrosilylation of CO2 to methanol 
 
 211 
or methoxy silanes, although only few examples are known. The iridium complex 
Ir(CN)(CO)dppe (dppe = 1,2-bis(diphenylphosphino)ethane)41 and the N-heterocyclic 
carbene 1,3-bis(2,4,6-trimethylphenyl)imidazolium carboxylate42 are the only examples 
of catalysts that achieve selective formation of the methoxy species. Indeed, other 
catalysts tend to either react further to generate methane,43 or to stop at the silyl acetal 
(Scheme 10), with only traces of the methoxy silane compounds.44 In this section, we 
further investigate the mechanism of hydrosilylation of CO2 by silanes catalyzed by [κ3-
Tptm]ZnH, and we also report the catalytic hydrosilylation of silyl formates and CO2 to 
methoxy silane species by [κ3-Tptm]ZnH , therefore correspond to a formal reduction of 






R3Si SiR3 R3Si O H
H H
CH4
R3SiH R3SiH R3SiH R3SiH
- R3SiOSiR3 - R3SiOSiR3
silyl formate silyl acetal methoxy silane  
Scheme 10 
 
3.4.2 Reactivity of [κ3-Tptm]ZnH with silyl formates  
We decided to further investigated the mechanism for the hydrosilylation of CO2  to 
silyl formates.  1H NMR spectroscopy demonstrate that the resting state for the catalyst 
in this reaction is [κ4-Tptm]ZnOC(O)H. This observation is supported by the fact that 
[κ3-Tptm]ZnH reacts readily with CO2 at room temperature to form [κ4-
Tptm]ZnOC(O)H, whereas [κ4-Tptm]ZnOC(O)H requires higher temperatures to react 
with (EtO)3SiH. In addition, reaction between a catalytic amount of [κ3-Tptm]ZnH (10 
mol%) and (EtO)3SiOC(O)H in the absence of CO2 cleanly produces [κ4-
Tptm]ZnOC(O)H. This suggests that the regeneration of [κ3-Tptm]ZnH from [κ4-
Tptm]ZnOC(O)H using (EtO)3SiH is an in fact an equilibrium reaction, which lays 
mostly on the side of the zinc formate (Scheme 11). The presence of such equilibrium 
could justify the need of high temperatures to drive the formation of [κ3-Tptm]ZnH to 
 
 212 
complete the catalytic cycle. In this sense, this system clearly differs from the 
hydrosilylation of aldehydes and ketones system, for which the zinc alkoxide species 
formed by insertion of the carbonyl in the Zn–H bond readily reacts with a silane at 











Scheme 11: Revised mechanism for the hydrosilylation of CO2 catalyzed by [κ3-
Tptm]ZnH  
 
In the absence of CO2, the silyl formate (EtO)3SiOC(O)H can further react with two 
equivalents of (EtO)3SiH, in the presence of catalytic amount of [κ3-Tptm]ZnH (2 mol%), 
to produce (EtO)3SiOMe and alkoxide redistribution products, as well as 
(EtO)3SiOSi(OEt)3 (Scheme 12). With a TON of 50 in a reaction time of 4 days at 100°C, 
the TOF of 0.52 h-1 is in the range reported for this reaction (0.039-25.5 h-1).41,42 The fact 
that this reaction is not observed in the catalytic hydrosilylation of CO2 reported by 
Wesley Sattler means that CO2 is more reactive towards the zinc hydride than 
(EtO)3SiOC(O)H, and therefore inhibits further reduction of the silyl formate. 
Observation of further hydrosilylation steps in the absence of CO2 also implies that the 
reaction between [κ3-Tptm]ZnH and (EtO)3SiOC(O)H leads to two different outcomes, 
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one being the formation [κ4-Tptm]ZnOC(O)H and (EtO)3SiH, and the other being the 










+(EtO)3SiOSi(OEt)3 (EtO)2Si(OMe)2  +  (EtO)4Si  +  ...+  
 
Scheme 12: Hydrosilylation of (EtO)3SiOC(O)H catalyzed by [κ3-Tptm]ZnH. 
 
The mechanism for the reaction was investigated to identify the two distinct paths for 
the reaction between [κ3-Tptm]ZnH and (EtO)3SiOC(O)H. The reaction between one 
equivalent of [κ3-Tptm]ZnH and one equivalent of (EtO)3SiOC(O)H in the absence of 
CO2 at room temperature confirms that [κ4-Tptm]ZnOC(O)H is not the only product, as 
a minor [Tptm]Zn product and (EtO)3SiOMe are produced as well. We propose that this 
compound corresponds to the alkoxy complex [Tptm]ZnOSi(OEt)3, which results from 
i) the insertion of the carbonyl of (EtO)3SiOC(O)H into the Zn–H bond of [κ3-Tptm]ZnH 
to form an acetal species [Tptm]ZnOCH2OSi(OEt)3, followed by ii) the dissociation of 
[Tptm]ZnOCH2OSi(OEt)3 into formaldehyde and [Tptm]ZnOSi(OEt)3. The 
formaldehyde generated reacts immediately with [κ3-Tptm]ZnH to form 
[Tptm]ZnOMe, which then readily reacts with (EtO)3SiH to regenerate [κ3-Tptm]ZnH 
and produce (EtO)3SiOMe. On the other hand, [Tptm]ZnOSi(OEt)3 reacts with (EtO)3SiH 
to generate the silyl ether (EtO)3SiOSi(OEt)3 (Scheme 13). The three last steps are 
reasonable based on the known reactivity of both [κ3-Tptm]ZnH towards aldehydes and 
[Tptm]Zn alkoxide species towards silanes.3 An alternative mechanism involves the 
reaction between [Tptm]ZnOCH2OSi(OEt)3 and (EtO)3SiH to form the bis silyl acetal 
(EtO)3SiOCH2OSi(OEt)3, which can dissociate to formaldehyde and (EtO)3SiOSi(OEt)3 on 
its own.45 However, the absence of signals in the 1H NMR in the typical range for acetals 
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disproves this mechanism. Indeed, several examples of CO2 hydrosilylation catalysts 
reported in the literature show the formation of methylene acetal species, wich are 
clearly observed in solution.44 In fact, the dissociation of such acetal into the 
formaldehyde and the corresponding ether is not straightforward and is known to 






















Scheme 13: Proposed mechanism for the hydrosilylation of (EtO)3SiOC(O)H to 
(EtO)3SiOMe catalyzed by [κ3-Tptm]ZnH. 
 
The formation of (EtO)3SiOMe is inevitably accompanied by the apparition of several 
side products of alkoxide redistribution such as (EtO)4Si, (EtO)2Si(OMe)2, and 
(EtO)Si(OMe)3. To avoid such reactions, the hydrosilylation of CO2 was investigated 
with (MeO)3SiH as the silane, as it would ultimately lead to the sole formation of 
(MeO)4Si. Interestingly, the hydrosilylation of CO2 with (MeO)3SiH catalyzed by [κ3-
Tptm]ZnH does not produce (MeO)3SiOC(O)H as expected, but directly (MeO)4Si and 
(MeO)3SiOSi(OMe)3. With a catalyst loading of 8 mol%, the reaction is complete after 
48h at 100°C, such that the TOF for this system is 0.26 h-1. Such outcome shows that 
(MeO)3SiOC(O)H is more reactive than (EtO)3SiOC(O)H to insert into the Zn–H bond of 
[κ3-Tptm]ZnH, despite the presence of CO2 in the mixture. Reaction with 13CO2 shows 
complete incorporation of 13C in the methyl groups of (MeO)4Si and 
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(MeO)3SiOSi(OMe)3, as a result from alkoxide redistribution. This is the first example of 
a one pot catalytic hydrosilylation of CO2 to methoxy silanes using a zinc complex. 
 
As redistribution of the methyl group of (MeO)4Si and (MeO)3SiOSi(OMe)3 was 
observed, it was still not definitive that the methoxy group originiates from CO2. To 
further avoid alkoxide redistribution, the silatrane κ4-N(CH2CH2O)3SiH was used in 
place of (MeO)3SiH, as the chelation provided by the atrane motif prevents such 
redistribution. Although it is less reactive than (MeO)3SiH, 33% of the silatrane can be 
converted to the formate κ4-N(CH2CH2O)3SiOC(O)H after 8 days at 100°C in the 
presence of CO2 and a catalytic amount of [κ3-Tptm]ZnH (10 mol%) (Scheme 14). The 
molecular structure of κ4-N(CH2CH2O)3SiOC(O)H was determined by X-ray diffraction, 
therefore confirming the transfer of the formate group to the silicon (Figure 12). 
Interestingly, κ4-N(CH2CH2O)3SiOC(O)H is the first structurally characterized silyl 
formate, despite numerous studies on the hydrosilylation of CO2 to silyl formates with 
many different silanes.36 The silatrane formate κ4-N(CH2CH2O)3SiOC(O)H can undergo 
further hydrosilylation with κ4-N(CH2CH2O)3SiH and catalytic amounts of [κ3-
Tptm]ZnH (10 mol%) to produce κ4-N(CH2CH2O)3SiOMe. The silatrane κ4-
N(CH2CH2O)3SiH can be also partially converted to the methoxy silatrane κ4-
N(CH2CH2O)3SiOMe directly from CO2 by using higher concentrations of [κ3-Tptm]ZnH 
(Scheme 14). Indeed, 1H NMR spectroscopy shows that the reaction between one 
equivalent of κ4-N(CH2CH2O)3SiH and one equivalent of [κ3-Tptm]ZnH in the presence 
of CO2 produces a mixture of the silyl formate as the minor product and the methoxy 
silatrane as the major product. Reaction with 13CO2 shows complete incorporation of 13C 
solely in the methoxy group of κ4-N(CH2CH2O)3SiOMe, proving that this carbon indeed 










































Scheme 14: Hydrosilylation of CO2 using κ4-N(CH2CH2O)3SiH and [κ3-Tptm]ZnH. 
 




It is therefore clear that [κ3-Tptm]ZnH is able to catalyze the hydrosilylation of silyl 
formates to methoxysilanes using alkoxysilanes, thereby providing a rare example of a 
catalyst capable of selectively reducing CO2 to derivatives of methanol. In the case of 
(MeO)3SiH, the one pot reduction of CO2 to methoxysilane is observed, which is an 
attractive reaction for the prospect of recycling CO2 into useful chemicals. 
 
3.5 Conclusion 
In conclusion, we reported the improved synthesis of [κ4-Tptm]ZnF using Me3SnF as the 
fluorination agent. The fluoride ligand can not only interact with the strong Lewis acid 
B(C6F5)3 to make a [Tptm]ZnFB(C6F5)3 adduct, but also participate in hydrogen bonding 
with water and indole, as well as halogen bonding with iodopentafluorobenzene. 
Notably, [κ4-Tptm]ZnF reacts with Ph3CCl to form Ph3CF, thereby providing the first 
example of C–F bond formation using a zinc fluoride complex as the fluorinating agent.  
 
Then, we expanded the scope of aldehydes and ketones substrates that undergo 
hydrosilylation with PhSiH3 and [κ3-Tptm]ZnH as the catalyst. Aldehydes were found 
to be more reactive than most ketones, with the exception of benzophenone. The 
mechanism of the reaction was investigated using [κ3-Tptm]ZnD, thereby confirming 
that the carbonyl inserts into the Zn–D bond to form a zinc alkoxide. The NMR spectra 
for the products of hydrosilylation of prochiral ketones were reported, and the presence 
of different diastereomers was identified as the source of the complexity of the 
spectroscopic features observed. 
 
Finally, [κ3-Tptm]ZnH was also shown to catalyze the hydrosilylation of CO2 to 
methoxy silane species using various silanes. In the triethoxysilane system, the silyl 
formate can only undergo further hydrosilylation reaction in the absence of CO2, as the 
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latter is more reactive towards [κ3-Tptm]ZnH than the former. In the case of (MeO)3SiH, 
no inhibition of CO2 is observed, such that the formation of the methoxy silyl 
compound can be achieved in one pot directly from CO2. The use of κ4-
N(CH2CH2O)3SiH as the silane allowed for the confirmation that the methoxy group 
formed in the reaction originates solely from CO2. 
 
3.6 Experimental section 
3.6.1 General Considerations 
All manipulations were performed using a combination of glovebox, high vacuum, and 
Schlenk techniques under a nitrogen or argon atmosphere.46 Solvents were purified and 
degassed by standard procedures.  1H NMR chemical shifts are reported in ppm relative 
to SiMe4 (δ = 0) and were referenced internally with respect to the protio solvent 
impurity (δ 7.16 for C6D5H, 7.26 for CHCl3).47  13C NMR spectra are reported in ppm 
relative to SiMe4 (δ = 0) and were referenced internally with respect to the solvent (δ 
128.06 for C6D6 and δ 77.16 for CDCl3).47  11B NMR are reported in ppm relative to 
BF3•Et2O (δ = 0) and were obtained by using the Ξ/100% value of 32.083974.48  19F NMR 
chemical shifts are reported in ppm relative to CFCl3 (δ = 0.0) and were obtained by 
using the Ξ/100% value of 94.094011.48 29Si chemical shifts are reported in ppm and 
were referenced internally with respect to SiMe4 (δ = 0).  Coupling constants are given 
in hertz.  Infrared spectra were recorded on Nicolet Avatar 370 DTGS spectrometer and 
are reported in cm-1.  All chemicals were obtained from Aldrich, with the exception of 
phenylsilane (97 %, Acros), Ph2SiH2 (Alfa Aesar), and (S)-(–)-1-phenylethanol (Fluka).  
PhCHO was distilled prior to use.  [κ4-Tptm]Li,2 [κ4-Tptm]ZnOSiMe3,2 [κ3-Tptm]ZnH,2 




3.6.2 X-ray Structure Determinations 
X-ray diffraction data were collected on a Bruker Apex II diffractometer.  Crystal data, 
data collection and refinement parameters are summarized in Table 4.  The structures 
were solved using direct methods and standard difference map techniques, and were 
refined by full-matrix least-squares procedures on F2 with SHELXTL (Version 2014/7).50 
 
3.6.3 Computational Details 
Calculations were carried out using DFT as implemented in the Jaguar 7.5 (release 207) 
suite of ab initio quantum chemistry programs.51  Geometry optimizations were 
performed with the B3LYP density functional52 using the 6-31G** (B, C, H, N, O, F) and 
LAV3P (Zn) basis sets.53  The energies of the optimized structures were reevaluated by 
additional single point calculations on each optimized geometry using cc-pVTZ(-f)54 
correlation consistent triple-ζ (B, C, H, N, O, F) and LAV3P (Zn) basis sets. 
3.6.4 Synthesis of [κ4-Tptm]ZnF  
(a)  A suspension of [κ3-Tptm]ZnH (300 mg, 0.73 mmol) in benzene (ca. 4 mL) was 
treated with Me3SnF (134 mg, 0.73 mmol) and stirred overnight.  After this period, the 
volatile components were removed in vacuo to give a pale yellow solid that was washed 
with pentane to afford [κ4-Tptm]ZnF (275 mg, 88%). 
(b)  A solution of [κ4-Tptm]ZnOSiMe3 (500 mg, 1.01 mmol) in benzene (ca. 5 mL) was 
treated with Me3SnF (188 mg, 1.03 mmol).   The mixture was stirred overnight at room 
temperature and then heated at 50 ˚C for 1 hour.  The mixture was allowed to cool to 
room temperature and filtered.  The precipitate was extracted into benzene (ca. 3 mL) 
and the extract was combined with the pale yellow filtrate, which was lyophilized.  The 
residue obtained was washed with pentane (2 × 3 mL) and dried in vacuo to give 
[κ4-Tptm]ZnF as a pale yellow powder (130 mg, 30%).   
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1H NMR (C6D6): 6.25 [broad m, 3H, FZnC(SC5H4N)3], 6.50 [broad m, 6H, 
FZnC(SC5H4N)3], 9.69 [broad, 3H, FZnC(SC5H4N)3]. 13C{1H} NMR (C6D6): not observed 
[1C, FZnC(SC5H4N)3], 119.2 [s, 3C, FZnC(SC5H4N)3], 120.1 [s, 3C, FZnC(SC5H4N)3], 138.3 
[s, 3C, FZnC(SC5H4N)3], 149.7 [s, 3C, FZnC(SC5H4N)3], 161.7 [s, 3C, FZnC(SC5H4N)3].  
19F{1H} NMR (C6D6):  -217.9 [s, 1F, FZnC(SC5H4N)3].  IR Data (KBr disk, cm-1): 3084 (w), 
3015 (w), 2346 (w), 1590 (s), 1557 (s), 1454 (s), 1417 (s), 1282 (m), 1252 (w), 1131 (m), 1093 
(w), 1046 (m), 1011 (m), 876 (w), 759 (s), 723 (m), 642 (m), 603 (m), 410 (w).  Anal. calcd. 
for [κ4-Tptm]ZnF: C, 45.0%; H, 2.8%; F, 4.5%; N, 9.8%. Found: C, 44.7%; H, 2.6%; F, 4.7%; 
N, 9.7%. 
 
3.6.5 Synthesis of [κ4-Tptm]ZnF•H2O  
A solution of [κ4-Tptm]ZnF (27 mg, 0.06 mmol) in benzene was treated with an excess of 
water [ca. 3 mL of a saturated solution in benzene (0.036 M)], which resulted to the 
immediate deposition of colorless needles (11 mg, 44%) identified as [κ4-Tptm]ZnF•H2O 
by X-ray diffraction (vide supra).  1H NMR (C6D6): 1.99 [s, 2H, H2O•FZnC(SC5H4N)3], 6.30 
[m, 3H, H2O•FZnC(SC5H4N)3], 6.51 [m, 6H, H2O•FZnC(SC5H4N)3], 9.56 [d, J = 6 Hz, 3H, 
H2O•FZnC(SC5H4N)3]. 19F{1H} NMR (C6D6):  -205.5 [s, 1F, H2O•FZnC(SC5H4N)3].  
 
3.6.6 Synthesis of [κ4-Tptm]ZnBr  
A suspension of [κ4-Tptm]Li (10 mg, 0.03 mmol) in C6D6 (ca. 0.5 mL) in an NMR tube 
equipped with a J. Young valve was treated with ZnBr2 (7 mg, 0.03 mmol). The reaction 
was monitored by 1H NMR spectroscopy, thereby demonstrating the formation of 




3.6.7 Treatment of [κ4-Tptm]ZnOSiMe3 with Me3SiF 
A solution of [κ4-Tptm]ZnOSiMe3 (ca. 5 mg, 0.010 mmol) in C6D6 was prepared in an 
NMR tube equipped with a J. Young valve and treated with a solution of Me3SiF in 
C6D6) to give a 1:1 mixture as determined by 1H NMR spectroscopy.  The sample was 
monitored by 1H NMR spectroscopy, thereby demonstrating that [κ4-Tptm]ZnF was not 
formed over a period of 1 day at room temperature.  
 
3.6.8 Hydrogen bonding of water to [κ4-Tptm]ZnF in solution  
A solution of [κ4-Tptm]ZnF in C6D6 (30 mM) was titrated with a saturated solution of 
water in C6D6 (36 mM)55 and monitored by 19F NMR spectroscopy.  The variation in 
chemical shift is summarized in Table 3.  At the end of the titration, a drop of water was 
added to obtain the 19F NMR chemical shift in the presence of a saturated solution of 
















3.6.9 Hydrogen Bonding of Indole to [κ4-Tptm]ZnF in solution 
(a)  Equimolar solutions of (i) [κ4-Tptm]ZnF in C6D6 (25 mM) and (ii) indole in C6D6 (25 
mM) were prepared by using mesitylene as an internal standard.  The solutions were 
combined in different ratios, such that the total volume was kept constant in all the 
samples.  The samples were monitored by 1H and 19F NMR spectroscopies and the 
stoichiometry of the [κ4-Tptm]ZnF•••indole adduct was obtained from a Job plot of 
ΔδxF(init) versus xI(init), where Δδ = δ{[κ4-Tptm]ZnF} – δobs, and xF(init) and xI(init) are 
respectively the mole fractions of [κ4-Tptm]ZnF and indole that are present prior to the 
establishment of equilibration.  For analysis by 1H NMR spectroscopy, Δδ refers to the 
change in chemical shift of the signal at δ 9.69 in pure [κ4-Tptm]ZnF.  The observation 
that the maximum occurs at a mole fraction of ca. 0.5 for both the 1H and 19F NMR 
spectroscopic data indicates that the adduct has a 1:1 composition. 
(b)  A solution of [κ4-Tptm]ZnF in C6D6 (30 mM) was treated with aliquots of a solution 
of indole in C6D6 (653 mM) and monitored by 1H and 19F NMR spectroscopies, as 
illustrated below, where [[κ4-Tptm]ZnF]init is the concentration that is present prior to 
the establishment of equilibration, i.e. the total concentration of all zinc species at 
equilibrium.  The equilibrium constant for coordination of indole [85 ±7 M–1] was 
determined by using WinEQNMR2.56 
 
3.6.10 [κ4-Tptm]ZnF and C6F5I equilibrium studies  
A solution of [κ4-Tptm]ZnF in C6D6 (30 mM) was treated with aliquots of a solution of 
C6F5I in C6D6 (4.73 M) and monitored by 1H and 19F NMR spectroscopies, as illustrated 
below.  The equilibrium constant for coordination of C6F5I [9.0 ± 5 M–1] was determined 




3.6.11 Synthesis of [κ4-Tptm]ZnFB(C6F5)3   
A suspension of [κ4-Tptm]ZnF (10 mg, 0.02 mmol) in benzene (ca. 2 mL) was treated 
with B(C6F5)3 (12 mg, 0.02 mmol).  The mixture was shaken to obtain a pale yellow 
solution that was allowed to slowly evaporate at room temperature, thereby depositing 
yellow crystals over a period of two days.  The crystals were isolated, washed with 
pentane and dried in vacuo to afford [κ4-Tptm]ZnFB(C6F5)3 (18 mg, 83%). %).  1H NMR 
(C6D6): 5.97 [m, 3H, (C6F5)3BFZnC(SC5H4N)3], 6.22 [m, 3H, (C6F5)3BFZnC(SC5H4N)3], 6.32 
[m, 3H, (C6F5)3BFZnC(SC5H4N)3], 8.81 [d, J = 6 Hz, 3H, (C6F5)3BF ZnC(SC5H4N)3].  13C{1H} 
NMR (C6D6): 119.5 [s, 3C, (C6F5)3BFZnC(SC5H4N)3], 121.1 [s, 3C, 
(C6F5)3BFZnC(SC5H4N)3], 139.7 [s, 3C, (C6F5)3BFZnC(SC5H4N)3], 148.9 [s, 3C, 
(C6F5)3BFZnC(SC5H4N)3], 164.1 [s, 3C, (C6F5)3BFZnC(SC5H4N)3] (carbon atoms devoid of 
hydrogen atom substituents were not observed). 19F NMR (C6D6): -198.6 [broad s, 
(C6F5)3BFZnC(SC5H4N)3], –163.8 [m, (C6F5)3BFZnC(SC5H4N)3], –157.8 [t, J = 21 Hz, 
(C6F5)3BFZnC(SC5H4N)3], -133.0 [m, (C6F5)3BFZnC(SC5H4N)3]. 11B NMR (C6D6): 2.17 
[broad s, (C6F5)3BFZnC(SC5H4N)3], Anal. calcd. for [κ4-Tptm]ZnFB(C6F5)3•0.33C6H6: C, 
44.8%; H, 1.5%; F, 31.5%; N, 4.4%. Found: C, 45.1%; H, 1.5%; F, 31.8%; N, 4.3%. 
 
3.6.12 Self-Diffusion Constants 
Self-diffusion constants for [κ4-Tptm]ZnX were determined by pulsed gradient spin-
echo (PGSE) diffusion NMR spectroscopic experiments employing the Bruker stebpg1s 
pulse sequence. 
 
3.6.13 Reaction of [κ4-Tptm]ZnF with Me3SiX (X = Br, I)  
 (a)  A solution of [κ4-Tptm]ZnF (20 mg, 0.05 mmol) in C6D6 (ca. 0.5 mL) in an NMR tube 
equipped with a J. Young valve was treated with Me3SiBr (15 µL, 0.11 mmol) resulting 
in the formation of a pale yellow precipitate. The reaction was monitored by 1H NMR 
 
 224 
spectroscopy, thereby demonstrating the conversion to [κ4-Tptm]ZnBr over a period of 
10 minutes at room temperature. 
(b)  A solution of [κ4-Tptm]ZnF (20 mg, 0.05 mmol) in C6D6 (ca. 0.5 mL) in an NMR tube 
equipped with a J. Young valve was treated with Me3SiI via vacuum transfer, resulting 
in the formation of a pale yellow precipitate. The reaction was monitored by 1H NMR 
spectroscopy, thereby demonstrating the conversion to [κ4-Tptm]ZnI over a period of 10 
minutes at room temperature.General procedure for catalytic comparisons of 
hydrosilylation reactions 
(i) 1:1 PhSiH3:RC(O)R’.   A solution of PhSiH3 (79 mg, 0.73 mmol) and RC(O)R’ (0.73 
mmol) in C6D6 (0.7 mL) was treated with [κ3-Tptm]ZnH (3 mg, 0.0073 mmol) in an NMR 
tube equipped with a  J. Young valve.  The catalytic reactions were monitored by 1H 
NMR spectroscopy and the products were identified by a combination of 1H, 13C and 
29Si NMR spectroscopy (below). 
(ii) 1:3.3 PhSiH3:RC(O)R’.  A solution of PhSiH3 (24 mg, 0.22 mmol) and RC(O)R’ (0.73 
mmol) in C6D6 (0.7 mL) was treated with [κ3-Tptm]ZnH (3 mg, 0.0073 mmol) in an NMR 
tube equipped with a  J. Young valve.  The catalytic reactions were monitored by 1H 
NMR spectroscopy and the products were identified by 1H, 13C and 29Si NMR 
spectroscopy (below).   
 
3.6.15 Neat hydrosilylation of PhC(O)Me by PhSiH3  
A suspension of [κ3-Tptm]ZnH (6 mg, 0.015 mmol) in PhSiH3 (48 mg, 0.44 mmol) was 
treated with PhC(O)Me (175 mg, 1.5 mmol) in a vial. The mixture was shaken and heat 
was rapidly generated. After 2 minutes, an aliquot was taken and analyzed by 1H NMR 
spectroscopy, showing complete conversion of PhSiH3 to a 0.53:1 mixture of 
PhSiH[OCH(Me)Ph]2 and PhSi[OCH(Me)Ph]3 (TON = 78, TOF = 2310 h-1). After 1h, an 
 
 225 
other aliquot was taken and analyzed by 1H NMR spectroscopy, showing that the 
mixture was fully converted to PhSi[OCH(Me)Ph]3 (TON = 88, TOF = 88 h-1). 
 
3.6.16 Spectroscopic evidence for an alkoxide intermediate, [Tptm]ZnOCH(R)R’   
(i) A suspension of [κ3-Tptm]ZnH (5 mg, 0.012 mmol) in C7D8 (0.7 mL) in an NMR tube 
equipped with a  J. Young valve was treated with PhC(O)Me and monitored by 1H 
NMR spectroscopy, thereby demonstrating the immediate formation of an alkoxide 
compound, [Tptm]Zn[OCH(Me)Ph], as indicated by the observation of a quartet signal 
at δ  5.41 assignable to [Tptm]Zn[OCH(Me)Ph] and a doublet at δ 1.59 assignable to 
[Tptm]Zn[OCH(Me)Ph].  Addition of an excess of PhSiH3 to the intermediate results in 
the formation of a mixture of alkoxysilanes and [κ3-Tptm]ZnH. 
(ii) A suspension of [Tptm]ZnD (5 mg, 0.012 mmol) in C6D6 (0.7 mL) in an NMR tube 
equipped with a  J. Young valve was treated with PhC(O)Me and monitored by 1H 
NMR spectroscopy, thereby demonstrating the immediate formation of an alkoxide 
compound, [Tptm]Zn[OCD(Me)Ph], as indicated by the observation of a singlet signal 
at δ 1.65 assignable to [Tptm]Zn[OCD(Me)Ph]. Addition of an excess of PhSiH3 to the 
intermediate results in the formation of a mixture of deuterated alkoxysilanes and 
[κ3-Tptm]ZnH. 
(iii) A suspension of [κ3-Tptm]ZnH (5 mg, 0.012 mmol) in C6D6 (0.7 mL) in an NMR tube 
equipped with a  J. Young valve was treated with Ph2CO and monitored by 1H NMR 
spectroscopy, thereby demonstrating the immediate formation of an alkoxide 
compound, [Tptm]Zn[OCHPh2], as indicated by the observation of a singlet at δ 6.28 
assignable to [Tptm]Zn[OCHPh2].  Addition of an excess of PhSiH3 to the intermediate 
results in the formation of a mixture of alkoxysilanes and [κ3-Tptm]ZnH. 
(iv) A suspension of [Tptm]ZnD (5 mg, 0.012 mmol) in C6D6 (0.7 mL) in an NMR tube 
equipped with a  J. Young valve was treated with Ph2CO and monitored by 1H NMR 
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spectroscopy, thereby demonstrating the immediate formation of an alkoxide 
compound, [Tptm]Zn[OCDPh2], with the site of deuterium incorporation being 
demonstrated by the absence of a signal at δ 6.28.  Addition of an excess of PhSiH3 to the 
intermediate results in the formation of a mixture of deuterated alkoxysilanes and 
[κ3-Tptm]ZnH. 
(v) A suspension of [κ3-Tptm]ZnH (5 mg, 0.012 mmol) in C6D6 (0.7 mL) in an NMR tube 
equipped with a  J. Young valve was treated with PhCHO and monitored by 1H NMR 
spectroscopy, thereby demonstrating the immediate formation of an alkoxide 
compound, [Tptm]Zn[OCH2Ph], as indicated by the observation of a singlet at δ 5.39 
assignable to [Tptm]Zn[OCH2Ph].  Addition of an excess of PhSiH3 to the intermediate 
resulted in the formation of a mixture of alkoxysilanes and [κ3-Tptm]ZnH. 
(vi) A suspension of [κ3-Tptm]ZnD (5 mg, 0.012 mmol) in C6D6 (0.7 mL) in an NMR tube 
equipped with a  J. Young valve was treated with PhCHO and monitored by 1H NMR 
spectroscopy, thereby demonstrating the immediate formation of an alkoxide 
compound, [Tptm]Zn[OCH(D)Ph], with the site of deuterium incorporation being 
demonstrated by reduction in the intensity of the signal at δ 5.39 (there is no observable 
incorporation of deuterium into the aldehyde site on the basis of integration).  Addition 
of an excess of PhSiH3 to the intermediate resulted in the formation of a mixture of 
deuterated alkoxysilanes and [κ3-Tptm]ZnH. 
 
3.6.17 [κ3-Tptm]ZnH catalyzed alcoholysis of PhSiH3 with (S)-(–)-1-phenylethanol  
A suspension of [κ3-Tptm]ZnH (3 mg, 0.0073 mmol) in C6D6 (0.7 mL) in an NMR tube 
equipped with a J. Young valve was treated with PhSiH3 (24 mg, 0.22 mmol). (S)-(–)-1-
Phenylethanol (52 µL, 0.43 mmol) was added, thereby resulting in evolution of H2 over 
a period of ca. 20 min.  The sample was analyzed by 1H NMR spectroscopy, thereby 
demonstrating the conversion to SS-PhSiH[OCH(Me)Ph]2. 1H NMR (C6D6, selected 
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resonances): δ 1.38 [d, J = 6 Hz, 3H, PhSiH[OCH(Me)Ph]2], 1.43 [d, J = 6 Hz, 3H, 
PhSiH[OCH(Me)Ph]2], 4.991 [q, J = 6 Hz, 1H, PhSiH[OCH(Me)Ph]2, 4.987 [q, J = 6 Hz, 
1H, PhSiH[OCH(Me)Ph]2, 5.29 [s, 1H, PhSiH[OCH(Me)Ph]2. 13C{1H} NMR : 26.68 [s, 1C, 
PhSiH[OCH(Me)Ph]2], 26.74 [s, 1C, PhSiH[OCH(Me)Ph]2], 72.32 [s, 1C, 
PhSiH[OCH(Me)Ph]2], 72.36 [s, 1C, PhSiH[OCH(Me)Ph]2]. 29Si{1H} NMR (C6D6) –32.13. 
 
3.6.18 NMR Spectroscopic data for PhSiH3-x[OCH(R)R’]x  
The alkoxysilanes PhSi(OCH2Ph)3,57 PhSiH(OCH2Ph)2,58 PhSi[OCH(Me)Ph]3,59,60,58,61 
PhSiH[OCH(Me)Ph]2,59,60 PhSi(OCHPh2)3,59 PhSiH(OCHPh2)2,59 PhSiH2(OCHPh2),62 
PhSi(OEt)3,60,63 PhSiH(OEt)2,60,64 PhSiH2(OEt),63 PhSi(OPri2)3,59 PhSiH(OPri2)2,60,62,63 
PhSiH2(OPri2),62 PhSi[OCH(Me)Et]3,65 PhSiH2[OCH(Me)Et],66 PhSi(OCy)3,67 
PhSiH(OCy)2,67 PhSiH2(OCy),67 have been previously described and NMR spectra for 
these compounds have been listed for a variety of solvents.  Additional data obtained 
here for solutions in C6D6 are provided below. 
 
PhSiH[OCH(Me)Ph]2.68 The compound exists as a mixture of the RR/SS, RrS, and RsS 
diastereomers in a 2:1.06:0.93 ratio. 1H NMR (C6D6, selected resonances) (a) RrS: 
δ 1.36 [d, J = 6 Hz, 6H, PhSiH[OCH(Me)Ph]2], 4.97-5.06 [m, 2H, PhSiH[OCH(Me)Ph]2, 
overlap with RsS and RR/SS], 5.37 [s, 1H, PhSiH[OCH(Me)Ph]2]. (b) RsS: δ 1.36 [d, J = 6 
Hz, 6H, PhSiH[OCH(Me)Ph]2], 4.97-5.06 [m, 2H, PhSiH[OCH(Me)Ph]2, overlap with RrS 
and RR/SS], 5.24 [s, 1H, PhSiH[OCH(Me)Ph]2]. (c) RR/SS: δ 1.38 [d, J = 6 Hz, 3H, 
PhSiH[OCH(Me)Ph]2], 1.43 [d, J = 6 Hz, 3H, PhSiH[OCH(Me)Ph]2], ], 4.97-5.06 [m, 2H, 
PhSiH[OCH(Me)Ph]2, overlap with RrS and RsS], 5.30 [s, 1H, PhSiH[OCH(Me)Ph]2]. 
13C{1H} NMR (C6D6, selected resonances): (a) RrS: 26.16 [s, 2C, PhSiH[OCH(Me)Ph]2], 
72.27 [s, 2C, PhSiH[OCH(Me)Ph]2]. (b) RsS: 26.07 [s, 2C, PhSiH[OCH(Me)Ph]2], 72.31 [s, 
2C, PhSiH[OCH(Me)Ph]2]. (c) RR/SS: 26.68 [s, 2C, PhSiH[OCH(Me)Ph]2], 26.74 [s, 2C, 
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PhSiH[OCH(Me)Ph]2], 72.33 [s, 2C, PhSiH[OCH(Me)Ph]2], 72.37 [s, 2C, 
PhSiH[OCH(Me)Ph]2]. 29Si{1H} NMR (C6D6) –32.15 (RR/SS), –32.25 (RsS), –32.41 (RrS)  
 
PhSiH2(OCHPh2).69   1H NMR (C6D6, selected resonances): 5.20 [s, 2H, 
PhSiH2(OCHPh2)], 5.81 [s, 1H, PhSiH2(OCHPh2)]. 13C{1H} NMR (C6D6, selected 
resonances) 79.50 [s, 1C, PhSiH2(OCHPh2)]. 
 
PhSi[OCH(Me)Et]3.70 The compound exists as a statistical mixture of the RRR/SSS and 
RSS/SRR diastereomers in a 1:3 ratio. 1H NMR (C6D6): (a) RRR/SSS: 0.914 [t, J = 7 Hz, 
9H, PhSi[OCH(Me)CH2CH3]3], 1.236 [d, J = 6 Hz, 9H, PhSi[OCH(Me)Et]3], 1.45-1.66 [m, 
6H, PhSi[OCH(Me)CH2CH3]3, overlapping with RRS/RSS], 4.12-4.19 [m, 3H, 
PhSi[OCH(Me)Et]3, overlapping with RRS/RSS], 7.21-7.28 [m, 3H, PhSi[OCH(Me)Et]3, 
overlapping with RRS/RSS], 7.90 [m, 2H, PhSi[OCH(Me)Et]3, overlapping with 
RRS/RSS]. (b) RRS/RSS: 0.916 [t, J = 7 Hz, 3H, PhSi[OCH(Me)CH2CH3]3], 0.918 [t, J = 7 
Hz, 3H, PhSi[OCH(Me)CH2CH3]3], 0.920 [t, J = 7 Hz, 3H, PhSi[OCH(Me)CH2CH3]3], 
1.230 [d, J = 6 Hz, 3H, PhSi[OCH(Me)Et]3], 1.233 [d, J = 6 Hz, 3H, PhSi[OCH(Me)Et]3], 
1.234 [d, J = 6 Hz, 3H, PhSi[OCH(Me)Et]3], 1.45-1.66 [m, 6H, PhSi[OCH(Me)CH2CH3]3, 
overlapping with RRR/SSS], 4.12-4.19 [m, 3H, PhSi[OCH(Me)Et]3, overlapping with 
RRR/SSS], 7.21-7.28 [m, 3H, PhSi[OCH(Me)Et]3, overlapping with RRR/SSS], 7.90 [m, 
2H, PhSi[OCH(Me)Et]3, overlapping with RRR/SSS]. 13C{1H} NMR (C6D6): (a) RRR/SSS: 
9.99 [s, 3C, PhSi[OCH(Me)CH2CH3]3, overlapping with RRS/RSS], 23. 11 [s, 3C, 
PhSi[OCH(Me)Et]3], 32.51 [s, 3C, PhSi[OCH(Me)CH2CH3]3, overlapping with RRS/RSS], 
70.60 [s, 3C, PhSi[OCH(Me)Et]3, overlapping with RRS/RSS], 127.97 [s, 2C, 
PhSi[OCH(Me)Et]3, overlapping with RRS/RSS], 130.15 [s, 1C, PhSi[OCH(Me)Et]3, 
overlapping with RRS/RSS], 134.08 [s, 1C, PhSi[OCH(Me)Et]3, overlapping with 
RRS/RSS], 135.29 [s, 2C, PhSi[OCH(Me)Et]3, overlapping with RRS/RSS]. (b) RRS/RSS: 
9.98 [s, 2C, PhSi[OCH(Me)CH2CH3]3], 9.99 [s, 1C, PhSi[OCH(Me)CH2CH3]3, overlapping 
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with RRR/SSS], 23.07 [s, 1C, PhSi[OCH(Me)Et]3], 23.08 [s, 1C, PhSi[OCH(Me)Et]3], 23.10 
[s, 1C, PhSi[OCH(Me)Et]3], 32.51 [s, 3C, PhSi[OCH(Me)CH2CH3]3, overlapping with 
RRR/SSS], 70.60 [s, 3C, PhSi[OCH(Me)Et]3, overlapping with RRR/SSS], 70.61 [s, 6C, 
PhSi[OCH(Me)Et]3], 127.97 [s, 2C, PhSi[OCH(Me)Et]3, overlapping with RRR/SSS], 
130.15 [s, 1C, PhSi[OCH(Me)Et]3, overlapping with RRR/SSS], 134.08 [s, 1C, 
PhSi[OCH(Me)Et]3, overlapping with RRR/SSS], 135.29 [s, 2C, PhSi[OCH(Me)Et]3, 
overlapping with RRR/SSS]. 29Si{1H} NMR (C6D6): –62.26 (RRR/SSS), –62.30 (RSS/SRR). 
 
PhSiH[OCH(Me)Et]2.68 The compound exists as a mixture of the RR/SS, RrS, and RsS 
diastereomers in a 2:1.10:0.93 ratio. 1H NMR (C6D6, selected resonances): (a) RrS: δ 0.89s 
[t, J = 7 Hz, 6H, PhSiH[OCH(Me)CH2CH3]2], 1.169 [d, J = 6 Hz, 6H, 
PhSiH[OCH(Me)Et]2], 1.39-1.47 [m, 8H, PhSiH[OCH(Me)CH2CH3]2, overlapping RrS 
and RsS], 3.94-4.00 [m, 2H, PhSiH[OCH(Me)Et]2, overlapping RrS, RsS and RR/SS], 5.30 
[s,1H, PhSiH[OCH(Me)Et]2]. (b) RsS: δ 0.890 [t, J = 7 Hz, 6H, 
PhSiH[OCH(Me)CH2CH3]2], 1.167 [d, J = 6 Hz, 6H, PhSiH[OCH(Me)Et]2], 3.94-4.00 [m, 
2H, PhSiH[OCH(Me)Et]2, overlapping RrS, RsS and RR/SS], 5.29 [s, 1H, 
PhSiH[OCH(Me)Et]2].  (c)  RR/SS: δ 0.87 [t, J = 7 Hz, 6H, PhSiH[OCH(Me)CH2CH3]2], 
1.18 [d, J = 6 Hz, 3H, PhSiH[OCH(Me)Et]2], 1.19 [d, J = 6 Hz, 3H, PhSiH[OCH(Me)Et]2], 
1.52-1.60 [m, 4H, PhSiH[OCH(Me)CH2CH3]2], 3.94-4.00 [m, 2H, PhSiH[OCH(Me)Et]2, 
overlapping with RrS and RsS], 5.29 [s, 1H, PhSiH[OCH(Me)Et]2]. 13C{1H} NMR (C6D6, 
selected resonances): (a) RrS: δ 10.07 [s, 2C, PhSiH[OCH(Me)CH2CH3]2, overlapping 
with RsS and RR/SS], 23.20 [s, 2C, PhSiH[OCH(Me)Et]2], 32.44 [s, 2C, 
PhSiH[OCH(Me)CH2CH3]2, overlapping with RsS], 71.29 [s, 2C, PhSiH[OCH(Me)Et]2].  
(b) RsS: δ 10.07 [s, 2C, PhSiH[OCH(Me)CH2CH3]2, overlapping with RrS and RR/SS], 
23.12 [s, 2C, PhSiH[OCH(Me)Et]2], 32.44 [s, 2C, PhSiH[OCH(Me)CH2CH3]2 overlapping 
with RrS], 71.57 [s, 2C, PhSiH[OCH(Me)Et]2]. (c) RR/SS: 10.07 [s, 2C, PhSiH[OCH(Me) 
CH2CH3]2, overlapping with RrS and RrS], 23.16 [s, 2C, PhSiH[OCH(Me)Et]2], 32.41 [s, 
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2C, PhSiH[OCH(Me) CH2CH3]2], 71.24 [s, 1C, PhSiH[OCH(Me)Et]2], 71.62 [s, 1C, 
PhSiH[OCH(Me)Et]2]. 29Si{1H} NMR (C6D6): –33.24 (RsS), –34.18 (RrS), -33.66 (RR/SS). 
 
PhSiH2[OCH(Me)Et].69 1H NMR (C6D6, selected resonances): 0.82 [t, J = 7 Hz, 3H, 
PhSiH2[OCH(Me)CH2CH3]], 1.08 [d, J = 6 Hz, 3H, PhSiH2[OCH(Me)Et]], 3.66-3.72 [m, 
1H, PhSiH2[OCH(Me)Et]], 5.24 [s, 2H, PhSiH2[OCH(Me)Et]]. 13C{1H} NMR (C6D6, 
selected resonances): 22.61 [s, 1C, PhSiH2[OCH(Me)CH2CH3]], 32.13 [s, 1C, 
PhSiH2[OCH(Me)Et]], 73.20 [s, 1C, PhSiH2[OCH(Me)Et]]. 
 
PhSi(OCHEt2)3.69  1H NMR (C6D6): 0.93 [t, J = 7 Hz, 18H, PhSi[OCH(CH2CH3)2]3], 1.55-
1.67 [m, 12H, PhSi[OCH(CH2CH3)2]3], 4.03 [quint, J = 6 Hz, 3H, PhSi(OCHEt2)3], 7.21 [m, 
3H, PhSi(OCHEt2)3], 7.90-7.92 [m, 2H, PhSi(OCHEt2)3]. 13C{1H} NMR (C6D6): 9.72 [s, 6C, 
PhSi[OCH(CH2CH3)2]3], 29.21 [s, 6C, PhSi[OCH(CH2CH3)2]3], 75.58 [s, 3C, 
PhSi(OCHEt2)3], 127.93 [s, 1C, PhSi(OCHEt2)3], 130.09 [s, 1C, PhSi(OCHEt2)3], 134.21 [s, 
1C, PhSi(OCHEt2)3], 135.33 [s, 1C, PhSi(OCHEt2)3]. 29Si{1H} NMR (C6D6): –63.04. 
 
PhSiH2(OCHEt2).69  1H NMR (C6D6, selected resonances): 0.85 [t, J = 7 Hz, 6H, 
PhSiH2[OCH(CH2CH3)2]], 1.37-1.60 [m, 4H, PhSiH2[OCH(CH2CH3)2]], 3.51 [tt, J = 5 Hz, J 
= 7 Hz, 1H, PhSiH2(OCHEt2)], 5.27 [s, 2H, PhSiH2(OCHEt2)]. 13C{1H} NMR (C6D6, 
selected resonances): 10.06 [s, 2C, PhSiH2[OCH(CH2CH3)2]], 29.55 [s, 2C, 
PhSiH2[OCH(CH2CH3)2]], 78.62 [s, 1C, PhSiH2(OCHEt2)]. 
 
PhSiH(OCHEt2)2.68   1H NMR (C6D6, , selected resonances): 0.88 [t, J = 7 Hz, 6H, 
PhSiH[OCH(CH2CH3)2]2], 0.93 [t, J = 7 Hz, 6H, PhSiH[OCH(CH2CH3)2]2], 1.37-1.60 [m, 
8H, PhSiH[OCH(CH2CH3)2]2], 3.80 [tt, J = 5Hz, J = 7 Hz, 2H, PhSiH(OCHEt2)2], 5.33 [s, 
1H, PhSiH(OCHEt2)2]. 13C{1H} NMR (C6D6, selected resonances): 9.95, [s, 2C, 
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PhSiH[OCH(CH2CH3)2]2], 9.96 [s, 2C, PhSiH[OCH(CH2CH3)2]2], 29.60 [s, 4C, 
PhSiH[OCH(CH2CH3)2]2], 76.56 [s, 2C, PhSiH(OCHEt2)2]. 29Si{1H} NMR (C6D6): –32.55. 
 
PhSi(OCy)3. 1H NMR (C6D6): δ 1.13-1.25 [m, 4H, PhSi[OCH(C5H10)]3], 1.31-1.39 [m, 4H, 
PhSi[OCH(C5H10)]3], 1.53-1.62 [m, 4H, PhSi[OCH(C5H10)]3], 1.66-1.73 [m, 4H, 
PhSi[OCH(C5H10)]3], 1.92-1.95 [m, 4H, PhSi[OCH(C5H10)]3], 4.14 [tt, J = 4 Hz, J = 9 Hz, 
3H, PhSi[OCH(C5H10)]3], 7.23-7.29 [m, 3H, PhSi(OCy)3], 7.94-7.97 [m, 2H, PhSi(OCy)3]. 
13C{1H} NMR: δ 24.13 [s, 6C, PhSi[OCH(C5H10)]3], 26.01 [s, 3C, PhSi[OCH(C5H10)]3], 35.88 
[s, 6C, PhSi[OCH(C5H10)]3], 71.13 [s, 3C, PhSi[OCH(C5H10)]3], 130.21 [s, 1C, PhSi(OCy)3], 
134.13 [s, 1C, PhSi(OCy)3], 135.24 [s, 2C, PhSi(OCy)3]. 29Si{1H} NMR: –61.62. 
 
PhSiH(OCy)2.68     1H NMR (C6D6, selected resonances): δ 3.97 [tt, J = 9 Hz, J = 4 Hz, 2H, 
PhSiH[OCH(C5H10)]2], 5.34 [s, 1H, PhSiH(OCy)2]. 13C{1H} NMR: 72.01 [s, 2C, 
PhSiH[OCH(C5H10)]2]. 29Si{1H} NMR: –34.63. 
 
PhSiH2(OCy).69    1H NMR (C6D6, selected resonances): δ 3.68 [tt, J = 9 Hz, J = 4 Hz, 1H, 
PhSiH2[OCH(C5H10)]], 5.26 [s, 2H, PhSiH2(OCy)]. 13C{1H} NMR (C6D6, selected 
resonances): δ 73.69 [s, 1C, PhSiH2[OCH(C5H10)]].[κ3-Tptm]ZnH catalyzed 
hydrosilylation of (EtO)3SiOC(O)H using (EtO)3SiH  
A suspension of [κ3-Tptm]ZnH (1mg, 0.0024 mmol) and (EtO)3SiOC(O)H (25.4 mg, 0.12 
mmol) in benzene (ca.0.5 mL) in an NMR tube equipped with a J. Young valve was 
treated with (EtO)3SiH (40 mg, 0.24 mmol). The solution was heated at 100°C for 4 days, 
showing complete consumption of (EtO)3SiOC(O)H and the formation of (EtO)3SiOMe, 
(EtO)2Si(OMe)2, EtOSi(OMe)3, and (MeO)4Si  in a 1:0.09:0.006:0.015 ratio and 
(EtO)3SiOSi(OEt)3. 1H NMR (C6D6): (a) (EtO)3SiOMe (selected resonances): 3.51 [s, 3H, 
(CH3CH2)3SiOCH3]. (EtO)2Si(OMe)2 (selected resonances): 3.49 [s, 6H, 
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(CH3CH2)2Si(OCH3)2]. EtOSi(OMe)3 (selected resonances): 3.48 [s, 6H, 
(CH3CH2)Si(OCH3)3]. 
 
3.6.20 [κ3-Tptm]ZnH catalyzed alcoholysis of (EtO)3SiH using MeOH  
A suspension of [κ3-Tptm]ZnH (2mg, 0.0049 mmol) and (EtO)3SiH (10 mg, 0.061 mmol) 
in benzene (ca.0.5 mL) was treated with MeOH (2.5 µL, 0.061 mmol) in an NMR tube 
equipped with a J. Young valve. The rapid evolution of H2 was observed over a period 
of 20 minutes, after which the reaction was allowed to stand overnight. The sample was 
analyzed by 1H NMR spectroscopy, thereby demonstrating the formation of 
(EtO)3SiOMe, (EtO)2Si(OMe)2, EtOSi(OMe)3, and (MeO)4Si  in a 1:0.35:0.09:0.02 ratio. 
 
3.6.21 Reaction between (EtO)3SiOC(O)H and (EtO)3SiH  
A solution of (EtO)3SiOC(O)H (5 mg, 0.024 mmol) in benzene (ca. 0.5 mL) was treated 
with (EtO)3SiH (4 mg, 0.024 mmol) in an NMR tube equipped with a J. Young valve. 
The solution was heated at 100°C for 17 days, after which the sample was analyzed by 
1H NMR spectroscopy, thereby demonstrating the absence of reaction. 
 
3.6.22 Reaction between [κ 4-Tptm]ZnOC(O)H and (EtO)3SiH  
A solution of [κ4-Tptm]ZnOC(O)H (10 mg, 0.022 mmol) in benzene (ca. 0.5 mL) was 
treated with (EtO)3SiH (3.6 mg, 0.022 mmol) in an NMR tube equipped with a J. Young 
valve. The sample was analyzed by 1H NMR spectroscopy, thereby demonstrating the 
absence of reaction at room temperature. Upon heating at 100°C over a period of 3 days, 





3.6.23 Reaction between [κ3-Tptm]ZnH and excess (EtO)3SiOC(O)H  
A suspension of [κ3-Tptm]ZnH (5 mg, 0.012 mmol) in benzene (ca. 2mL) was treated 
with (EtO)3SiOC(O)H (24 mg, 0.12 mmol) in an NMR tube equipped with a J. Young 
valve. The sample was analyzed by 1H NMR spectroscopy, thereby demonstrating the 
complete conversion of [κ3-Tptm]ZnH in [κ4-Tptm]ZnOC(O)H. 
 
3.6.24 Reaction between [κ3-Tptm]ZnH and (EtO)3SiOC(O)H  
A suspension of [κ3-Tptm]ZnH (10 mg, 0.024 mmol) in benzene (ca. 2mL) was treated 
with (EtO)3SiOC(O)H (5 mg, 0.024 mmol) in an NMR tube equipped with a J. Young 
valve. The sample was analyzed by 1H NMR spectroscopy, thereby demonstrating the 
complete conversion of [κ3-Tptm]ZnH to a mixture of [κ4-Tptm]ZnOC(O)H and 
[Tptm]ZnOSi(OEt)3 in a 1:0.43 ratio, as well as the complete disappearance of 
(EtO)3SiOC(O)H and the appearance of (EtO)3SiOMe. 1H NMR (C6D6) of 
[Tptm]ZnOSi(OEt)3 (selected resonances): 1.42 [t, J = 7 Hz, 9H, 
(C5H4NS)3CZnOSi(OCH2CH3)3], 4.21 [q, J = 7 Hz, 6H, (C5H4NS)3CZnOSi(OCH2CH3)3], 
9.60 [d, J = 5.7 Hz, 3H, (C5H4NS)3CZnOSi(OCH2CH3)3]. 
 
3.6.25 [κ3-Tptm]ZnH catalyzed hydrosilylation of CO2 using (MeO)3SiH  
A suspension of [κ3-Tptm]ZnH (20 mg, 0.02 mmol) and (MeO)3SiH (30 mg, 0.25 mmol) 
in C6D6 (ca. 0.5 mL) was treated with CO2 (1 atm) in an NMR tube equipped with a J. 
Young valve. The resulting pale yellow solution was heated at 100°C for 2 days. The 
sample was analyzed by 1H NMR spectroscopy, thereby demonstrating the complete 




3.6.26 [κ3-Tptm]ZnH catalyzed hydrosilylation of 13CO2  using (MeO)3SiH  
A suspension of [κ3-Tptm]ZnH (20 mg, 0.02 mmol) and (MeO)3SiH (30 mg, 0.25 mmol) 
in C6D6 (ca. 0.5 mL) was treated with 13CO2 (1 atm) in an NMR tube equipped with a J. 
Young valve. The resulting pale yellow solution was heated at 100°C for 2 days. The 
sample was analyzed by 1H NMR spectroscopy, thereby demonstrating the complete 
conversion of (MeO)3SiH into 13C-enriched (MeO)4Si and (MeO)3SiOSi(OMe)3. 
 
3.6.27 [κ3-Tptm]ZnH catalyzed hydrosilylation of CO2 using κ4-N(CH2CH2O)3SiH  
A suspension of [κ3-Tptm]ZnH (4 mg, 0.01 mmol) and κ4-N(CH2CH2O)3SiH (17 mg, 
0.098 mmol) in C6D6 (ca. 0.5 mL) was treated with CO2 (1 atm) in an NMR tube 
equipped with a J. Young valve. The resulting pale yellow solution was heated at 100°C 
for 3 days. The sample was analyzed by 1H NMR spectroscopy, thereby demonstrating 
the partial conversion of κ4-N(CH2CH2O)3SiH to κ4-N(CH2CH2O)3SiOC(O)H (26%). 
Removal of the CO2 atmosphere from the mixture, followed by heating over a period of 




3.6.28 Hydrosilylation of CO2 using κ4-N(CH2CH2O)3SiH and [κ3-Tptm]ZnH  
A suspension of [κ3-Tptm]ZnH (10 mg, 0.024 mmol) and κ4-N(CH2CH2O)3SiH (4 mg, 
0.024 mmol) in C6D6 (ca. 0.5 mL) was treated with CO2 (1 atm) in an NMR tube 
equipped with a J. Young valve. The resulting pale yellow solution was heated at 100°C 
for 11 days. The sample was analyzed by 1H NMR spectroscopy, thereby demonstrating 
the complete conversion of κ4-N(CH2CH2O)3SiH into a mixture of κ4-
N(CH2CH2O)3SiOC(O)H and κ4-N(CH2CH2O)3SiOMe in a 0.25:0.75 ratio. 1H NMR (C6D6) 
of κ4-N(CH2CH2O)3SiOC(O)H: 2.13 [t, J = 6 Hz, 6H, N(CH2CH2O)3SiOC(O)H], 8.93 [s, 
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1H, N(CH2CH2O)3SiOC(O)H. 13C{1H} NMR (C6D6): 50.89 [s, 3C, 
N(CH2CH2O)3SiOC(O)H], 57.55 [s, 3C, N(CH2CH2O)3SiOC(O)H], 161.36 [s, 1C, 
N(CH2CH2O)3SiOC(O)H]. 
 
3.6.29 Hydrosilylation of 13CO2 using κ4-N(CH2CH2O)3SiH and [κ3-Tptm]ZnH  
A suspension of [κ3-Tptm]ZnH (10 mg, 0.024 mmol) and κ4-N(CH2CH2O)3SiH (4 mg, 
0.024 mmol) in C6D6 (ca. 0.5 mL) was treated with 13CO2 (1 atm) in an NMR tube 
equipped with a J. Young valve. The resulting pale yellow solution was heated at 100°C 
for 11 days. The sample was analyzed by 1H NMR spectroscopy, thereby demonstrating 
the complete conversion of κ4-N(CH2CH2O)3SiH into a mixture of κ4-




3.6.30 Crystallographic data 





formula weight 218.27 









temperature (K) 130(2) 
radiation (λ, Å) 0.71073 
ρ (calcd.) g cm-3 1.535 
µ (Mo Kα), mm-1 0.246 
θ max, deg. 30.604 
no. of data collected 30666 
no. of data 5783 
no. of parameters 261 
R1 [I > 2σ(I)] 0.0683 
wR2 [I > 2σ(I)] 0.1554 
R1 [all data] 0.1375 
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4.1.1 Mechanism of decomposition of [TitmPri,benzo]H 
Although the [TitmMe] and [TitmPri,benzo]Ligands have been successfully used to access a 
variety of zinc complexes, they suffer several drawbacks that limit their use with other 
metals. First, the ligands tend to isomerize at high temperature in the presence of Lewis 
acids, such that the nitrogen atom of the imidazole attaches to the methane carbon 
rather than the sulfur atom,1 as observed with the complex [κ4-S3-TitmPri,benzo]HgPh in 
Chapter 1. Although this reaction is of interest to access sulfur rich [S3] coordination 
environments, it prevents the use of the [Titm] ligand for reactions requiring high 
temperatures. Such isomerization processes are typical for tris substituted methane 
compounds with several nucleophilic sites on the substituents, such as, for example, 
tris(3-phenylpyrazolyl)methane2 and tris(2-pyridonyl)methane,3 which both require a 
heating step in the presence of paratoluenesulfonic acid to drive the isomerization of the 
kinetic regioisomers to the thermodynamically favored compound. In the case of 
[TitmMe]H, the isomerization from the tris imizadole to the tris thione isomer can be 
achieved by heating in the presence of catalytic amounts of either Brönsted acids, such 
as paratoluenesulfonic acid, or an equimolar amount of compounds such as KPF6, 























The isomerization reaction implies the existence of a mechanism by which the 
mercaptoimidazole groups of the [TitmMe]Ligand can detach from the central carbon of 
the ligand and attach again. This reactivity is typical of (RS)3CH compounds in basic 
conditions, as they have been shown to dissociate, upon deprotonation of the methane 
carbon, into the carbene species (RS)2C: and a thiolate RS– group (Scheme 2).4 This 
reaction resembles that of the formation of dichlorocarbene from chloroform in basic 
conditions. The particular stability of the carbene intermediate is explained by the 
presence of the two sulfur atoms in (RS)2C: which help stabilize the carbene through 
conjugation. Although there are no structurally characterized examples of such a 
carbene, indirect evidence for its formation has been observed. For example, the 
formation of (PhS)3CLi is accompanied by the production of the ethylene compound 
(PhS)2C=C(SPh)2. This compound is proposed to result from the reaction between the 
carbene (PhS)2C: and (PhS)3CLi to form the coupled product (PhS)3C–CLi(SPh)2, which 
then eliminates LiSPh to form the tetrakis ethylene (PhS)2C=C(SPh)2 compound.5  


















Figure 1: Molecular structure of (ImiPr,benzoS)2C=C(SImiPr,benzo)2  
 
In the case of [TitmPri,benzo]H, we observe the same reactivity upon deprotonation of the 
methane carbon with bases such as BunLi, MN(SiMe3)2 (M = Li, Na, K), or NaH, which 
cleanly produces (ImiPr,benzoS)2C=C(SImiPr,benzo)2 instead of [TitmPri,benzo]Li, confirming the 
formation of the (ImiPr,benzoS)2C: carbene (Figure 1). Interestingly, the fact that [Tptm]Li 
and [TitmMe]Li can both be isolated highlights the unique reactivity of the 
thiobenzimidazole group. However, similar reactivity takes place in other [Tptm] 
compounds, as illustrated by the complex [FeI(pyt)(bptmd)] (pyt = 2-pyridinethiolate, 
bptmd = bis(2-pyridylthio)methylidene)6 in which the [Tptm]Ligand dissociates into the 
carbene and thiopyridine. Interestingly, the [Tptm] motif can be regenerated by 























Scheme 3: Dissociation of the [Tptm]Ligand. See reference 6 
 
Therefore, isomerization and carbene reactivity limit the applications for 
[TitmPri,benzo]Ligands, as they provide decomposition pathways. Moreover, the 
inaccessibility of [TitmPri,benzo] M (M = Li, Na, K) limits the synthesis of [TitmPri,benzo] 
complexes, as alkali metal precursor are very convenient starting materials for metal 
complexes via transmetalation reactions.7 Since both of these decomposition pathways 
are a direct consequence of the presence of the sulfur atom, we explored new 
tetradentate ligands in which the sulfur linker was substituted for different groups.  
 
4.1.2 Silicon-based tripodal ligands 
The tris(dimethylsilyl)methane moiety has previously appeared in tetradentate ligands. 
For example, the reaction between (Me2SiCl)3CH and various primary amines in the 
presence of base produces tripodal (Me2SiNHR)3CH ligands, which can form complexes 
with various transition metals and main group elements.8 Substitution of the chlorine 
atoms of (Me2SiCl)3CH with LiPPh2 yields the tripodal ligand 
tris{(diphenylphosphino)dimethylsilyl}methane.9 Fluxional hypodentate coordination 
of this ligand has been observed in molybdenum complexes with only two phosphine 
arms coordinating, similar to [κ3-TitmMe]ZnMe, [κ3-Tptm]ZnH and [κ3-
TitmPri,benzo]ZnMe.10 Additionally, the bromine atoms in (Me2SiBr)3CH can be substituted 
for chalcogens to yield the [(Me2SiE)3CH]3- (E = S, Se, Te) moiety, which can bind to 
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main group elements.11 Finally, the reaction between (Me2SiBr)3CH and 
































Ar = Tol  
Figure 2: Examples of compounds containing tripodal and tetradentate ligands that 
incorporate the tris(dimethylsilyl)methane moiety. From left to right: 
[HC(Me2SiNTol)3]ZrCH2Ph, tris{(diphenylphosphino)dimethylsilyl}methane, 
[HC(Me2SiSe)3]GeMe, and [κ4-C(SiMe2PPh2)3]Li 
 
Inspired by these precedents, we sought to replace the sulfur linkers in [TitmPri,benzo] by 
(SiMe2) groups to access tris(benzimidazol-2-yldimethylsilyl)methane, [TismPri,benzo], 
compounds. We expect enhanced stability of the [TismPri,benzo] ligand, because of the 
inertness of the (SiMe2) groups, such that isomerization and carbene formation is less 
favorable. Moreover, the two additional methyl groups on the silicon provide a 
protective pocket around the central methane carbon. In this chapter, we report the 
synthesis of [TismPri,benzo] precursors such as [TismPri,benzo]H and [κ4-TismPri,benzo]Li. 
Investigation of the mechanism of the formation of [κ4-TismPri,benzo]Li led to the isolation 
of a doubly base silene intermediate [κ3-C(SiMe2benzimidiPr)2]SiMe2, which shows 
remarkable reactivity. The precursors were used to generate metal complexes 




4.2 Synthesis of [κ 4-TismPri,benzo]Li 
Reported syntheses of tris(dimethylsilyl)methane ligands motivated the use 
(Me2SiCl)3CH as the precursor for the synthesis of the [TismPri,benzo] ligand. Reaction of 
(Me2SiCl)3CH with three equivalents of 1-Pribenzimidazolyllithium,13 followed by the 
addition of one equivalent of methyllithium in benzene yields [κ4-TismPri,benzo]Li after 
heating overnight at 100°C (Scheme 4). The reaction conditions were optimized, such 
that the reaction could easily be done on a multi-gram scale. Protonation of the lithium 
compound by water in benzene cleanly yields [TismPri,benzo]H, which can in turn react 

































The molecular structure of [κ4-TismPri,benzo]Li was determined by X-ray diffraction, 
revealing a carbatrane structure similar to that observed in [κ4-Tptm]Li7 (Figure 3). The 
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geometry around the lithium center is almost trigonal monopyramidal with a τ4 
parameter of 0.87, an unusual geometry for 4-coordinate lithium complexes, which tend 
to be closer to tetrahedral.14 While the N-Li-N angles of 118.6° in [κ4-TismPri,benzo]Li 
approach the ideal value of 120° for an ideal trigonal monopyramidal geometry, the N-
Li-C angle is 96.9°, which is significantly larger than the ideal value of 90°. 
Consequently, the Li in [κ4-TismPri,benzo]Li is displaced from the [N3] plane towards the 
carbon by 0.242 Å. In comparison, the N-Li-C in [κ4-Tptm]Li is 92.2°, and the Li is 
displaced from the [N3] by only 0.075 Å, such that the geometry around the Li in [κ4-
Tptm]Li is closer to the ideal trigonal monopyramidal geometry than in [κ4-
TismPri,benzo]Li.  
 




The C-Li bond length [2.271 Å] in [κ4-TismPri,benzo]Li is similar to that of [κ4-Tptm]Li 
[2.210 Å] and to the average value for C-Li bond lengths listed in the CSD15 [2.259 Å]. 
The 7Li NMR exhibits a single peak at δ 5.28 ppm, which is downfield for typical alkyl 
lithium compounds, but in the range for lithium compounds featuring a [L3X] alkyl 
ligand. For example, whereas the signal for (Me3Si)3CLi in the 7Li NMR is at δ -0.2 ppm,19 
the signal for [κ4-Tptm]Li and [κ4-C(SiMe2PPh2)3]Li in the 7Li NMR is at δ 7.2 and 4.2 
ppm, respectively.7  
 
Interestingly, the geometry of the carbon center in [κ4-TismPri,benzo]Li is the same as that 
of the lithium, namely trigonal monopyramidal with Si-C-Si angles of 118.6° and Si-C-Li 
angle of 96.9°, and a τ4 parameter of 0.87. The carbon is surprisingly more planar than in 
[Tptm], [TitmMe] and [TitmPri,benzo] atrane complexes. Indeed, the distance between the 
carbon and the plane formed by the three silicons of the [TismPri,benzo] ligand in [κ4-
TismPri,benzo]Li [0.215 Å] is substantially smaller than the distance between the carbon 
and the plane formed by the three sulfurs in [κ4-Tptm]Li [0.397 Å].7 
 
The highest occupied molecular orbital (HOMO) of [κ4-TismPri,benzo]Li corresponds to a 
spn lone pair on the carbon (Figure 4) similar to that observed in [TitmMe] and 
[TitmPri,benzo] complexes (Chapter 1). However, this bonding differs from the zwitterionic 
description in [TitmMe] zinc complexes, as the zinc center in these complexes is 
displaced from the [N3] plane away from the carbanion, whereas the lithium center in 
[κ4-TismPri,benzo]Li is displaced from the [N3] plane towards the carbanion. The C–Li 
interaction therefore consists of a negatively charged carbanion and a positively 




Figure 4: (left) HOMO of [κ4-TismPri,benzo]Li. This orbital is mostly comprised of a p lone 
pair on the carbon. (right) Antibonding orbital corresponding to a combination of three 
Si–C σ*. This orbital has the right orientation to interact with the lone pair. 
 
The trigonal monopyramidal geometry is very unusual for a carbanion; only three 
previously reported structures contain a carbanion binding to a metal in a trigonal 
monopyramidal fashion.16 Notably, the reported trigonal monopyramidal carbanions 
are all part of a similar [CSi3] moiety, in which the three silyl groups are in the α 
position relative to the carbanion. The presence of silyl groups in these structures is not 
a coincidence, as the α-silyl stabilization of carbanions via hyperconjugation is a well-
known physical-organic phenomenon that has been studied in detail both theoretically17 
and experimentally in the gas phase,18 by NMR spectroscopy19 and by X-ray diffraction,16 
and has applications in many organic reactions, such as the Peterson olefination.20 The 
interaction between the Si–C σ* and the lone pair on the carbanion is believed to be 
responsible for the stabilization of the carbanion (Figure 5). In the case of [κ4-
TismPri,benzo]Li, the fact that three silyl groups provide such stabilization explains the 






Si–C σ* p lone pair
 
Figure 5: α-silyl stabilization of a carbanion by interaction between the Si–C σ* and the 
lone pair of the carbanion  
 
4.2.1 Mechanism of formation of [κ 4-TismPri,benzo]Li  
The formation of [κ4-TismPri,benzo]Li could correspond to a simple substitution of the three 
chlorides in (Me2SiCl)3CH by the benzimidazolyl groups by 1-Pribenzimidazolyllithium 
to afford [TismPri,benzo]H, followed by subsequent deprotonation of the methane carbon 
by MeLi to form [κ4-TismPri,benzo]Li. However, investigation of the mechanism of the 
formation of [κ4-TismPri,benzo]Li showed that the reaction is not straightforward.  
 
The reaction proceeds in two steps, which are separated by the addition of MeLi. The 
reaction between (Me2SiCl)3CH and three equivalents of 1-Pribenzimidazolyllithium in 
the absence of MeLi, was monitored by 1H NMR spectroscopy and shows the formation 
of two compounds. The first compound was identified as the protonated 1-
Pribenzimidazole, whereas the second compound was isolated and identified to be the 
doubly base stabilized silene compound 1 [κ3-C(SiMe2benzimidiPr)2]SiMe2 (Scheme 5).  
This compound results from the substitution of two chlorides by 1-Pribenzimidazolyl 
groups, and deprotonation of the central methane carbon by 1-
Pribenzimidazolyllithium to produce 1-Pribenzimidazole, and the alkyl lithium, which 
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readily eliminates LiCl to form a silene species. Both benzimidazole groups then chelate 








































The role of the additional equivalent of MeLi in the preparation of [κ4-TismPri,benzo]Li is to 
react with the 1-Pribenzimidazole produced during the formation of [κ3-
C(SiMe2benzimidiPr)2]SiMe2, and regenerate one equivalent of 1-
Pribenzimidazolyllithium. This additional equivalent of 1-Pribenzimidazolyllithium 
then reacts with [κ3-C(SiMe2benzimidiPr)2]SiMe2 to produce [κ4-TismPri,benzo]Li at high 
temperatures. Indeed, the independent reaction between [κ3-C(SiMe2benzimidiPr)2]SiMe2 
and one equivalent of 1-Pribenzimidazolyllithium at room temperature followed by 
heating, shows complete conversion to [κ4-TismPri,benzo]Li (Scheme 6). The same outcome 
is observed when one equivalent of MeLi is added to a 1:1 mixture of [κ3-
C(SiMe2benzimidiPr)2]SiMe2 and 1-Pribenzimidazole , thereby demonstrating that the 































Scheme 6  
 
The heating step is crucial, as the reaction between [κ3-C(SiMe2benzimidiPr)2]SiMe2 and 
one equivalent of 1-Pribenzimidazolyllithium at room temperature produces a mixture 
of products, namely compound 2 and [κ4-TismPri,benzo]Li (Scheme 7). Upon heating, 
compound 2 converts quantitatively to [κ4-TismPri,benzo]Li, suggesting that this additional 
product is a kinetic product, which can be converted to the thermodynamic product [κ4-
TismPri,benzo]Li at high temperatures. Compound 2 is believed to be [κ4-N2C-
C(SiMe2benzimidiPr)2(SiMe2-N-Pribenzimidazol-2-ylidene)]Li, which is an isomer of [κ4-
TismPri,benzo]Li in which two benzimidazole groups are attached to the SiMe2 groups via a 
carbon atom, and the third benzimidazole group is attached to the SiMe2 groups via a 
nitrogen atom (Scheme 7). In the third benzimidazole group, the carbon that binds to 
the lithium center can be described as a carbene, hence the benzimidazol-2-ylidene 
denomination for the corresponding benzimidazole group. The lithium center in [κ4-
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N2C-C(SiMe2benzimidiPr)2(SiMe2-N-Pribenzimidazol-2-ylidene)]Li is therefore in a [N2C] 
environment, as opposed to the [N3] environment in [κ4-TismPri,benzo]Li. This hypothesis 
is supported by the analysis of 1H NMR spectrum for the mixture, which shows two 
signals for the 1-Pri groups in a 2:1 ratio corresponding to the two benzimidazoles and 







































 [κ4-N2C-C(SiMe2benzimidiPr)2(SiMe2-N-Pribenzimidazol-2-ylidene)]Li results from the 
[2+3] addition of 1-Pribenzimidazolyllithium to [κ3-C(SiMe2benzimidiPr)2]SiMe2, where 
the Li–C–N fragment adds across the C–Si bond (Figure 6). Formation of [κ4-
TismPri,benzo]Li from [κ4-N2C-C(SiMe2benzimidiPr)2(SiMe2-N-Pribenzimidazol-2-ylidene)]Li 
consists of an isomerization step where the carbene from the benzimidazol-2-ylidene 
group migrates from the lithium to bind to the SiMe2 group, and the nitrogen migrates 
from the SiMe2 group to bind to the lithium (Scheme 7). DFT calculations confirm that 
[κ4-N2C-TismPri,benzo]Li is indeed higher in energy than [κ4-TismPri,benzo]Li by 10.6 kcal mol-1 




















[2+3] addition  
Figure 6: [2+3] addition between 1-Pribenzimidazolyllithium and [κ3-
C(SiMe2benzimidiPr)2]SiMe2 to form [κ4-N2C-C(SiMe2benzimidiPr)2(SiMe2-N-
Pribenzimidazol-2-ylidene)]Li 
 
4.2.2 Structural characterization of [κ3-C(SiMe2benzimidiPr)2]SiMe2 
[κ3-C(SiMe2benzimidiPr)2]SiMe2 is a stable compound that can be isolated and purified 
from the reaction between (Me2SiCl)3CH and three equivalents of 1-
Pribenzimidazolyllithium. The molecular structure of [κ3-C(SiMe2benzimidiPr)2]SiMe2 
was determined by X-ray diffraction, confirming the presence of both a trigonal planar 
carbon and a pentacoordinated silicon. The 5-coordinate silicon is in a slightly distorted 
trigonal bipyramidal geometry, with the two nitrogen atoms from the benzimidazole 
occupying the axial positions (Figure 7). The calculated τ5 parameter for the silicon atom 
is 0.91, approaching the ideal value of 1 corresponding to an ideal trigonal bipyramidal 
geometry. The carbon C1 is virtually trigonal planar as it is only 0.019 Å away from the 
plane containing the three silicon atoms, and exhibits Si-C-Si angles of 118.7° and 122.4°. 
The plane of SiMe2 group of the pentacoordinate silicon Si1 is orthogonal to the plane 
containing the carbanion. The Si1-C1 bond length of 1.801(4) Å is in between the 




Figure 7: Molecular structure of [κ3-C(SiMe2benzimidiPr)2]SiMe2 
 
The trigonal planar geometry of the sp2 carbon in [κ3-C(SiMe2benzimidiPr)2]SiMe2 implies 
presence of a p orbital on the carbon perpendicular to the plane of the three silicon 
atoms. Normally, this orbital should be involved in a π bonding interaction with 
another orbital from an adjacent sp2 center. However, in the case of [κ3-
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C(SiMe2benzimidiPr)2]SiMe2, the orbital of the sp2 silicon is prevented from forming a π 
bond with the carbon because of the coordination of the two benzimidazole arms, 
which force the p orbital on the SiMe2 group to be perpendicular to the p orbital on the 
carbon. NBO calculations were performed to confirm the absence of π interaction 
between the trigonal planar carbon and the pentacoordinated silicon. The HOMO-3 
corresponds to the lone pair on the carbon C1, and shows a participation of only 4% of 
Si1 orbitals. Therefore, [κ3-C(SiMe2benzimidiPr)2]SiMe2 can be formally described as a 
silene based on the fact that it contains sp2 carbon and a sp2 silicon adjacent to each 
other, but the silicon is stabilized by coordination of two donor groups. Formally, it can 
be drawn as a zwitterionic species, with the negative charge on C1 and the positive 
charge on Si2 (Scheme 5). However, despite the presence of a formal positive charge on 
the silicon, this compound cannot be described a silyl cation, as this classification 
applies strictly to trigonal planar, tris coordinated silicon centers.21 We therefore prefer 
to refer to [κ3-C(SiMe2benzimidiPr)2]SiMe2 as a doubly base stabilized silene. However, it 
is important to note that, although it derives from a silene, this compound differs from 




Figure 8: HOMO-3 of [κ3-C(SiMe2benzimidiPr)2]SiMe2 
 
The 29Si NMR spectrum shows a signal at -42.03 ppm for the pentacoordinated silicon, 
which is significantly upfield from the previously reported values for true 3-coordinate 
silenes.22 However, it has been observed that coordination of a Lewis base to the silicon 
of the silene shifts its signal upfield.23 In fact, the signal is in the range of shifts observed 
for pentacoordinated silicon cations.24 DFT calculations show that the zwitterionic 
configuration is energetically favored by 30 kcal mol-1 over the silene configuration, in 
which there is a double bond between the carbon and the silicon, and both 
benzimidazole groups do not coordinate the silicon (Figure 9). Double stabilization is 
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also favored by 4 kcal mol-1 over single stabilization, the configuration in which only 
one benzimidazole group stabilizes the silicon. In that regard, the energy loss from the 
breaking of the double bond is compensated by the coordination of the benzimidazole 
groups to the silicon (Figure 9). The enhanced stability of the zwitterionic form of [κ3-
C(SiMe2benzimidiPr)2]SiMe2 is explained by both the coordination of the benzimidazole 
groups to the Lewis acidic silicon, and the presence of α-stabilizing interactions 
between the carbanion and the adjacent silicon centers. 




Figure 9: Energy difference between the geometry optimized structures for [κ3-
C(SiMe2benzimidiPr)2]SiMe2 
 
Silenes have increased reactivity compared to alkenes because of the high Lewis acidity 
of the three-coordinate silicon.25 The few examples of stable, isolable silenes in the 
literature feature enhanced steric bulk around the silicon center to prevent further 
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reactivity.26 Several studies also use Lewis bases to stabilize the C=Si bond of silenes, as 
they readily bind to the silicon Lewis acidic center and prevent further reactivity. As 
silenes have become valuable synthetic targets, there is great interest in understanding 
how the coordination of the one and two donors to silicon would affect the structure 
and the reactivity of the C=Si double bond.27 Interestingly, there are only reports of 
singly base stabilized silenes,28 and no examples of doubly base stabilized silenes. The 
only instance of DFT calculations on a doubly base stabilized silene, namely 1,1-bis[N-
(dimethylamino)acetimidato]silene, show that the doubly based conformation is lower 
in energy than both the singly base stabilized silene and the uncoordinated silene,29 
similarly to calculations on [κ3-C(SiMe2benzimidiPr)2]SiMe2. Several attempts were made 
to synthesize doubly base stabilized silenes, such as, for example, 1-[2,6-
bis(dimethylaminomethyl)phenyl]-1-phenyl-2,2-bis(trimethylsilyl)silene, which consists 
of a silene in which the substituent on the silicon possesses two dimethyl amino groups 
capable to stabilize the silicon. Unfortunately, the molecular structure shows only one 
of the donor groups interacting with the silicon, while the C=Si double bond is retained 
(Figure 10).30 In that regard, [κ3-C(SiMe2benzimidiPr)2]SiMe2 represents the first example 









Figure 10: Example of an attempt to produce a doubly base stabilized silene motif. 
However, in 1-[2,6-bis(dimethylaminomethyl)phenyl]-1-phenyl-2,2-
bis(trimethylsilyl)silene, the second dimethylamino group does not coordinate to the 
silicon, such that the compound remains a singly base stabilized silene. See reference 30 
 
4.3 Reactivity of [κ 4-TismPri,benzo]Li 
The well-defined tetradentate complex, [κ4-TismPri,benzo]Li, is a convenient reagent for the 
synthesis of a variety of [TismPri,benzo] compounds. For example, the reaction between [κ4-
TismPri,benzo]Li and CuCl(PMe3) yields [κ4-TismPri,benzo]Cu (Scheme 8). The molecular 
structure of [κ4-TismPri,benzo]Cu was determined by X-ray diffraction (Figure 11). The 
structure of the ligand is not perturbed significantly by the presence of the copper 
center, as the Cu–C [2.279(4) Å] bond is almost identical to the C–Li bond in [κ4-
TismPri,benzo]Li [2.271(3) Å]. [κ4-TismPri,benzo]Cu was observed to bind reversibly to CO, a 
reactivity commonly observed for Cu(I) complexes, and is considered to be of relevance 
to the electrochemical reduction of CO2 and CO to methanol by copper electrodes.31,32 
Interestingly, upon heating at 100°C overnight, [κ4-TismPri,benzo]Cu cleanly isomerizes to 
form the tris carbene compound [κ4-C3-TismPri,benzo]Cu (Scheme 9). Although tripodal tris 
carbene ligands have been reported before,33 this example is the first that features an 
additional X type binding site. The observation that the tris carbene isomer is 
thermodynamically favored over the tris benzimidazole isomer in the case of the copper 
is noteworthy, because it shows that the [TismPri,benzo] ligand also undergoes 
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isomerization reactions, much like the [TitmMe]Ligand. However, the thermodynamics 
of the isomerization to the tris carbene ligand seem to depend on the metal to which the 
[TismPri,benzo] ligand is attached. Indeed DFT calculations show that, while the tris 
carbene compound [κ4-C3-TismPri,benzo]Cu has virtually the same energy as [κ4-
TismPri,benzo]Cu, [κ4-TismPri,benzo]Li is lower in energy than the tris carbene compound [κ4-

















































Figure 12: Molecular structure of [κ4-C3-TismPri,benzo]Cu 
 
[κ4-TismPri,benzo]Li also reacts with NiBr2(PPh3)2 to form [κ4-TismPri,benzo]NiBr (Scheme 10), 
for which the molecular structure was determined by X-ray diffraction (Figure 13). 
Unlike [κ4-TismPri,benzo]Cu, the ligand scaffold in [κ4-TismPri,benzo]NiBr is very distorted, 
such that the three nitrogen from the benzimidazole groups adopt a T-shaped geometry 
around the metal center. Reduction of [κ4-TismPri,benzo]NiBr with potassium on graphite 
at room temperature yields the isomerized Ni(0) compound {[κ4-C3-
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TismPri,benzo]Ni}K(THF)6 (Scheme 10). The molecular structure of this compound was 
determined by X-ray diffraction, which confirmed the isomerization to produce the tris 
carbene motif already observed in [κ4-C3-TismPri,benzo]Cu (Figure 14). This compound is 
very sensitive and attempts to react this complex with several substrates were 
unsuccessful. The tris carbene structures observed with copper and nickel complexes 
elucidate that the [TismPri,benzo] is also prone to isomerization akin to [TitmPri,benzo] and 





































Figure 14: Molecular structure of {[κ4-C3-TismPri,benzo]Ni}K(THF)6 
 
Reaction between the protonated ligand, namely [TismPri,benzo]H, and ZnMe2 affords the 
zinc methyl compound [κ3-TismPri,benzo]ZnMe (Scheme 11). The molecular structure of 
[κ3-TismPri,benzo]ZnMe was determined by X-ray diffraction, and confirmed the 
hypodentate coordination of the [TismPri,benzo] ligand (Figure 15). In this regard, the 
coordination mode in [κ3-TismPri,benzo]ZnMe resembles to that of the related zinc methyl 
compounds [κ3-Tptm]ZnMe, [κ3-TitmMe]ZnMe and [κ3-TitmPri,benzo]ZnMe ligands, which 
all exhibit κ3 coordination for the ligand. The coordination chemistry of the [TismPri,benzo] 
ligand to magnesium has also been investigated by colleagues in the Parkin lab. Thus, 
[TismPri,benzo]H reacts with MgMe2 to form [κ4-TismPri,benzo] MgMe, which, in the presence 
of PhSiH3, forms the reactive magnesium hydride species [TismPri,benzo] MgH. Examples 



























4.4 Reactivity of [κ3-C(SiMe2benzimidiPr)2]SiMe2  
[κ3-C(SiMe2benzimidiPr)2]SiMe2 possesses interesting reactivity due to the presence of 
both a strong nucleophilic carbanion and a Lewis acid silicon center adjacent to each 
other. The compound reacts cleanly with ZnMe2 to afford [κ3-
C(SiMe3)(SiMe2benzimidiPr)2]ZnMe, which corresponds to the formal [2+2] addition of 
the Zn-Me bond addition across the C-Si bond (Scheme 12). The compound was 
structurally characterized by X-Ray diffraction, thereby confirming the coordination of 
the carbanion to the zinc center, as well as demonstrating the transfer of the methyl 
group from the zinc to the silicon. This reaction is consistent with the polarity of both 
the C–Si bond and the Zn–Me bond, as the partially positively charged zinc atom of 
ZnMe2 binds to the negatively charged carbon of [κ3-C(SiMe2benzimidiPr)2]SiMe2, and 
the partially negatively charged methyl group of ZnMe2 binds to the partially positively 
charged silicon. This type of reactivity is unusual for diakly zinc species, as there are 
very few examples of formal [2+2] additions of dialkyl zinc reported in the literature, all 





















Figure 16: Molecular structure of [κ3-C(SiMe3)(SiMe2benzimidiPr)2]ZnMe 
 
Similar to [κ3-TitmMe]ZnMe and [κ3-TitmPri,benzo]ZnMe, [κ3-
C(SiMe3)(SiMe2benzimidiPr)2]ZnMe readily reacts with ArOH (Ar = OC6H4-p-Br) to form 
[κ3-C(SiMe3)(SiMe2benzimidiPr)2]ZnOAr. The zinc phenoxide undergoes metathesis with 
PhSiH3 to generate the zinc hydride species [κ3-C(SiMe3)(SiMe2benzimidiPr)2]ZnH. 
Although the zinc hydride could not be isolated, evidence of its formation has been 
provided by the formation of [κ3-C(SiMe3)(SiMe2benzimidiPr)2]ZnOC(O)H when exposed 
to an atmosphere of CO2 (Scheme 13). [κ3-C(SiMe3)(SiMe2benzimidiPr)2]ZnOAr can be 
used as a precursor for the catalytic hydrosilylation of CO2 by (EtO)3SiH to silyl formate 
and methoxy silanes. The mechanism is believed to be the same as that of [κ3-Tptm]ZnH 
reported in Chapter 3, where the zinc hydide [κ3-C(SiMe3)(SiMe2benzimidiPr)2]ZnH, 
formed in situ by the reaction between [κ3-C(SiMe3)(SiMe2benzimidiPr)2]ZnOAr 
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and(EtO)3SiH, inserts CO2 to make the formate [κ3-
C(SiMe3)(SiMe2benzimidiPr)2]ZnOC(O)H. This compound then undergoes metathesis 
with the silane to regenerate [κ3-C(SiMe3)(SiMe2benzimidiPr)2]ZnH and produce the silyl 
formate (EtO)3SiOCOH. In addition, [κ3-C(SiMe3)(SiMe2benzimidiPr)2]ZnH is also active 
for the hydrosilylation of (EtO)3SiOCOH to (EtO)3SiOMe in the absence of CO2, 
similarly to [κ3-Tptm]ZnH. However, preliminary results show that [κ3-Tptm]ZnH is 





























Ar = (C6H4-p-Br, C6H4-p-NO2)  
Scheme 13 
 


























Figure 18: Proposed mechanism for the hydrosilylation of CO2 and (EtO)3SiOC(O)H by 
(EtO)3SiH catalyzed by [κ3-C(SiMe3)(SiMe2benzimidiPr)2]ZnH. 
 
In addition to reactions with organometallic compounds, [κ3-C(SiMe2benzimidiPr)2]SiMe2 
also cleanly reacts with CO2 at room temperature. Unfortunately, the instability of the 
resulting compound renders its isolation difficult. The product is considered to be the 
silyl β-lactone 3,3-bis((benzimidiPr)dimethylsilyl)-2,2-dimethyl-1,2-oxasiletan-4-one, 
which results from the formal [2+2] addition between a C=O bond of CO2 and the C-–Si+ 
bond of [κ3-C(SiMe2benzimidiPr)2]SiMe2 (Scheme 14). Experimental evidence includes the 
13C{1H} NMR spectrum for the reaction between [κ3-C(SiMe2benzimidiPr)2]SiMe2 and 
13CO2, which shows that the 13C carbon of the insertion product produces a signal at δ 
168.1 ppm, which is in the typical range for lactones. Interestingly, there is only one 
example of a reaction between a silene, namely PhCH=Si[2-(ArN)-3-
(NBut)2SiMe2phosphoniumphenylylide-bicylo[2,2,1]heptane] (Ar = 2,6-
diisopropylphenyl), and CO2, which also shows CO2 reacting in a [2+2] fashion to form 
a silyl β-lactone.36,37 In addition, reported reactions between silenes and aldehydes also 
show that the major products are [2+2] cyclic addition products.38 This unusual 





















In conclusion, we developed a method for the synthesis of the new 
tris(dimethylsilylbenzimidazole)methane ligand, [TismPri,benzo] . The lithium complex [κ4-
TismPri,benzo]Li was successfully synthesized on a multi-gram scale. The mechanism of 
formation of [κ4-TismPri,benzo]Li proceeds through the zwitterionic intermediate [κ3-
C(SiMe2benzimidiPr)2]SiMe2, which can also be synthesized independently. Further 
reaction of [κ3-C(SiMe2benzimidiPr)2]SiMe2 yields the kinetic product [κ4-N2C-
TismPri,benzo]Li, which can be converted quantitatively to the thermodynamic product [κ4-
TismPri,benzo]Li upon heating. 
 
 [κ4-TismPri,benzo]Li has been used as a precursor in the formation of various metal 
complexes, such as [κ4-TismPri,benzo]Cu and [κ4-TismPri,benzo]NiBr. Both compounds show 
interesting reactivity, such that the copper compound [κ4-TismPri,benzo]Cu can isomerize 
to the tris carbene compound [κ4-C3-TismPri,benzo]Cu, and [κ4-TismPri,benzo]NiBr can be 
reduced to the tris carbene compound {[κ4-C3-TismPri,benzo]Ni}K(THF)6. 
 
Finally, [κ3-C(SiMe2benzimidiPr)2]SiMe2 represent a new example of a doubly base 
stabilized silene. The compound can be accurately drawn as a zwitterion, with a 
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positive charge on the pentacoordinated silicon and a negative charge on the trigonal 
planar carbon. This unusual structure leads to interesting reactivity for [κ3-
C(SiMe2benzimidiPr)2]SiMe2, as demonstrated by its reactivity with ZnMe2 and CO2. The 
product of the reaction [κ3-C(SiMe2benzimidiPr)2]SiMe2 and CO2 may provide a rare 
example of [2+2] addition of CO2 to a substrate, thus opening new pathways for the 




4.6 Experimental Section 
4.6.1 General Considerations 
All manipulations were performed by a combination of glovebox, high vacuum, and 
Schlenk techniques under a nitrogen or argon atmosphere.39 Solvents were purified and 
degassed by standard procedures. 1H NMR chemical shifts are reported in ppm relative 
to SiMe4 (δ = 0) and were referenced internally with respect to the protio solvent 
impurity (δ 7.16 for C6D5H, 7.26 for CHCl3).40 13C NMR spectra are reported in ppm 
relative to SiMe4 (δ = 0) and were referenced internally with respect to the solvent (δ 
128.06 for C6D6 and δ 77.16 for CDCl3).40 7Li NMR are reported in ppm relative to LiCl (δ 
= 0) and were obtained by by the Ξ/100% value of 38.863797.41 29Si NMR chemical shifts 
are reported in ppm relative to SiMe4 (δ = 0.0) and were obtained by by the Ξ/100% 
value of 19.867187.41 Coupling constants are given in hertz. Infrared spectra were 
recorded on Nicolet Avatar 370 DTGS spectrometer and are reported in cm-1. All 
chemicals were obtained from Aldrich. (Me2SiCl)3CH,42 1-Pribenzimidazole ,43 
CuCl(PMe3),44 were prepared according to the literature methods. 
 
4.6.2 X-ray Structure Determinations 
X-ray diffraction data were collected on a Bruker Apex II diffractometer. Crystal data, 
data collection and refinement parameters are summarized in Table 1. The structures 
were solved by direct methods and standard difference map techniques, and were 
refined by full-matrix least-squares procedures on F2 with SHELXTL (Version 2014/7).45 
 
4.6.3 Computational Details 
Calculations were carried out by DFT as implemented in the Jaguar 7.5 (release 207) 
suite of ab initio quantum chemistry programs.46 Geometry optimizations were 
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performed with the B3LYP density functional47 by the 6-31G** (Li, C, H, N, Si) basis 
set.48  
 
4.6.4 Synthesis of (ImiPr,benzoS)2C=C(SImiPr,benzo)2 
[TitmPri,benzo]H (100 mg, 0.17 mmol) was added to a suspension of KH (10mg, 0.25 mg) in 
THF (ca. 2 mL) under vigorous stirring. Rapid evolution of H2 was observed over a 
period of 10 min. One hour after the evolution of gas was finished, the mixture was 
filtered, and was allowed to stand. Crystals formed over a period 2 days, after what the 
mother liquor was decanted and the crystals were washed with benzene and pentane to 
afford (ImiPr,benzoS)2C=C(SImiPr,benzo)2 (47 mg, 35 %). 1H NMR (C6D6): 1.27 [d, J = 6.9 Hz, 24, 
((C6H4N2CH(CH3)2CS)2C)2], 4.86 [sept, J = 6.9 Hz, 4H, ((C6H4N2CH(CH3)2CS)2C)2], 7.10 
[m, 8H, ((C6H4N2CH(CH3)2CS)2C)2], 7.24 [m, 4H, ((C6H4N2CH(CH3)2CS)2C)2], 7.73 [m, 4H, 
((C6H4N2CH(CH3)2CS)2C)2]. 
 
4.6.5 Synthesis of 1-Pribenzimidazolyllithium  
Neat 1-Pribenzimidazole (5.4 g, 33.7 mmol) was added drop wise to a solution of 
methyllithium (855 mg, 39 mmol) in 30 mL of THF at room temperature over a period 
of 1h under vigorous stirring. The solution turns colorless to pale orange. Removing the 
solvent in vacuo affords a bright orange oil, which is then dissolved in pentane. The 
solvent was removed in vacuo, yielding a pale orange solid identified as 1-
Pribenzimidazole•0.5THF (6.6 g, 96%). 1H NMR (THF-D8): 1.59 [d, J = 6.9 Hz, 6H, 
C6H4N2CH(CH3)2CLi], 4.89 [bs, 1H, C6H4N2CH(CH3)2CLi], 6.72 [m, 2H, 





4.6.6 Synthesis of [κ 4-TismPri,benzo]Li  
To a solution of fresh 1-Pribenzimidazolyllithium (made from 7.37g, 46 mmol of 1-
Pribenzimidazole by the procedure above) and MeLi (15.2 mmol, obtained from the 
evaporation of 9.5 mL of a 1.6M solution in Et2O) in benzene (ca. 30 mL) was added a 
solution of (Me2SiCl)3CH (4.5g, 15.3 mmol) in benzene (ca. 20 mL) via canula under 
vigorous stirring. The solution turns dark red, accompanied by fast bubbling, and the 
apparition of a white precipitate. The mixture was heated at 100°C and stirred 
overnight, after what, more benzene was added (ca. 40 mL) and the mixture was 
decanted. The mother liquor was transferred into a new vessel and the remaining white 
solid was washed with benzene and decanted again. The two organic phases were 
combined and the resulting solution was concentrated in vacuo and was allowed to 
stand during a period of 3 days during which pale yellow crystals formed. The crystals 
were decanted and washed with benzene ( mL) and ether ( mL) and dried in vacuo to 
afford [κ4-TismPri,benzo]Li (3.4g, 33%). Crystals of [κ4-TismPri,benzo]Li suitable for X-ray 
diffraction were obtained from slow evaporation from benzene. 1H NMR (C6D6): 0.63 [s, 
18H, (C6H4N2CH(CH3)2CSi(CH3)2)3CLi], 1.23 [d, J = 7 Hz, 18H, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CLi], 4.84 [sept, J = 7 Hz, 3H, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CLi], 7.06 [m, 6H, (C6H4N2CH(CH3)2CSi(CH3)2)3CLi], 7.28 
[m, 3H, (C6H4N2CH(CH3)2CSi(CH3)2)3CLi], 8.00 [m, 3H, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CLi]. 13C NMR (C6D6): 6.23 [s, 6C, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CLi], 21.18 [s, 6C, (C6H4N2CH(CH3)2CSi(CH3)2)3CLi], 49.40 
[s, 3C, (C6H4N2CH(CH3)2CSi(CH3)2)3CLi], 112.73 [s, 3C, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CLi], 119.78 [s, 3C, (C6H4N2CH(CH3)2CSi(CH3)2)3CLi], 
121.91 [s, 3C, (C6H4N2CH(CH3)2CSi(CH3)2)3CLi], 121.96 [s, 3C, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CLi], 134.21 [s, 3C, (C6H4N2CH(CH3)2CSi(CH3)2)3CLi], 
145.52 [s, 3C, (C6H4N2CH(CH3)2CSi(CH3)2)3CLi], 169.31 [s, 3C, 
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(C6H4N2CH(CH3)2CSi(CH3)2)3CLi]. 29Si NMR (C6D6): -14.52 [s, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CLi]. 7Li NMR (C6D6): 5.28. Anal. calc. for [κ4-TismPri,benzo]Li: 
C, 66.3%; H, 7.7%; N, 12.5%. Found: C, 66.5%; H, 7.4%; N, 12.3%.  
 
4.6.7 Synthesis of [TismPri,benzo]H  
A solution of [κ4-TismPri,benzo]Li (10 mg, 0.015 mmol) in benzene (ca. 0.5 mL) was treated 
with H2O (0.41 mL, 0.036 M in C6D6) in an NMR tube equipped with a J Young valve. 1H 
NMR spectroscopy demonstrated the immediate conversion into [TismPri,benzo]H. 1H 
NMR (C6D6): 0.55 [s, 18H, (C6H4N2CH(CH3)2CSi(CH3)2)3CH], 1.40 [d, J = 6.9 Hz, 18 Hz, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CH], 2.30 [s, 1H, (C6H4N2CH(CH3)2CSi(CH3)2)3CH], 5.09 
[sept, J = 6.9 Hz, 3H, (C6H4N2CH(CH3)2CSi(CH3)2)3CH], 7.23 [m, 3H, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CH], 7.38 [m, 3H, (C6H4N2CH(CH3)2CSi(CH3)2)3CH], 8.04 
[m, 3H, (C6H4N2CH(CH3)2CSi(CH3)2)3CH]. 
MeLi was added to the solution, which was then heated at 100°C over a period of 3 
days, thereby confirming the formation of [κ4-TismPri,benzo]Li. 
 
4.6.8 Synthesis of [κ3-C(SiMe2benzimidiPr)2]SiMe2 
a) (Me2SiCl)3CH (500 mg, 1.7 mmol) was dissolved in THF (ca. 10 mL), giving a clear 
solution which was cooled down to -78°C. Solid 1-Pribenzimidazolyllithium•0.5THF 
(1g, 4.9 mmol) was added to the solution under vigorous stirring. The solution was 
allowed to warm up to room temperature, while slowing turning bright orange. The 
mixture was stirred for 2h, and the solvent was removed in vacuo to give a dark yellow 
oil. 1H NMR spectroscopy of the crude oil demonstrate the conversion to a mixture of 
[κ3-C(SiMe2benzimidiPr)2]SiMe2 and 1-Pribenzimidazole. The oil was dissolved in 
benzene (2 mL), then 20 mL of pentane were added, resulting in the rapid precipitation 
of a white solid. The solution was filtered, and the precipitate was washed 2 times with 
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pentane. The filtrate and the pentane solutions were combined and the solvent was 
removed in vacuo. The resulting yellow solid was triturated in benzene, centrifuged and 
dried in vacuo to afford a yellow solid identified as [κ3-C(SiMe2benzimidiPr)2]SiMe2 (190 
mg). The mother liquor was allowed to evaporate slowly at room temperature to give 
another batch of [κ3-C(SiMe2benzimidiPr)2]SiMe2 crystals suitable for X-ray diffraction (90 
mg, final yield: 33%). 1H NMR (C6D6): 0.74 [s, 12H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CSi(CH3)2], 1.02 [s, 6H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CSi(CH3)2], 1.18 [d, J = 6.9 Hz, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CSi(CH3)2], 4.72 [sept, J = 6.9 Hz, 2H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CSi(CH3)2], 7.11 [m, 2H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CSi(CH3)2], 7.25 [t, J = 7.9 Hz, 4H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CSi(CH3)2], 8.08 [d, J = 8 Hz, 2H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CSi(CH3)2]. 13C NMR (C6D6): 5.91 [s, 4C, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CSi(CH3)2], 10.85 [s, 2C, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CSi(CH3)2], 21.09 [s, 4C, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CSi(CH3)2], 51.06 [s, 2C, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CSi(CH3)2], 113.31 [s, 2C, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CSi(CH3)2], 118.61 [s, 2C, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CSi(CH3)2], 122.50 [s, 2C, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CSi(CH3)2], 122.73 [s, 2C, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CSi(CH3)2], 135.18 [s, 2C, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CSi(CH3)2], 140.22 [s, 2C, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CSi(CH3)2], 167.35 [s, 2C, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CSi(CH3)2]. 29Si NMR (C6D6): -42.03 [s, 1Si, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CSi(CH3)2], -13.45 [s, 2Si, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CSi(CH3)2]. Anal. calc. for [κ3-
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C(SiMe2benzimidiPr)2]SiMe2.0.33(C6H6): C, 65.1%; H, 8.0%; N, 10.5%. Found: C, 65.5%; H, 
7.5%; N, 9.5%. 
 
4.6.9 Synthesis of [κ 4-TismPri,benzo]Li from [κ3-C(SiMe2benzimidiPr)2]SiMe2  
a) A solution of [κ3-C(SiMe2benzimidiPr)2]SiMe2 (10 mg, 0.02 mmol) in benzene (ca. 0.5 
mL) was treated with 1-Pribenzimidazolyllithium•0.5THF (4 mg, 0.02 mmol) in an 
NMR tube equipped with a J Young valve. 1H NMR spectroscopy demonstrated the 
immediate conversion into a mixture of [κ4-TismPri,benzo]Li and [κ4-N2C-TismPri,benzo]Li in a 
1:2.25 ratio. 1H NMR for [κ4-N2C-TismPri,benzo]Li (selected resonances): 0.59 [s, 12H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2(C6H4CN(CH(CH3)2)NSi(CH3)2)CLi], 0.74 [s, 6H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2(C6H4CN(CH(CH3)2)NSi(CH3)2)CLi], 1.23 (overlap with [κ4-
TismPri,benzo]Li) [m, 12H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2(C6H4CN(CH(CH3)2)NSi(CH3)2)CLi], 1.48 [d, J = 6.5 Hz, 
(C6H4N2CH(CH3)2CSi(CH3)2)2(C6H4CN(CH(CH3)2)NSi(CH3)2)CLi], 4.17 [sept, J = 6.6 Hz, 
1H, (C6H4N2CH(CH3)2CSi(CH3)2)2(C6H4CN(CH(CH3)2)NSi(CH3)2)CLi], 4.84 (overlap with 
[κ4-TismPri,benzo]Li) [m, 2H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2(C6H4CN(CH(CH3)2)NSi(CH3)2)CLi], 7.73 [m, 1H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2(C6H4CN(CH(CH3)2)NSi(CH3)2)CLi], 8.06 [m, 2H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2(C6H4CN(CH(CH3)2)NSi(CH3)2)CLi]. Heating this mixture 
to 100°C overnight enables the complete conversion of [κ4-N2C-TismPri,benzo]Li to [κ4-
TismPri,benzo]Li.  
b) A mixture of [κ3-C(SiMe2benzimidiPr)2]SiMe2 (10 mg, 0.02 mmol) in benzene (ca. 0.5 
mL) and 1-Pribenzimidazole (3 mg, 0.02 mmol) was treated with MeLi (0.5 mg, 0.02 
mmol) in an NMR tube equipped with a J Young valve. 1H NMR spectroscopy 





4.6.10 Synthesis of [κ 4-TismPri,benzo]Cu  
CuCl(PMe3) (2.6 mg, 0.015 mmol) was added to a solution of [κ4-TismPri,benzo]Li (10 mg, 
0.015 mmol) in benzene (ca. 0.4 mL). The solution rapidly turned yellow and a white 
precipitate appeared. After 1h, the mixture was filtered and pentane was allowed to 
slowly diffuse in the solution to produce pale yellow crystals of [κ4-TismPri,benzo]Cu (8 
mg, 73%). The crystals as obtained from the reaction were suitable for X-Ray diffraction. 
1H NMR (C6D6) 0.58 [s, 18H, (C6H4N2CH(CH3)2CSi(CH3)2)3CCu], 1.23 [d, J = 7 Hz, 18H, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CCu], 4.77 [sept, J = 7 Hz, 3H, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CCu], 7.02 [m, 3H, (C6H4N2CH(CH3)2CSi(CH3)2)3CCu], 7.11 
[m, 3H, (C6H4N2CH(CH3)2CSi(CH3)2)3CCu], 7.26 [d, J = 8.1 Hz, 3H, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CCu], 8.29 [d, J = 8 Hz, 3H, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CCu]. 13C NMR (C6D6): 5.65 (6C, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CCu], 21.24 [6C, (C6H4N2CH(CH3)2CSi(CH3)2)3CCu], 49.64 
[3C, (C6H4N2CH(CH3)2CSi(CH3)2)3CCu], 112.64 [3C, (C6H4N2CH(CH3)2CSi(CH3)2)3CCu], 
120.21 [3C, (C6H4N2CH(CH3)2CSi(CH3)2)3CCu], 121.91 [3C, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CCu], 122.02 [3C, (C6H4N2CH(CH3)2CSi(CH3)2)3CCu], 
134.13 [3C, (C6H4N2CH(CH3)2CSi(CH3)2)3CCu], 144.34 [3C, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CCu], 168.12 [3C, (C6H4N2CH(CH3)2CSi(CH3)2)3CCu]. Anal. 
calc. for [κ4-TismPri,benzo]Cu: C, 61.1%; H, 7.1%; N, 11.6%. Found: C, 60.8%; H, 7.0%; N, 
11.4%. 
 
4.6.11 Reaction between [κ 4-TismPri,benzo]Cu and CO  
A solution of [κ4-TismPri,benzo]Cu (5 mg, 0.007 mmol) in benzene (ca. 0.5 mL) in an NMR 
tube equipped with a J Young valve was treated with CO (1 atm). 1H NMR 
spectroscopy demonstrated the binding of CO to [κ4-TismPri,benzo]Cu. 1H NMR (C6D6): 
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0.74 [s, 18H, (C6H4N2CH(CH3)2CSi(CH3)2)3CCuCO], 1.20 [d, J = 7 Hz, 18H, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CCuCO], 4.76 [sept, J = 7 Hz, 3H, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CCuCO], 7.01 [m, 3H, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CCuCO], 7.19 [m, 3H, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CCuCO], 7.28 [d, J = 8.1 Hz, 3H, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CCuCO], 8.13 [d, J = 8 Hz, 3H, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CCuCO]. The solution was lyophilized and the resulting 
solid was identified as [κ4-TismPri,benzo]Cu by 1H NMR spectroscopy, thereby confirming 
the reversibility of the CO binding. 
 
4.6.12 Synthesis of [κ 4-C3-TismPri,benzo]Cu  
CuCl(PMe3) (8.5 mg, 0.049 mmol) was added to a solution of [κ4-TismPri,benzo]Li (20 mg, 
0.03 mmol) in benzene (ca. 0.4 mL) in an NMR tube equipped with a J Young valve. The 
solution was heated at 100°C for 3 hours. Upon cooling, large crystals deposited, which 
were decanted. The mother liquor was allowed to evaporate slowly, which lead to the 
formation of more crystals. The crystals were collected and washed with pentane and 
dried in vacuo to afford [κ4-C3-TismPri,benzo]Cu (16 mg, 73%). The crystals as obtained from 
the reaction were suitable for X-Ray diffraction. 1H NMR (THF-d8): 0.32 [s, 18H, 
(C6H4CNCH(CH3)2NSi(CH3)2)3CCu], 1.67 [d, J = 7 Hz, 18H, 
(C6H4CNCH(CH3)2NSi(CH3)2)3CCu], 5.43 [sept, J = 8 Hz, 3H, 
(C6H4CNCH(CH3)2NSi(CH3)2)3CCu], 7.02 [m, 6H, (C6H4CNCH(CH3)2NSi(CH3)2)3CCu], 
7.44 [m, 6H, (C6H4CNCH(CH3)2NSi(CH3)2)3CCu]. Anal. calc. for [κ4-C3-





4.6.13 Synthesis of [κ 4-TismPri,benzo]NiBr  
[κ4-TismPri,benzo]Li (50 mg, 0.075 mmol) and NiBr2(PPh3)2 (55 mg) were dissolved in THF 
(ca. 2 mL). The green solution was briefly shaken, and was then allowed to stand over a 
period of 2 days, during which green crystals deposited. The mother liquor was 
decanted and the crystals were washed with THF (ca. 1 mL) and pentane (ca. 1 mL) and 
dried in vacuo to afford [κ4-TismPri,benzo]NiBr (37 mg, 61%). The crystals as obtained from 
the reaction were suitable for X-Ray diffraction. Anal. calc. for [κ4-TismPri,benzo]NiBr: C, 
55.4%; H, 6.4%; N, 10.5%. Found: C, 54.1%; H, 6.6%; N, 9.1%. 
 
4.6.14 Synthesis of {[κ 4-C3-TismPri,benzo]Ni}K(THF)6  
A suspension of [κ4-TismPri,benzo]NiBr (10 mg, 0.012 mmol) in THF (ca. 0.5 mL) was 
treated with KC8 (4 mg, 0.03 mmol). The solution turned dark purple upon mixing. 
After 2h, the mixture was filtered and the solution was allowed to stand at -17°C over a 
period of 3 days, during which crystals of {[κ4-C3-TismPri,benzo]Ni}K(THF)6 suitable for X-
Ray diffraction deposited. Isolation of the crystals from the mother liquor led to quick 
decomposition over the period of 20 minutes. 
 
4.6.15 Synthesis of [κ 3-TismPri,benzo]ZnMe  
A solution of [TismPri,benzo]H (10 mg, 0.015 mmol) in benzene (ca. 0.5 mmol) was treated 
with ZnMe2 (11 mg, 0.11 mmol) in an NMR tube equipped with a J Young valve. The 
solution was heated at 100°C for 2 days, after what the mixture was lyophilized. The 
white solid was recrystallized from vapor diffusion in a benzene solution to afford [κ3-
TismPri,benzo]ZnMe (6 mg, 54%) as white crystals suitable for X-ray diffraction. 1H NMR 
(C6D6): 0.31 [s, 3H, (C6H4N2CH(CH3)2CSi(CH3)2)3CZnCH3], 0.71 [s, 18H, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CZnCH3], 1.14 [d, J = 6.9 Hz, 18H, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CZnCH3], 4.70 [sept, J = 7 Hz, 3H 
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(C6H4N2CH(CH3)2CSi(CH3)2)3CZnCH3], 7.05 [m, 3H, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CZnCH3], 7.23 [d, J = 8.2 Hz, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CZnCH3], 8.22 [d, J = 8 Hz, 
(C6H4N2CH(CH3)2CSi(CH3)2)3CZnCH3]. 
 
4.6.16 Synthesis of [κ3-C(SiMe3)(SiMe2benzimidiPr)2]ZnMe  
A solution of [κ3-C(SiMe2benzimidiPr)2]SiMe2 (30 mg, 0.06 mmol) in benzene (ca. 0.5 
mmol) was treated with ZnMe2 (30 mg, 0.1 mmol) in an NMR tube equipped with a J 
Young valve. The yellow solution quickly became colorless, and 1H NMR spectroscopy 
demonstrated the complete conversion of [κ3-C(SiMe2benzimidiPr)2]SiMe2 into [κ3-
C(SiMe3)(SiMe2benzimidiPr)2]ZnMe in a period of 10 minutes. The solution was 
lyophilized to yield [κ3-C(SiMe3)(SiMe2benzimidiPr)2]ZnMe as a white solid (28 mg, 
79%). 1H NMR (C6D6): 0.21 [s, 3H, (C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnCH3], 0.27 
[s, 6H, (C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnCH3], 0.44 [s, 9H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnCH3], 0.67 [s, 6H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnCH3], 1.14 [d, J = 7 Hz, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnCH3], 1.17 [d, J = 7 Hz, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnCH3], 4.58 [sept, J = 7 Hz, 2H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnCH3], 7.04 [m, 4H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnCH3], 8.15 [m, 2H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnCH3]. -10.5 [s, 1C, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnCH3], 4.39 [s, 2C 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnCH3], 5.03 [s, 2C, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnCH3], 5.97 [s, 3C, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnCH3], 21.14 [s, 4C, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnCH3], 50.28 [s, 2C, 
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(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnCH3], 112.93 [s, 2C, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnCH3], 119.45 [s, 2C, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnCH3], 122.81 [s, 2C, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnCH3], 122.98 [s, 2C, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnCH3], 134.45 [s, 2C, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnCH3], 143.30 [s, 2C, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnCH3], 166.89 [s, 2C, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnCH3]. 29Si NMR (C6D6): -7.32 [s, [s, 2C, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnCH3]. 
 
4.6.17 Synthesis of [κ3-C(SiMe3)(SiMe2benzimidiPr)2]ZnOC6H4-p-Br  
A solution of [κ3-C(SiMe3)(SiMe2benzimidiPr)2]ZnMe (5 mg, 0.008 mmol) in benzene (ca. 
0.5 mL) was treated with para-bromophenol (1.5 mg, 0.008 mmol) in an NMR tube 
equipped with a J Young valve. 1H NMR spectroscopy demonstrated the formation of 
[κ3-C(SiMe3)(SiMe2benzimidiPr)2]ZnOC6H4-p-Br over a period of 10 minutes. The solution 
was lyophilized to afford [κ3-C(SiMe3)(SiMe2benzimidiPr)2]ZnOC6H4-p-Br as a white solid 
(5.7 mg, 98%). 1H NMR (C6D6): 0.18 [s, 6H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnOC6H4Br], 0.38 [s, 9H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnOC6H4Br], 0.61 [s, 6H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnOC6H4Br], 1.08 [s, J = 7 Hz, 6H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnOC6H4Br], 1.13 [s, J = 7 Hz, 6H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnOC6H4Br], 4.48 [sept, J = 7 Hz, 2H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnOC6H4Br], 7.01 [m, 6H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnOC6H4Br], 7.24 [d, J = 7.2 Hz, 2H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnOC6H4Br], 8.16 [d, J = 8 Hz, 2H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnOC6H4Br]. 29Si NMR (C6D6): -6.04 [s, 2Si , 
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(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnOC6H4Br], -3.55 [s, 1Si, 
(C6H4N2CH(CH3)2CSi(CH3)2)2C(Si(CH3)3)ZnOC6H4Br]. 
 
4.6.18 Hydrosilylation of CO2 with (EtO)3SiH catalyzed by [κ3-
C(SiMe3)(SiMe2benzimidiPr)2]ZnOC6H4-p-Br [sr.6.220] 
A solution of (EtO)3SiH (10 mg, 0.06 mmol) and [κ3-
C(SiMe3)(SiMe2benzimidiPr)2]ZnOC6H4-p-Br (50 µL, 0.01 M in C6D6) in benzene (ca. 0.5 
mL) was treated with CO2 (1 atm) in an NMR tube equipped with a J Young valve. 1H 
NMR spectroscopy demonstrated the conversion of (EtO)3SiH into a mixture of 
(EtO)3SiOC(O)H and (EtO)3SiOMe in a 2:1 ratio over a period of 20 days at 100°C. 
 
4.6.19 Hydrosilylation of (EtO)3SiOC(O)H with (EtO)3SiH catalyzed by [κ3-
C(SiMe3)(SiMe2benzimidiPr)2]ZnOC6H4-p-Br [sr.6.220] 
A solution of (EtO)3SiH (10 mg, 0.06 mmol) and [κ3-
C(SiMe3)(SiMe2benzimidiPr)2]ZnOC6H4-p-Br (50 µL, 0.01 M in C6D6) in benzene (ca. 0.5 
mL) was treated with (EtO)3SiOC(O)H (12.7 mg, 0.06 mmol) in an NMR tube equipped 
with a J Young valve. 1H NMR spectroscopy demonstrated the disappearance of 
(EtO)3SiH and the formation of (EtO)3SiOMe over a period of 17 days at 100°C. Upon 
cooling, crystals of [κ3-C(SiMe3)(SiMe2benzimidiPr)2]ZnOC(O)H suitable for X-ray 
diffraction deposited. 
 
4.6.20 Reaction between [κ3-C(SiMe2benzimidiPr)2]SiMe2 and CO2  
A solution of [κ3-C(SiMe2benzimidiPr)2]SiMe2 (5 mg, 0.001 mmol) in benzene was treated 
with CO2 (1 atm) in in an NMR tube equipped with a J Young valve. 1H NMR 1H NMR 
spectroscopy demonstrated the complete conversion into a mixture of 1-
Pribenzimidazole and the silyl β-lactone 3,3-bis((benzimidiPr)dimethylsilyl)-2,2-
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dimethyl-1,2-oxasiletan-4-one. 1H NMR (C6D6): 0.22 [s, 6H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CC(O)OSi(CH3)2], 0.53 [s, 6H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CC(O)OSi(CH3)2], 0.64 [s, 6H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CC(O)OSi(CH3)2], 1.31 [t, J = 6.7 Hz, 12H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CC(O)OSi(CH3)2], 4.77 [m, 2H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CC(O)OSi(CH3)2], 7.32 [m, 6H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CC(O)OSi(CH3)2], 8.07 [m, 2H, 
(C6H4N2CH(CH3)2CSi(CH3)2)2CC(O)OSi(CH3)2]. 
 
4.6.21 Reaction between [κ3-C(SiMe2benzimidiPr)2]SiMe2 and 13CO2  
A solution of [κ3-C(SiMe2benzimidiPr)2]SiMe2 (2 mg, 0.004 mmol) in benzene was treated 
with 13CO2 (1 atm) in in an NMR tube equipped with a J Young valve. 1H NMR 1H NMR 
spectroscopy demonstrated the complete conversion into a mixture of 1-
Pribenzimidazole and the silyl β-lactone 3,3-bis((benzimidiPr)dimethylsilyl)-2,2-





4.6.22 Crystallographic data 





lattice Monoclinic Cubic 
formula C46H56N8OS4 C37H51LiN6Si3 
formula weight 865.23 671.05 
space group P21/c I23 
a/Å 16.796(3) 20.191(2) 
b/Å 13.988(2) 20.191(2) 
c/Å 37.847(6) 20.191(2) 
α/˚ 90 90 
β/˚ 91.765(2) 90 
γ/˚ 90 90 
V/Å3 8888(2) 8231.2(15) 
Z 8 8 
temperature (K) 130(2) 130(2) 
radiation (λ, Å) 0.71073 0.71073 
ρ (calcd.) g cm-3 1.293 1.083 
µ (Mo Kα), mm-1 0.259 0.146 
θ max, deg. 30.67 30.51 
no. of data collected 139294 65610 
no. of data 27355 4198 
no. of parameters 1033 147 
R1 [I > 2σ(I)] 0.1215 0.0444 
wR2 [I > 2σ(I)] 0.1885 0.0503 
R1 [all data] 0.2761 0.1094 
wR2 [all data] 0.2938 0.1123 
GOF 1.681 1.109 










lattice Orthorhombic Cubic 
formula C33H46N4Si3 C37H51CuN6Si3 
formula weight 583.01 727.64 
space group Pnma I23 
a/Å 19.644(8) 20.1294(17) 
b/Å 18.329(7) 20.1294(17) 
c/Å 9.241(4) 20.1294(17) 
α/˚ 90 90 
β/˚ 90 90 
γ/˚ 90 90 
V/Å3 3327(2) 8156(2) 
Z 4 8 
temperature (K) 130(2) 130(2) 
radiation (λ, Å) 0.71073 0.71073 
ρ (calcd.) g cm-3 1.164 1.185 
µ (Mo Kα), mm-1 0.170 0.656 
θ max, deg. 32.79 30.490 
no. of data collected 55648 66485 
no. of data 6140 4176 
no. of parameters 202 142 
R1 [I > 2σ(I)] 0.0462 0.0571 
wR2 [I > 2σ(I)] 0.0647 0.0824 
R1 [all data] 0.1173 0.1138 
wR2 [all data] 0.1305 0.1224 
GOF 1.058 1.024 











lattice Trigonal Monoclinic 
formula C80H108Cu2N12Si6 C43H57BrN6NiSi3 
formula weight 511.13 880.83 
space group R-3 P21/c 
a/Å 16.4836(19) 12.702(3) 
b/Å 16.4836(19) 18.819(5) 
c/Å 26.069(3) 18.915(5) 
α/˚ 90 90 
β/˚ 90 105.630(4) 
γ/˚ 120 90 
V/Å3 6134.3(16) 4354.3(19) 
Z 9 4 
temperature (K) 130(2) 130(2) 
radiation (λ, Å) 0.71073 0.71073 
ρ (calcd.) g cm-3 1.245 1.344 
µ (Mo Kα), mm-1 0.657 1.483 
θ max, deg. 30.548 30.560 
no. of data collected 33358 70162 
no. of data 4192 13279 
no. of parameters 151 487 
R1 [I > 2σ(I)] 0.0362 0.0639 
wR2 [I > 2σ(I)] 0.0395 0.1596 
R1 [all data] 0.0972 0.1132 
wR2 [all data] 0.1010 0.1401 
GOF 1.076 1.034 
Rint 0.0264 0.1673 
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Table 1: Crystallographic data 





lattice Hexagonal Triclinic 
formula C61H99KN6NiO6Si3 C41H57N6Si3Zn 
formula weight 1194.54 783.56 
space group R3c P-1 
a/Å 16.9156(16) 11.1387(6) 
b/Å 16.9156(16) 12.2980(7) 
c/Å 40.003(4) 17.7675(10) 
α/˚ 90 79.0698(9) 
β/˚ 90 75.1020(9) 
γ/˚ 120 65.8782(9) 
V/Å3 9912.9(16) 2136.8(2) 
Z 6 2 
temperature (K) 130(2) 130(2) 
radiation (λ, Å) 0.71073 0.71073 
ρ (calcd.) g cm-3 1.201 1.218 
µ (Mo Kα), mm-1 0.462 0.694 
θ max, deg. 30.55 30.539 
no. of data collected 51252 69593 
no. of data 6756 13016 
no. of parameters 240 474 
R1 [I > 2σ(I)] 0.0333 0.0602 
wR2 [I > 2σ(I)] 0.0372 0.1170 
R1 [all data] 0.0845 0.1248 
wR2 [all data] 0.0880 0.1496 
GOF 1.062 1.038 












lattice Monoclinic Triclinic 
formula C29H46N4Si3Zn C40H52Br2N4O2Si3Zn 
formula weight 600.34 930.32 
space group P21/n P-1 
a/Å 18.545(2) 9.851(5) 
b/Å 17.876(2) 14.432(8) 
c/Å 21.969(3) 16.889(9) 
α/˚ 90 81.278(8) 
β/˚ 113.3775(16) 83.251(8) 
γ/˚ 90 70.207(7) 
V/Å3 6685.4(14) 2227(2) 
Z 8 4 
temperature (K) 130(2) 130(2) 
radiation (λ, Å) 0.71073 0.71073 
ρ (calcd.) g cm-3 1.193 1.387 
µ (Mo Kα), mm-1 0.865 2.463 
θ max, deg. 30.551 31.028 
no. of data collected 108431 36877 
no. of data 20452 14022 
no. of parameters 691 474 
R1 [I > 2σ(I)] 0.0470 0.1307 
wR2 [I > 2σ(I)] 0.0658 0.2427 
R1 [all data] 0.1207 0.3328 
wR2 [all data] 0.1336 0.3759 
GOF 1.004 1.047 









formula weight 630.32 









temperature (K) 130(2) 
radiation (λ, Å) 0.71073 
ρ (calcd.) g cm-3 1.273 
µ (Mo Kα), mm-1 0.887 
θ max, deg. 30.644 
no. of data collected 53230 
no. of data 10147 
no. of parameters 367 
R1 [I > 2σ(I)] 0.0356 
wR2 [I > 2σ(I)] 0.0537 
R1 [all data] 0.0788 







4.6.23 Computational data 
[κ4-TismPri,benzo]Li 
-2645.48181481884 
atom x y z 
Li 0 0 -0.410340325 
Si -0.856922619 -1.60111292 2.040346333 
N -0.026663958 -2.010202041 -0.648323087 
N -0.762495684 -3.9680413 0.145314264 
C 0 0 1.872109109 
C -2.759018666 -1.508074028 2.118807792 
H -3.097380984 -1.113398733 3.08237336 
H -3.197540954 -2.506908038 2.007941934 
H -3.171089445 -0.878298221 1.324485765 
C -0.350254574 -2.688791196 3.533800168 
H -1.144064995 -3.381107322 3.838879477 
H -0.151569127 -2.034843579 4.390360714 
H 0.555503078 -3.276559762 3.356589206 
C -0.522437982 -2.629809565 0.421719438 
C 0.0720137 -2.95328106 -1.653077556 
C 0.540828617 -2.81937417 -2.966214684 
H 0.904920042 -1.860464176 -3.323630183 
C 0.533292417 -3.946174313 -3.77891609 
H 0.891838853 -3.874429315 -4.801743404 
C 0.071689213 -5.186243633 -3.296861741 
H 0.08047216 -6.048797241 -3.957108252 
 
 298 
C -0.393170549 -5.336785762 -1.994243817 
H -0.739505597 -6.30250691 -1.644910418 
C -0.388759615 -4.20084241 -1.174285072 
C -1.351344657 -4.943724023 1.076427508 
H -1.535814089 -4.38262218 1.992556053 
C -0.36324894 -6.069433147 1.412508548 
H 0.571404158 -5.657154741 1.803567449 
H -0.124667649 -6.680239067 0.537560243 
H -0.793586298 -6.726753071 2.174936645 
C -2.704823082 -5.460895886 0.568117901 
H -3.384793558 -4.62770166 0.367597787 
H -3.163737836 -6.10445969 1.325702173 
H -2.603796552 -6.043455978 -0.351154358 
Si -0.958143154 1.542673218 2.040346333 
N -1.727554055 1.028192686 -0.648323087 
N -3.055176728 2.644361282 0.145314264 
C 0.073478914 3.143417269 2.118807792 
H 0.584458904 3.239109984 3.08237336 
H -0.572275569 4.022605714 2.007941934 
H 0.824916151 3.185393128 1.324485765 
C -2.153434194 1.647724957 3.533800168 
H -2.356092337 2.681343011 3.838879477 
H -1.686441669 1.148684504 4.390360714 
H -3.11533553 1.157200104 3.356589206 
C -2.016262899 1.767349347 0.421719438 
C -2.593623272 1.414274836 -1.653077556 
C -2.712063962 0.941315764 -2.966214684 
 
 299 
H -2.06366926 0.146548343 -3.323630183 
C -3.684133412 1.511242376 -3.77891609 
H -3.801273638 1.164859555 -4.801743404 
C -4.527263343 2.531037137 -3.296861741 
H -5.278648153 2.954707685 -3.957108252 
C -4.42520677 3.008888565 -1.994243817 
H -5.088378293 3.791684088 -1.644910418 
C -3.443656437 2.437096908 -1.174285072 
C -3.605718265 3.642160814 1.076427508 
H -3.027555098 3.521365106 1.992556053 
C -5.074658822 3.349299383 1.412508548 
H -5.184941798 2.333726854 1.803567449 
H -5.722922911 3.448084884 0.537560243 
H -5.428745896 4.05064243 2.174936645 
C -3.376863023 5.072893445 0.568117901 
H -2.31531042 5.245168038 0.367597787 
H -3.70474825 5.792107182 1.325702173 
H -3.931888127 5.276681949 -0.351154358 
Si 1.815065773 0.058439703 2.040346333 
N 1.754218013 0.982009355 -0.648323087 
N 3.817672411 1.323680018 0.145314264 
C 2.685539752 -1.635343241 2.118807792 
H 2.512922079 -2.125711251 3.08237336 
H 3.769816523 -1.515697677 2.007941934 
H 2.346173294 -2.307094907 1.324485765 
C 2.503688768 1.041066239 3.533800168 
H 3.500157332 0.699764312 3.838879477 
 
 300 
H 1.838010795 0.886159075 4.390360714 
H 2.559832452 2.119359658 3.356589206 
C 2.538700881 0.862460218 0.421719438 
C 2.521609572 1.539006224 -1.653077556 
C 2.171235346 1.878058406 -2.966214684 
H 1.158749218 1.713915833 -3.323630183 
C 3.150840995 2.434931937 -3.77891609 
H 2.909434786 2.70956976 -4.801743404 
C 4.45557413 2.655206496 -3.296861741 
H 5.198175993 3.094089555 -3.957108252 
C 4.818377319 2.327897197 -1.994243817 
H 5.82788389 2.510822822 -1.644910418 
C 3.832416052 1.763745502 -1.174285072 
C 4.957062922 1.301563209 1.076427508 
H 4.563369187 0.861257073 1.992556053 
C 5.437907762 2.720133764 1.412508548 
H 4.61353764 3.323427887 1.803567449 
H 5.84759056 3.232154183 0.537560243 
H 6.222332194 2.676110641 2.174936645 
C 6.081686106 0.388002441 0.568117901 
H 5.700103978 -0.617466378 0.367597787 
H 6.868486086 0.312352508 1.325702173 






atom x y z 
Si 1.328233523 3.015814974 7.586190187 
Si 2.550902339 4.614877824 5.213159203 
N 2.567645423 2.479406023 5.177324459 
N 2.110614259 0.494165555 6.068098127 
C 1.589113583 4.58741381 3.558065695 
C 3.658073218 1.616005855 3.054642185 
C 4.456351791 4.588855832 5.028717379 
C -0.509727724 2.562101583 7.835885898 
C 2.736022111 0.238003137 4.849002117 
C 2.031170898 1.854944242 6.223905806 
C 1.71671089 4.601160188 6.83667986 
C 2.186459557 2.563113252 9.230388563 
C 3.077694491 -0.943117262 4.179688287 
C 3.709956876 -0.818681315 2.947017404 
C 0.472469211 -1.332552427 6.462885963 
C 1.612130176 -0.487666751 7.047624179 
C 3.99646573 0.44250404 2.392196171 
C 2.755994958 -1.329073621 7.629262922 
C 3.019601235 1.508613817 4.296614917 
Si 1.318202935 6.178326468 7.598479025 
N 2.560229052 6.715846754 5.199543251 
N 2.106019932 8.704840602 6.077648169 
C 3.656796742 7.556424145 3.073816354 
 
 302 
C -0.520735414 6.629622382 7.842213075 
C 2.736023847 8.952752633 4.858215823 
C 2.022510048 7.346350228 6.241649397 
C 2.170428544 6.629471057 9.246014626 
C 3.084768769 10.12718329 4.181226271 
C 3.719680364 9.99025157 2.951188776 
C 0.467060635 10.53509441 6.455571706 
C 1.603792882 9.692659961 7.049361367 
C 4.001891435 8.724404232 2.404649379 
C 2.745867475 10.53705311 7.630051979 
C 3.017267787 7.678636452 4.313695546 
H 1.186438 9.091572319 7.860103182 
H 1.197919752 0.117678773 7.856625401 
H -0.334508504 9.891748871 6.081869968 
H 0.050662361 11.18975507 7.227491152 
H 0.811275491 11.16526992 5.631054523 
H 3.217985176 11.16552775 6.870100241 
H 2.357612868 11.193361 8.415116855 
H 3.5151136 9.894983168 8.068238837 
H -0.986699028 5.925173903 8.542526038 
H -0.675182462 7.635770587 8.251895764 
H -1.06945057 6.553403059 6.897897566 
H 3.258936051 6.555757312 9.154487666 
H 1.920968687 7.634142726 9.609660914 
H 1.865423846 5.922675443 10.02791894 
H 1.94369643 1.556202524 9.592529953 
H 3.274277211 2.642883423 9.136203741 
 
 303 
H 1.879650416 3.266142132 10.01492308 
H -0.663857663 1.553975886 8.240609428 
H -0.972662648 3.26278987 8.542057214 
H -1.062284473 2.644061713 6.894304154 
H 0.812317668 -1.965835195 5.638911305 
H 0.059975397 -1.984236334 7.239467325 
H -0.330972019 -0.690469747 6.090938801 
H 3.526732845 -0.684257207 8.060850222 
H 2.370504809 -1.980626087 8.419654823 
H 3.225629463 -1.961899713 6.871435378 
H 4.773357442 4.40046305 3.994821881 
H 4.906616982 5.534705003 5.342009203 
H 4.883693671 3.792357166 5.645153894 
H 0.811887539 3.817903969 3.590877123 
H 1.104471303 5.545610542 3.352090132 
H 2.235459694 4.354184868 2.702346328 
H 4.499010678 8.661509997 1.441326193 
H 3.872053306 6.579594738 2.655820158 
H 4.003589076 10.88215761 2.400773694 
H 2.875673594 11.1101863 4.58594297 
H 4.491969004 0.497656327 1.427437398 
H 3.879521387 2.586796755 2.627099116 
H 3.988386211 -1.715679365 2.401883243 
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